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Abstract 
Adverse drug reactions (ADRs) in neonates exhibit different profiles to those seen in older 
children and adults. Neonates are a unique population who exhibit their own risk factors for 
developing ADRs, one of which is the high proportion of off-label drug use. However, a lack of 
appropriate methods for the detection and assessment of ADRs in this population means the 
rate of underreporting is high, and thus little influence on improving medicines for neonates 
can be expected from pharmacovigilance. The aim of this research was to generate 
prospective neonatal ADR data to allow the comparison of several causality assessment tools 
in the neonatal setting. A prospective observational study conducted at the Liverpool Women’s 
Hospital neonatal unit collected suspected cases of neonatal ADRs. A sample of these cases 
were analysed by six different assessors using three existing causality assessment tools; the 
Karch and Lasagna algorithm, the ‘New Adverse Drug Reactions Algorithm for Infants in the 
Neonatal Intensive Care Unit’ algorithm (Du Lehr), and the Liverpool ADR Causality 
Assessment Tool (LCAT). Statistical analyses were performed to evaluate the inter-rater and 
inter-tool reliability when using the three methods. Over a period of nine weeks, 63 cases of 
suspected neonatal ADR cases were collected, detailing a wide range of ADRs to many 
different drugs, almost 50% of which were prescribed off-label. When a sample of 34 of these 
cases were assessed for causality using the three methods, global kappa scores of less than 
0.3 for each tool suggested only ‘fair’ inter-rater reliability was exhibited by each method. Inter-
tool reliability measures suggested that the consistent use of one methodology within and 
across pharmacovigilance studies will produce more reliable results than varying methods. 
The results of this research suggest that the three tools evaluated may need to be adapted 
before they can be used to reliably assess neonatal ADRs.   
 
  
3 
 
Acknowledgements 
I would like to say thank you to all those who have helped me with the conduction of this study 
and the writing of the thesis. To Karen Wilding, and the Research and Development 
department at the Liverpool Women’s Hospital for the efficient study set up. To Patrick, Karen 
and Jo, the NICU research nurses who gave me advice and confidence throughout my time 
on the unit. To all the doctors, nurses, pharmacists and clinical support staff who contributed 
to the results of the study, particularly to the consultants and registrars who took the time to 
perform the causality assessments. To all the patients and parents who were resident on the 
unit throughout the study period. To Dr Jamie Kirkham for his help with the statistical analysis 
involved in the study and for answering many questions. To Dr Mark Turner and Dr Dan 
Hawcutt, who have been supportive and committed supervisors throughout the year, and who 
have encouraged me enormously, including giving me the opportunity to present at the 
European Society for Developmental, Perinatal and Paediatric Pharmacology Congress. 
Finally, to my extremely supportive friends and family, who kept me going throughout the year.   
 
 
 
  
4 
 
Publications and outputs 
Oral presentation: 
ADRIN 1 methodology study: Adverse drug reactions in neonates: what are the best ways to 
evaluate suspected adverse drug reactions in neonates? 
Presented at the 16th European Society for Developmental, Perinatal and Paediatric 
Pharmacology Congress, Leuven, Belgium, June 2017. 
 
Poster presentation: 
Adverse drug reactions in neonates: Comparing retrospective spontaneous Yellow Card 
reports to prospectively collected reports 
Presented at the 16th European Society for Developmental, Perinatal and Paediatric 
Pharmacology Congress, Leuven, Belgium, June 2017. 
  
5 
 
Contents 
Abstract  ...…………………………………………………………………………………………….2 
Acknowledgements ............................................................................................................... 3 
Publications and outputs ....................................................................................................... 4 
List of tables ............................................................................................................ 9 
List of figures ......................................................................................................... 10 
List of abbreviations ............................................................................................... 11 
Chapter 1: Introduction……………………………………………………………………13 
1.1 Background ................................................................................................................... 13 
1.1.1 Definitions ..................................................................................................... 13 
1.1.2 ADRs as an important health problem .......................................................... 14 
1.1.3 Medicines use in neonates ........................................................................... 15 
1.1.4 Medicines research in neonates ................................................................... 17 
1.2 Neonatal pharmacology ................................................................................................ 20 
1.2.1 Absorption .................................................................................................... 20 
1.2.2 Distribution .................................................................................................... 21 
1.2.3 Metabolism ................................................................................................... 21 
1.2.4 Excretion ...................................................................................................... 21 
1.3 ADRs in neonates ......................................................................................................... 21 
1.3.1 ADRs in neonates - incidence ....................................................................... 22 
1.3.2 ADRs in neonates - causative drugs ............................................................. 22 
1.3.3 ADRs in neonates - reaction characteristics .................................................. 25 
1.3.4 ADRs in neonates - risk factors ..................................................................... 30 
1.3.5 ADRs in neonates - current reporting practices ............................................. 30 
1.4 Evaluating ADRs in neonates ........................................................................................ 31 
1.4.1 Causality ....................................................................................................... 32 
1.4.2 Severity ........................................................................................................ 32 
1.4.3 Avoidability ................................................................................................... 33 
1.5 Conclusion .................................................................................................................... 33 
6 
 
1.6 Aims and objectives ...................................................................................................... 34 
Chapter 2: Systematic review protocol .............................................................. 35 
2.1 Objectives ..................................................................................................................... 35 
2.2 Review question development....................................................................................... 36 
2.3 Evidence gathering and study selection ........................................................................ 36 
2.4 Paper exclusion and data extraction.............................................................................. 37 
2.5 Dissemination ............................................................................................................... 39 
Chapter 3: Methodology ...................................................................................... 43 
3.1.1 Study setting ................................................................................................. 43 
3.1.2 Study introduction ......................................................................................... 43 
3.1.3 Study materials design.................................................................................. 44 
3.2 ADR case collection ...................................................................................................... 55 
3.2.1 Participants ................................................................................................... 55 
3.2.2 ADR case data collection .............................................................................. 55 
3.2.3 Drug inclusion and exclusion ........................................................................ 59 
3.2.4 ADR definition ............................................................................................... 59 
3.3 Comparison of results to Yellow Card reports to the MHRA .......................................... 60 
3.4 Causality assessment process ...................................................................................... 60 
3.4.1 Three compared methods ............................................................................. 60 
                 3.4.2 Assessment process……………………………………………………………….67 
3.5 Severity assessment ..................................................................................................... 69 
3.6 Statistical analysis ......................................................................................................... 69 
3.6.1 Statistical analysis of ADR cases .................................................................. 69 
3.6.2 Statistical analysis of causality assessments ................................................ 69 
3.6.3 Study approval .............................................................................................. 71 
3.7 Discussion..................................................................................................................... 71 
Chapter 4: Prospective observation of adverse drug reactions in neonates .. 73 
4.1 ADRs on the neonatal unit ............................................................................................ 73 
4.1.1 Neonate characteristics ................................................................................ 75 
7 
 
4.1.2 Drugs prescribed on the neonatal unit .......................................................... 81 
4.1.3 ADR report characteristics ............................................................................ 85 
4.1.4 Suspected ADRs to maternal medication ...................................................... 96 
4.1.5 Reporter characteristics ................................................................................ 96 
4.2 Comparison to Yellow Card reports ............................................................................... 98 
4.3 Discussion................................................................................................................... 101 
4.3.1 Incidence and frequency of reactions .......................................................... 101 
4.3.2 Types of reactions ...................................................................................... 103 
4.3.3 Types of drugs ............................................................................................ 104 
4.3.4 Risk factors ................................................................................................. 105 
4.3.5 Reporting and underreporting ..................................................................... 106 
4.3.6 Comparison of results to Yellow Card reports to the MHRA ........................ 108 
4.3.7 Summary .................................................................................................... 110 
Chapter 5: Causality assessment of adverse drug reactions in neonates..... 111 
5.1 Inter-rater reliability ..................................................................................................... 115 
5.2 Inter-tool reliability ....................................................................................................... 122 
5.3 Assessor view of tool usability ..................................................................................... 124 
5.4 Discussion................................................................................................................... 129 
5.4.1 Causality assessment tools ........................................................................ 129 
5.4.2 Inter-rater reliability ..................................................................................... 129 
5.4.3 Inter-tool reliability ....................................................................................... 130 
5.4.4 Variability amongst causality assessment methods .................................... 131 
5.4.5 Variability amongst assessors ..................................................................... 133 
5.4.6 Characteristics of cases .............................................................................. 134 
5.4.7 Usability ...................................................................................................... 136 
5.4.8 Question adaptation .................................................................................... 137 
5.4.9 Wider applications ...................................................................................... 139 
5.4.10 Summary .................................................................................................. 139 
Chapter 6: Strengths, limitations, future research and conclusions.............. 141 
8 
 
6.1 Strengths of the study ................................................................................................. 141 
6.1.1 Study design ............................................................................................... 141 
6.1.2 Aims of the study ........................................................................................ 142 
6.1.3 Scope for further research .......................................................................... 142 
6.2 Limitations ................................................................................................................... 143 
6.2.1 Study materials and resources .................................................................... 143 
6.2.2 Underreporting ............................................................................................ 143 
6.3 Future research ........................................................................................................... 144 
6.3.1 Extending ADRIN ........................................................................................ 144 
6.3.2 Identifying ADRs in neonates ...................................................................... 145 
6.3.3 Understanding ADRs in neonates ............................................................... 146 
6.3.4 Evaluating ADRs in neonates ..................................................................... 147 
6.4 Conclusion .................................................................................................................. 148 
References ......................................................................................................... 150 
Appendix ............................................................................................................ 158 
Appendix 1 - Study protocol .............................................................................................. 159 
Appendix 2 - ADR alert form ............................................................................................. 178 
Appendix 3 - Causality tool evaluation form ...................................................................... 179 
 
 
  
9 
 
List of tables 
Table 1 Drugs known to cause ADRs that are specific to neonates ....................... 16 
Table 2 Number of ADRs by subtype seen in three studies ................................... 27 
Table 3 Pre-determined search strategy for systematic review .............................. 40 
Table 4 Test run of search strategy using four databases ...................................... 42 
Table 5 Details of the six individuals who carried out causality assessments ......... 68 
Table 6 ADR reports and the number of neonates, reactions and drugs reported .. 74 
Table 7 Demographics of neonates experiencing at least one ADR ....................... 77 
Table 8 Results of statistical analysis of demographic subgroups .......................... 80 
Table 9 Drugs prescribed to all neonates on the neonatal unit over study period ... 82 
Table 10 Clinical presentations of the observed ADRs .......................................... 86 
Table 11 Drug groups and ADRs suspected to have been caused ........................ 90 
Table 12 Drugs prescribed to the neonate off-label ............................................... 92 
Table 13 All ADRs observed and the given severity ratings ................................... 94 
Table 14 Number of alerts to ADRs by different members of clinical team ............. 97 
Table 15 Comparison of neonatal Yellow Card reports and study reports ............ 100 
Table 16 Six assessors' causality ratings using three different methods .............. 112 
Table 17 Frequency of ratings per assessor per tool ........................................... 116 
Table 18 Karch and Lasagna algorithm inter-rater reliability ................................ 118 
Table 19 Du Lehr inter-rater reliability .................................................................. 119 
Table 20 LCAT Inter-rater reliability ..................................................................... 120 
Table 21 Global kappa scores using three causality assessment methods .......... 121 
Table 22 Inter-tool reliability ................................................................................. 123 
 
  
10 
 
List of figures 
Figure 1 Number of ADR reports per neonate (total number of reports=63)………….……..76 
Figure 2 ‘The tool was easy to use’ - assessor opinions regarding three methods………. 125 
Figure 3 'The tool was appropriate to use for a neonatal ADR case' - assessor opinions 
regarding three methods………………………………………………………………………….125 
Figure 4 'The tool fairly assessed all causality aspects of the case' - assessor opinions 
regarding three methods………………………………………………………………………….126 
Figure 5 'I would use this tool in clinical practice if it were available' - assessor opinion 
regarding three methods………………………………………………………………………….126 
 
  
11 
 
List of abbreviations 
ADR Adverse Drug Reaction 
ADRIN Adverse Drug Reactions in Neonates 
ADRIC Adverse Drug Reactions in Children 
AKI Acute Kidney Injury 
ANNP Advanced Neonatal Nurse Practitioner 
ATC Anatomical Therapeutic Chemical 
(classification) 
BP Blood Pressure 
BNFc British National Formulary for children 
CI Confidence Interval 
CYP Cytochrome P450 
EMA European Medicines Agency 
FDA Food and Drug Administration 
GFR Glomerular Filtration Rate 
GI Gastrointestinal 
HCA Healthcare Assistant  
HDU High Dependency Unit 
HRA Health Research Authority 
ICH International Conference on 
Harmonisation of Technical 
Requirements for Registration of 
Pharmaceuticals for Human Use 
IRAS Integrated Research Application System  
ITU Intensive Treatment Unit 
IV Intravenous 
LCAT Liverpool ADR Causality Assessment 
Tool  
LWH Liverpool Women’s Hospital 
MHRA Medicine and Healthcare products 
Regulatory Agency 
NICU Neonatal Intensive Care Unit 
PDA Patent Ductus Arteriosus 
PICU Paediatric Intensive Care Unit 
REC  Research Ethics Committee  
SHO Senior House Officer 
12 
 
TPN Total Parenteral Nutrition  
WHO World Health Organisation 
  
13 
 
Chapter 1: Introduction 
1.1 Background 
Approximately 90,000 neonates are admitted to neonatal units each year in the UK(1,2). Many 
of these neonates will be prescribed medicines, and yet most previous pharmacovigilance 
studies have omitted all or part of the inpatient neonatal population from their work. An adverse 
drug reaction (ADR) is defined by the World Health Organisation as ‘a response to a drug 
which is noxious and unintended, and which occurs at doses normally used in man’(3). Recent 
studies into adverse drug reactions in children have indicated a considerable health risk for 
this population, with incidence rates ranging from 0.4% to 10.3% for paediatric hospital 
admissions related to ADRs and 0.6% to 16.8% for the proportion of children experiencing an 
ADR during an admission(4). Between 2000 and 2009 the highest number of spontaneous 
ADR reports for children was for those under one year of age but to date there is limited 
research studying ADRs in neonates alone(5). A review of the UK ‘Yellow Card Scheme’ for 
spontaneous reports of ADRs found that only 97 reports of ADRs in neonates had been 
submitted in the 10 year period between 2001 and 2010(6). If an estimated 900,000 neonates 
were admitted to neonatal units during this time, there was approximately one report for every 
9278 neonates admitted. Even if the lowest estimate of the incidence of ADRs in children is 
the most accurate, 3600 ADRs would have occurred in these 900,000 neonates. As only 97 
reports were filed to the Medicines and Healthcare products Regulatory Agency (MHRA) this 
reflects an underreporting rate of 97%, which is in keeping with findings from other 
pharmacovigilance studies(6,7).   
1.1.1 Definitions 
Several definitions of an ADR are used currently. To monitor adverse drug reactions efficiently 
and effectively, it is important to harmonise the terminology used to describe ADRs. The World 
Health Organisation’s definition of an ADR has been used for over 40 years(3). This definition 
has been criticised in the past for lack of clarity about the inclusion of minor side-effects. 
Further definitions more clearly exclude such effects, for example Laurence’s definition, ‘a 
harmful or significantly unpleasant effect caused by a drug at doses intended for therapeutic 
effect (or prophylaxis or diagnosis) which warrants reduction of dose or withdrawal of the drug 
and/or foretells hazard from future administration’(8).   
In their review of such definitions, Edwards and Aronson concluded their definition as ‘an 
appreciably harmful or unpleasant reaction, resulting from an intervention related to the use 
of a medicinal product, which predicts hazard from future administration and warrants 
prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the 
product’(9).  
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As with any surveillance, ADR monitoring, and thus the definitions used, should be population-
specific. Allegaert et al suggested a definition more suitable for neonates as ‘an unintended 
and harmful effect resulting from the use of medications intended for diagnostic or therapeutic 
reasons (irrespective of the dose)’(10).   
Another issue is that the term ‘neonate’ refers to different populations in different work. The 
definition suggested from the International Conference on Harmonisation is a baby within 28 
days of birth(11). However, this definition does not allow for the predating of prematurity and 
thus more advanced definitions include commentary on the use of estimated date of delivery 
for a more accurate measurement of age. A more appropriate definition is up to 44 weeks post 
menstrual age, where post menstrual age is time from first day of last normal menstrual period 
to day of assessment. This definition has been adopted by the European Medicines Agency 
as outlined in the guideline on the investigation of medicinal products in the term and preterm 
neonate(12).   
It is quite possible that the lack of a clear definition of an ADR is contributing to underreporting. 
The absence of a universally accepted definition combined with recent changes in Medicines 
and Healthcare products Regulatory Agency (MHRA) guidance regarding ADR reporting 
leaves individuals confused about when and what to report, such that the easier option is to 
not report at all(13).  
1.1.2 ADRs as an important health problem  
The importance of ADRs in relation to hospital mortality was highlighted in a systematic review 
suggesting they could be the 4th largest cause of death in the USA(14). The incidence of 
adverse drug reactions that cause admission to hospital is estimated to be 4-7% in the adult 
population(15,16). One of the largest research programmes about ADRs in children to date 
was conducted at Alder Hey Children’s Hospital in Liverpool (ADRIC: Adverse Drug Reactions 
in Children). In this study, 17.7% of inpatient children experienced at least one ADR(17). Of 
the admissions 2.9% were related to an adverse drug reaction(18). Only limited data about 
neonatal admissions related to ADRs exists. Although one of the largest studies of its kind, 
ADRIC only included surgical neonatal care data, at the request of the funder’s peer review. 
There is therefore a need to include tertiary neonatal medical care in future pharmacovigilance 
research. The Adverse Drug Reactions in Neonates (ADRIN) project is an extension to the 
ADRIC study that considers neonates. This study is the first element of ADRIN and focuses 
on methodological issues.  
As well as being an important problem for the health of a population, ADRs contribute to 
healthcare expenditure. A study set in two Merseyside hospitals, Royal Liverpool University 
Hospital and Wirral Hospitals NHS Trust, found that 6.5% of admissions among adults related 
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to an ADR, of which 80% were directly due to the ADR. These admissions accounted for 4% 
of the hospitals’ bed capacity. When extrapolated to the whole NHS, the cost of ADRs was 
estimated to be £466m (2004; €706m, $847m)(15). In an international multicentre study of 
328 identified ADRs in a paediatric population, hospitalisation was increased by an average 
of two days among those children experiencing an ADR compared to those who did not(19).  
1.1.3 Medicines use in neonates 
The clinical speciality of neonatology usually revolves around the care of neonates who are 
born prematurely, who incur illness as a result of labour or delivery, or who have developed 
illness in utero. Sick neonates are often hospitalised for weeks or months after birth and can 
be exposed to multiple medications throughout their time as an inpatient. As with any sub-
specialty of medicine, some medicines are commonly prescribed. The complex and unusual 
illnesses presenting to a neonatal unit, often require a wide range of medicines.   
A linear correlation between the incidence of ADRs and exposure to an increasing number of 
medications has been demonstrated(20). One study conducted in a neonatal intensive care 
unit reported that 29.6% of neonates received more than four medications and 7.6% received 
10 or more(21). Further studies show that up to 90% of inpatient neonates in intensive care 
receive off-label or unlicensed medications, which multiple studies suggest is a risk factor for 
developing an ADR(22-24). There are also some medications which have specific harms in 
neonates (table 1, (11)). Despite emerging data regarding medicines that can be harmful to 
neonates, some of these medicines with published safety warnings are still used in NICUs 
worldwide e.g. meropenem, itraconazole and sulfadiazine, suggesting that the risks need to 
be considered in parallel with the benefits(24).  
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Table 1 Drugs known to cause ADRs that are specific to neonates  
Drug Recognised neonatal ADR 
Ceftriaxone and calcium co-
administration 
Death due to precipitation of ceftriaxone-
calcium salts 
Chloral hydrate Encephalopathy 
Chloramphenicol Grey-baby syndrome due to reduced 
glucuronidation in this age group compared 
to other ages 
Codeine Respiratory depression exacerbated by 
genetic polymorphisms 
Corticosteroids Restricted growth, altered brain 
development, hyperglycaemia 
Kaletra (lopinavir/ritonavir)  Adrenal dysfunction in HIV-infected infants 
Indomethacin Oliguria 
Oxygen Retinopathy of prematurity at high doses 
Sulphonamides Kernicterus due to displacement of bilirubin 
from plasma proteins 
Tolazoline Oliguria 
Vitamin E Sepsis 
Propylene glycol (as an excipient)  Hyperosmolarity, lactic acidosis and 
renal/hepatic toxicity  
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In addition to the associated harms, neonates have unique opportunities to benefit from 
medicines. For example, caffeine is a drug used frequently in neonatal care to treat apnoea of 
prematurity, but it was also found to increase the rate of survival without neurodevelopmental 
disability in children at 18-21 months corrected gestational age(25).     
A recent quasi-systematic review was conducted into medicines use in neonatal intensive care 
units (NICUs) across 12 different countries, including the UK, Ireland and the USA(24). 
Gentamicin and ampicillin were the most commonly cited medicines used, followed by 
caffeine, furosemide and multivitamins. Four other antibiotics were in the top 20 most 
commonly cited medications along with surfactant, dopamine and morphine. The differences 
in medications prescribed between countries was deemed insignificant and the median 
number of medicines prescribed per neonate ranged from three to eleven(24). However, a 
pan-European study found significant differences in the use of antibiotics across 21 countries. 
Differences were apparent in the proportion of neonates receiving systemic antibiotics and the 
dosing of the most frequently used antibiotics(26). In relation to patterns of medications 
prescribed, not all studies included in the quasi-systematic review reported on the same 
influencing factors. Three main observations were drawn from what was described; the 
number of medications prescribed is inversely proportional to gestational age and weight, and 
mortality rate is inversely proportional to gestational age. In agreement with previous research 
the review found 71%-100% of neonates were prescribed unlicensed or off-label medications, 
more often in preterm than term neonates(24).    
A paper outlined the changes in drug utilisation on a NICU between 1997 and 2004(27). The 
analysis revealed significant changes in the drugs used over time on this single NICU, 
including an increased use of antibiotics, cardiovascular, endocrine, gastrointestinal and 
central nervous system drugs. The ophthalmic drugs group was seen to decrease in use. It is 
likely that the increased number of neonates who are surviving preterm birth, and the 
improving detection of congenital abnormalities in utero, is contributing to these changes(27). 
However, the patterns of change across multiple sites worldwide would need to be analysed 
to better explore this.   
1.1.4 Medicines research in neonates 
Historically, medicines research in neonates and young children has been infrequent, with 
many pharmaceutical companies deciding not to include a paediatric population in their trials 
due to difficulty overcoming perceived ethical issues, and the lack of incentive for the extra 
cost and time. Nevertheless, some of the worst tragedies in the pharmaceutical industry 
involved neonates and prompted medicines legislation to encourage and improve medicines 
research for neonates and children. 
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Thalidomide is probably the most widely known of these tragedies. In the late 1950s and early 
1960s, thalidomide was prescribed to pregnant women across Europe, Japan and Australia 
for the treatment of morning sickness. By 1961, the drug had been banned in most countries 
after approximately 10,000 children were born with limb reduction abnormalities. Further 
defects, including heart, eye and ear abnormalities were also ascribed to thalidomide use. 
Laboratory studies had not produced the same effects in mice. Resulting from this tragedy, 
drugs now require systematic developmental toxicity testing in at least two separate species 
before authorisation for market. Thalidomide is used today to treat multiple myeloma and 
leprosy(28).     
Lesser known tragic ADRs include Gray baby syndrome; severe cyanosis, abdominal 
distension and cardiovascular collapse in neonates following treatment with chloramphenicol. 
Reye’s syndrome, which was linked to the use of aspirin in children, is now virtually eliminated 
as a result of reports to the Yellow Card Scheme. There was a period of 81 years, however, 
between first introduction of aspirin into clinical practice and the identification of a causative 
link between its use and Reye’s syndrome(29, 30) .  
The drive to produce better medicines for children has recently included work on designing 
age-appropriate formulations. For example, the practice of crushing a tablet and mixing half 
the powder into food or drink presumes equal distribution of the active ingredient within the 
tablet, as well as increasing the risk of losing active ingredient. There has been limited 
research about the management of age-inappropriate formulations, for example through 
manipulations, despite the widespread use of manipulations. A systematic review of dosage 
form manipulation identified a lack of evidence to support this practice in paediatrics. Of the 
50 studies that were included in the review, only two included paediatric settings and the 
majority of studies detailed tablet manipulations in adults(31). An observational study of drug 
manipulations occurring in three paediatric inpatient settings identified 310 manipulations 
when reviewing the 18 included wards for two weeks each. The highest number of observed 
manipulations occurred in neonatal settings and 68.2% of IV drug manipulations occurred on 
the neonatal wards(32). The need to manipulate medicines for children could also be 
contributing to inappropriate dosing causing adverse effects. Designing medicines for children 
that do not need to be manipulated to allow accurate dosing should be encouraged.    
Legislation 
Over the past few decades the expectation that children should be given medicines suitable 
for their bodies and needs has grown. Without further paediatric medicine development, 
clinicians are too often left with no choice but to prescribe unlicensed or off-label medicines to 
this most vulnerable population.  
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In recent years, regulations have been put in place to attract pharmaceutical companies to 
produce medicines for children, as is the case in the EU and the USA(33). However, 
regulations are only beneficial if they encourage change and improvement. The impact of the 
EU and US regulations is still being examined since they are relatively new, but there is 
evidence to suggest a positive influence. The ‘Physician’s Desk Reference’, used by US 
clinicians for prescribing guidance, has seen a 21% increase in the number of new medical 
entities with paediatric information when comparing 1999 to 2002-2008(34). Over 90% of the 
500 labelling changes approved by the US Food and Drug Administration (FDA) federal 
agency between July 1998 and September 2011 resulted from paediatric studies requested 
under the new regulations. Following the implementation of EU regulations and before the end 
of 2011, 24 Paediatric Investigation Plans (PIPs) led to new paediatrics indications, and 77 to 
new paediatric formulations whilst a further five found medicines inappropriate for use in 
children(35).         
Whilst EU and US regulations have promoted an improvement in paediatric drug research, 
neonates are still not receiving the same benefits as older children and adults, even though 
there is now widespread understanding that they exhibit different pharmacokinetics and 
pharmacodynamics. Following EU regulation until the end of 2011, only 60 of the 395 PIPs 
that were submitted for the opinion of the Paediatric Committee (PDCO) in the European 
Medicines Agency (EMA) included studies in neonates, whilst the remaining 335 sought 
waivers. The PDCO added neonatal inclusion to a further 50 of these remaining PIPs, 
suggesting some companies are not doing enough to attempt to design studies including 
neonates(35). Further studies are needed in the neonatal population to bring their safety of 
medicines in line with that of older children and the paediatric population in general.  
Pharmacovigilance is a prominent part of the regulatory regime in Europe. Pharmaceutical 
companies must file a Risk Management Plan when a market authorisation is granted. This 
ongoing gathering of information about the risk-benefit assessment after authorisation will 
become increasingly important particularly with the rise of adaptive licensing, that is the staged 
approval of medicines(36). In Europe, the Pharmacovigilance Regulation is another important 
development(37). There is a growing need for methods to assess ADRs in neonates and it is 
important to characterise these methods.  
Neonatal drug trials  
Designing clinical trials in neonates faces many challenges for example, the lack of knowledge 
surrounding neonatal pharmacology (drug disposition and pharmacodynamic endpoints), 
particularly that relating to premature neonates. Should these barriers be overcome, there 
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remains the difficulty of using neonatal subjects for interventional research e.g. low blood 
volumes for sampling, difficulty measuring drug concentrations etc(38).  
Recent studies, that have overcome the difficulties in designing a neonatal drug trial, have 
demonstrated the necessity of independent neonatal drug research. Anti-infectives provide 
some examples. Micafungin, an antifungal drug used for candidiasis infections, was 
demonstrated to have much higher total drug clearances in neonates than in older children 
and adults, suggesting a higher mg/kg dose is required in neonates(38). Several trials have 
also been conducted into the use of antibiotics in neonates, namely metronidazole, 
clindamycin, daptomycin, tazocin and meropenem. These studies reported the efficacy, safety 
and the pharmacokinetics of these drugs and how they differ from that known for older children 
and adults. Additionally, these studies show it is important to consider not only a difference in 
pharmacology between neonates and older children or adults, but also a difference between 
preterm and term neonates, and the effects of post-natal age, post-menstrual age and weight. 
These studies, like the limited amount of others of their kind, highlight that it is not valid to 
simply predict pharmacokinetics and pharmacodynamics of a drug based on its properties in 
older children or adults(38).   
1.2 Neonatal pharmacology 
Changes in the human body that occur as a child develops affect how the body handles the 
drug (pharmacokinetics) and responds to a drug (pharmacodynamics). Similarly, a drug has 
the potential to affect the body differently depending on the developmental stage of the body 
at which the drug is introduced. Development from birth to adulthood is a continuous process 
unique to each individual. As a result, it is difficult to categorise children into age groups or 
developmental stages that can be used to advise prescribing. Whilst a person over 18 years 
of age is generally accepted as an adult, it is almost impossible to definitively say when a 
neonate becomes an infant or an infant becomes a child. Prematurity complicates the 
transition from neonate to infant further.  
1.2.1 Absorption 
There are several age-related differences which affect the absorption of a drug in a neonate. 
Neonates have a larger gastrointestinal surface area relative to their size than adults, so have 
a relatively greater area for drug absorption. The neonatal gastrointestinal lining and skin are 
also more permeable at this age meaning drugs that may not be absorbed in a mature body 
could be absorbed in neonates and have the potential to cause harm(39,40). The surface area 
of the skin is similarly larger relative to their size, meaning care should be taken with the 
prescription of topical medicines such as steroid creams. The stratum corneum of neonatal 
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skin is thinner and the skin has a greater blood supply due to an immature vasomotor control. 
The premature neonate exhibits these features even more so(38).  
1.2.2 Distribution 
Protein-binding can dictate the distribution and elimination of a drug, but protein synthesis and 
binding varies with age and maturation. The combination of decreased concentrations of 
circulating proteins, namely albumin and α₁-acid glycoprotein, and a reduced affinity for drug-
protein binding increases the concentrations of circulating drugs. Protein binding is thought to 
increase with age such that the problem of decreased drug-protein binding is even more 
profound in premature neonates. In the typical sick premature neonate, there is also potential 
for drug competition for protein binding if multiple drugs are prescribed. An acidotic state is 
also thought to affect protein binding(40).   
1.2.3 Metabolism 
The majority of drug metabolism in the liver is dependent on cytochrome P450 (CYP) 
enzymes. The type and quantity of CYP enzymes produced varies with time and age (40). In 
addition, the expression and activity of CYP enzymes, which are involved in the metabolism 
of many drugs, have been found to be affected by exogenous substances such as drugs and 
food in adults(41). Blake et al found that neonates who were fed formula feeds had an 
accelerated maturation of the metabolism of certain drugs due to the increased activity of CYP 
enzymes(42). 
1.2.4 Excretion 
Age-related differences in glomerular filtration rate (GFR), renal tubular secretion and 
resorption all contribute to the ability of the kidneys to clear drugs from the blood, and hence 
renal clearance increases with age (gestational and postnatal) and weight. The effect of 
reduced renal clearance is even more pronounced in premature neonates.  Healthy neonates 
usually experience adult GFR by one year of age. The kidneys are not fully developed until 34 
weeks gestation and thus this rise in GFR is initially less steep in premature neonates. Sick 
neonates may be further compromised by reduced renal blood flow from PDAs (patent ductus 
arteriosus) or nephrotoxic drugs such as gentamicin(38). 
1.3 ADRs in neonates 
Due to the difficulties in designing and justifying neonatal medicines research, the practice of 
monitoring the side effects of medicines is paramount as a non-interventional way of improving 
the safety of medicines for this population.  
Pharmacovigilance is defined by WHO as ‘the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug-related 
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problem’(43). Pharmacovigilance should be incorporated into the role of any healthcare 
worker, but the rate at which ADRs are currently reported reflects that this is not the case, 
suggesting that the integration of pharmacovigilance into routine clinical practice needs 
improvement.  
ADRs can be unpredictable, and clinicians should always be vigilant for the side-effects of 
medicines. Detailed history taking, examination, investigation and consideration of risk factors 
and differential diagnoses are imperative as with any diagnosis. Further to this, reviewing 
published literature of ADRs, from case reports to Cochrane reviews, helps the clinician to 
identify any supportive evidence for their suspicions. The use of causality assessment tools 
may also be helpful. Some research has attempted to develop tools that are appropriate for 
use in paediatric settings, but to date few tools exist to specifically assess paediatric ADRs, 
let alone neonatal ADRs.   
ADRs should be reported to appropriate pharmacovigilance regulatory agencies. This aims to 
bring about change and contribute to the drive for safe and effective medicines, as well as 
alerting manufacturers. Anyone can now report an ADR in the UK, including patients and 
parents, but regularly changing guidance over reporting could be a source of confusion 
contributing to the rate of underreporting that is currently suspected.    
1.3.1 ADRs in neonates - incidence 
The ADRIC research programme conducted in Alder Hey Children’s Hospital between 2008 
and 2009 found that 2.9% of admissions were due to ADRs(18). Among children who spent 
more than 48 hours in the same hospital, 18% experienced at least one ADR(17). Both studies 
only included a surgical neonatal setting. ADRs have been found to be responsible for 0.2% 
of neonatal admissions(44). Whilst inpatient stays generate the most medicine use, this 
admissions figure still represents 180 neonates a year in the UK. The incidence in paediatric 
outpatients has been estimated to be much lower(45). A recent prospective observational 
study into ADRs in neonates found an incidence of 17% when 313 neonates were studied in 
13 months(46). The most recent estimate, published in April 2017, was higher at 27.4%(47). 
To provide an accurate estimation of ADR incidence, a large cohort of neonates needs to be 
studied over a considerable period.    
1.3.2 ADRs in neonates - causative drugs 
In the UK between 2001 and 2010, the swine flu vaccine and caffeine generated the most 
neonatal Yellow Card reports (8 and 5 respectively), with a total of 68 different medications 
being suspected to have caused a neonatal ADR. Despite approximately 7% of neonates 
receiving antibiotics to treat infection there was a reporting rate of one antibiotic Yellow Card 
report per year for neonates(6). Thousands of neonates born preterm and term receive 
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surfactant to aid lung function and reduce the need for mechanical ventilation. However, there 
were no Yellow Card reports of surfactant causing an ADR in a neonate between 2001 and 
2010, despite the BNF listing several possible ADRs to surfactant. Though listed as rare, these 
include bradycardia, decreased oxygen saturation, hypotension and pulmonary 
haemorrhage(6,48). A search of the MHRA’s interactive Drug Analysis Profiles shows there 
has only ever been 53 Yellow Card reports for surfactant, 29 filed for colfosceril (exosurf) and 
24 under the general pulmonary surfactants category. Apart from two reports, these were all 
filed in the 1990s. The reports mainly detailed respiratory reactions and 15 reports detailed 
fatal outcomes(49). However, the Drug Analysis Profiles detail all Yellow Card reports but do 
not make commentary on whether the reactions detailed have been proven to be related to 
the drug or not. Belén Rivas et al reported in their recent prospective observational study that 
caffeine citrate, ibuprofen and ferroglycine sulphate generated the highest number of ADRs. 
Antibiotics as a collective group generated a high total percentage of all reported ADRs, and 
antibiotics and caffeine citrate were the drugs prescribed most frequently on the unit(46). 
Systemic anti-infectives were also the drugs most frequently suspected to have caused an 
ADR in a recent observational study in neonates in Columbia(47).    
A recent review paper detailed several drugs which are uniquely harmful to neonates, 
exemplifying the danger of extrapolating understanding about the side-effects of drugs in 
adults or children(11). Verapamil is used to treat supraventricular tachycardia in adults, so was 
presumed safe for the same indication in neonates. Its use for this indication has been stopped 
since it was associated with a series of infant deaths(40).  
It is not only the active ingredient in drugs which can cause an adverse drug reaction. An 
excipient is a substance that is contained within the drug to help with the stability, solubility or 
form of the drug itself yet still has pharmacodynamic potential. A recent study conducted in 
Estonia identified that 97% of 348 neonates included in the study received at least one 
excipient classified as being potentially harmful and 88% of the neonates received at least one 
of the excipients known to be harmful specifically to neonates(50). Of the medicines prescribed 
on the two units included in the study, 68% contained excipients classified as being potentially 
harmful(50).   
This study however was conducted in one country only and prescribing practises may differ 
elsewhere. A pan-European observational study into the potentially harmful excipients in 
neonatal medicines included 21 countries. Of the 2095 prescriptions that were analysed, 31% 
contained at least one of the eight potentially harmful excipients that this study looked at, the 
most frequent of these being parabens. The prescriptions were administered to 63% of the 
neonates studied. The study also reported that geographical region determined the frequency 
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of prescription of four of the eight potentially harmful excipients, suggesting that alternative 
safer options are available and could be used to avoid side-effects(51). These studies 
identified that neonates are prescribed potentially harmful excipients but did not investigate 
whether any harmful adverse reactions occurred due to the prescriptions. Credible reports of 
suspected neonatal adverse drug reactions to excipients do exist elsewhere(52).   
There are further sources of ADRs to be considered in neonates including those drugs 
administered to the parents of the neonate pre-conception, in pregnancy, in labour and during 
breast feeding.  
Medication use in pregnancy 
A recent multinational cross-sectional web-based study found that 81.2% of women reported 
using at least one medication in pregnancy(53). Reports suggest that exposure to medications 
from a maternal source causes a significant portion of ADRs in children under two(54). A 
recent retrospective review of Yellow Card reports between 2001 and 2010 reported that there 
were 248 reports of transplacental ADRs detailing 221 different medications. Fluoxetine was 
the most commonly reported medication and 16 different psychotropic medications produced 
just over 100 reported reactions(6).  
Medication use whilst breastfeeding 
In the same retrospective review of Yellow Card reports, fluoxetine was also the most 
commonly reported drug in cases of suspected transmammary ADRs(6). A recent literature 
review of neonatal and infant ADRs to drugs in breast milk identified case reports of reactions 
to 45 different medications, all of which were identified as being probable or possible adverse 
drug reactions using the Naranjo algorithm(55). As with all ADRs, the clinical signs and 
symptoms of the reaction may not be evident immediately. In this review some of the reactions, 
such as hyperactivity and speech delay, only became apparent when the child was over four 
years old(55). 
Fathers using medication at time of conception 
Medications prescribed to fathers preconception are also a source of adverse drug reactions 
in foetuses or neonates. Hawcutt’s review of Yellow Card reports between 2001 and 2010 in 
the UK identified three reports detailing six reactions to four paternal drugs, all of which were 
reported by doctors. The four drugs reported were all used to treat autoimmune conditions 
and were suspected to have caused growth retardation, diarrhoea, developmental delay, 
hypotonia, fetal cardiac abnormality and development of a birth mark(6). However, a recent 
prospective observational multicentric study conducted in Italy followed the pregnancies and 
neonatal outcomes related to fathers with multiple sclerosis exposed and not exposed to 
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disease-modifying drugs at time of conception. The study found no significant association 
between fathers taking disease-modifying drugs and risk of spontaneous abortion or 
malformations. The length of time the children born in this study were followed up for varied 
from 0.1-10.7 years, thus little commentary can be made on the long term effects of paternal 
drugs taken around the time of conception(56). This is an area of pharmacovigilance that may 
offer more information with further investigation.  
Maternal use of recreational and illicit drugs  
Recreational and illegal drugs can also cause adverse drug reactions in the unborn child, 
some of which may not become apparent until the child is older. The effects of alcohol and 
tobacco are probably the most widely understood, and frequent media coverage and changing 
guidance means most women will aim to avoid both in pregnancy. Prenatal tobacco exposure 
has been shown to increase the risk of the child developing hearing difficulties, respiratory 
disease and metabolic disease. Alcohol consumption during pregnancy puts the unborn child 
at risk of Fetal Alcohol Spectrum Disorder which cannot be diagnosed until the effects can be 
assessed once the child is born. The spectrum includes a range of symptoms including pre 
and postnatal growth restriction, craniofacial abnormalities, hyperactivity and learning 
difficulties (57).  
In the case of illicit drug use it may be difficult to determine fetal effect for several reasons; 
lack of scientific understanding, concomitant drug use, other life style factors and parental 
honesty regarding use during pregnancy. In the case of prenatal cannabis exposure, the 
currently existing three prospective observational studies only agree on one result, that 
prenatal cannabis exposure seems to predispose affected offspring to aggressive and 
impulsive behavior(57). Behaviour is hard to measure objectively and may also be affected by 
lifestyle factors.       
1.3.3 ADRs in neonates - reaction characteristics 
Neonates show different signs and symptoms of adverse drug reactions in comparison to older 
children and adults. The development of a child from conception to adulthood is dynamic, and 
changes in organ function and body composition affect pharmacodynamics and 
pharmacokinetics.  
The retrospective review of Yellow Card reports in neonates between 2001 and 2010 showed 
the most common reactions to be rashes, erythema, bradycardia, convulsions and 
tachycardia, but whether or not this is an accurate reflection of the ADRs suspected in day to 
day practice is uncertain(6).  
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Belén Rivas et al reported feeding intolerance, phlebitis and tachycardia to be the most 
commonly suspected ADRs in their prospective study, with central hyperactivity, constipation 
and thrombocytopenia next most frequently reported with eight reports each. Whilst some of 
the serious reports in this study could be considered like those in adults, e.g. liver and renal 
failure, those that are neonate-specific are equally serious, such as necrotising enterocolitis. 
The parameters by which an ADR is defined will also differ in neonates compared to older 
children and adults. A heart rate of 64 beats per minute is within normal range for an adult but 
would be considered extreme bradycardia in a neonate and may be due to a drug, as 
suspected with morphine chloride(46). Table 2 outlines the results of three recently published 
papers which detail drugs documented to have caused ADRs in neonates.  
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Table 2 Number of ADRs by subtype seen in three studies 
Clinical presentation Study Total number of Neonatal 
ADRs reported in study 
Proportion of ADRs with 
this clinical presentation 
reported 
General disorders + 
administration site disorders 
Kaguelidou 2016 3127 12.5% (391) 
Feeding intolerance Rivas 2016 116 16.3% (19) 
Local reaction Hawcutt 2016 97 4.1% (4) 
Malaise Kaguelidou 2016 3127 1.5% (47) 
Phlebitis Rivas 2016 116 8.6% (10) 
Blood and lymphatic system 
disorders 
Kaguelidou 2016 3127 11.9% (373) 
Anaemia Rivas 2016 116 0.8% (1) 
 Kaguelidou 2016 3127 2.9% (91) 
Neutropenia Kaguelidou 2016 3127 4.0% (128) 
Thrombocytopenia  Rivas 2016 116 11.2% (13) 
Cardiovascular disorders    
Bradycardia Rivas 2016 116 0.8% (1) 
 Hawcutt 2016 97 6.1% (6) 
 Kaguelidou 2016 3127 1.9% (62) 
Cardiac arrest Hawcutt 2016 97 3.0% (3) 
Hypertension Rivas 2016 116 5.1% (6) 
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Clinical presentation Study Total number of Neonatal 
ADRs reported in study 
Proportion of ADRs with 
this clinical presentation 
reported 
Hypotension Rivas 2016 116 0.8% (1) 
 Hawcutt 2016 97 3.0% (3) 
Tachycardia Rivas 2016 116 8.6% (10) 
 Hawcutt 2016 97 5.1% (5) 
Respiratory disorders    
Bradypnoea Rivas 2016 116 0.8% (1) 
Decreased oxygen saturations Hawcutt 2016 97 3.0% (3) 
Dyspnoea Hawcutt 2016 97 3.0% (3) 
Gastrointestinal disorders Kaguelidou 2016 3127 8.1% (255) 
Constipation Rivas 2016 116 6.8% (8) 
Gastrointestinal haemorrhage Rivas 2016 116 3.4%(4) 
NEC Rivas 2016 116  1.7% (2) 
 Hawcutt 2016 97 3.0% (3) 
Hepatobiliary disorders    
Jaundice Rivas 2016  116 6.0% (7) 
Liver failure Rivas 2016 116 6.0% (7) 
Renal and urinary disorders    
Renal failure Rivas 2016 116 1.7% (2) 
Nervous system disorders Kaguelidou 2016 3127 7.8% (245) 
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Clinical presentation Study Total number of Neonatal 
ADRs reported in study 
Proportion of ADRs with 
this clinical presentation 
reported 
Central hyperactivity Rivas 2016 116 6.8% (8) 
Convulsion Hawcutt 2016 97 5.1% (5) 
Prolonged neuromuscular 
blockade 
Rivas 2016 116 0.8% (1) 
Metabolic disorders    
Hyperglycaemia  Rivas 2016 116 0.8% (1) 
Lactic acidosis Kaguelidou 2016 3127 2.1% (66) 
Dermatological disorders    
Erythema Hawcutt 2016 97 7.2% (7) 
Pruritis Hawcutt 2016 97 3.0% (3) 
Rashes Hawcutt 2016 97 14.4% (14) 
Investigation results Kaguelidou 2016 3127 8.0% (251) 
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1.3.4 ADRs in neonates - risk factors   
A better understanding of the factors which may predispose a neonate to suffer an ADR would 
raise awareness in care teams and help to plan to prevent ADRs in those most vulnerable.  
Although not neonate-specific, an international multicentre study conducted by Rashed et al. 
provided an insight into potential risk factors associated with ADRs in children. They concluded 
that age and gender are not associated with ADR incidence in children. Considerable 
commentary was provided on drug groups causing ADRs. Analgesics, anti-epileptics, 
antibacterials and antimycotics for systemic use, corticosteroids for systemic use and 
immunosuppressant agents (as classified by ATC classification) were defined as high-risk 
drugs in this study. These groups of drugs are all used in neonatal care. The number of high-
risk drugs prescribed was higher per patient in those children experiencing an ADR compared 
to those children who did not. The prescription of three or more high-risk drugs was deemed 
a strong predictor of ADR occurrence, as was the prescription of five or more low-risk drugs 
(19). A study conducted in the 1970s found 29.6% of neonates in the NICU received five or 
more medications(21). It is likely this number has increased now due to the introduction of 
more drugs for neonatal care and more neonates surviving preterm birth.   
As well as high numbers of drugs, literature reviews, cohort and control studies have 
suggested an increased incidence of ADRs in patients receiving unlicensed or off-label drug 
prescriptions (58–61). It has been estimated that up to 90% of neonates in a NICU may receive 
unlicensed or off-label drugs due to the lack of clinical trials including neonates(58)(62).   
1.3.5 ADRs in neonates - current reporting practices 
The UK pharmacovigilance system called the ‘Yellow Card Scheme’ was founded in 1964 by 
the MHRA and the Commission on Human Medicines after the tragedy of thalidomide left 
thousands of children with phocomelia. Since its introduction, the scheme has facilitated the 
spontaneous reporting of ADRs, which in turn has improved pharmacovigilance and thus 
influenced change in prescribing. However, despite these efforts, the suspected rate of 
underreporting for ADRs in all populations is estimated to be approximately 95%(7)(63)(64). 
Until recent years, the MHRA requested the reporting of all ADRs in children, in contrast to 
reporting only those considered most serious and severe in adults. In September 2014, the 
MHRA published a ‘Drug Safety Update’ outlining updated guidance to only report ADRs in 
children that are considered to be ‘serious or result in harm’, but even prior to this change 
reporting was low(6). This change was in response to feedback regarding the impracticalities 
of reporting all ADRs in children(13). Comments on this change refer to the positive impact of 
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bringing paediatric advice in line with that of adults; combating reluctance to report and aiming 
to improve the quality and quantity of paediatric ADR reports(29).  
The Yellow Card Scheme is not specifically designed for the reporting of ADRs suffered by 
neonates, and the need for a population-tailored method is apparent. The current scheme 
does not measure all outcomes needed to assess an ADR in this population. In the ten year 
period between 2001 and 2010, only 1% of 3496 ADR reports submitted for children less than 
two years of age recorded a gestational age, a factor that is understood to impact 
pharmacodynamics and kinetics(6). Some neonatal ADRs are being reported through the 
Yellow Card Scheme but to date no clinical warnings issued by the MHRA appear to have 
been influenced by those reports submitted in the UK(6).  
The ADRIC research programme observed an increasing ADR risk with increasing age of the 
child. However, the investigators hypothesised the reason for this was multifactorial and 
confounded by underreporting. Neonates and young children cannot communicate their 
symptoms and thus ADRs such as pain and nausea can be difficult to recognise. Some signs 
and symptoms are dismissed as being normal characteristics of children of a certain age, such 
as vomiting or irritability in neonates(17).  
1.4 Evaluating ADRs in neonates 
Ideally, the identification, reporting and evaluation of ADRs in any population should be a 
routine part of day to day clinical care. Neonates are sufficiently different from older patients 
such that the key variables concerned with ADRs in this population may not be of importance 
in older children or adult populations, and hence a neonate-specific approach is desirable. 
Examples of the important variables in neonates include age and weight.  Age is less important 
in mature adults but what is understood about pharmacokinetics and pharmacodynamics in 
preterm and term neonates suggests age to be of great importance for ADR evaluation in 
neonates. Weight in an adult is usually straightforward, but can be complex in neonates, 
including birth-weights, daily weights and working weights. The usual relationships in 
childhood between age and weight also break down, as in neonatal care weight and age are 
not always directly proportional.  
A low threshold for suspecting and reporting ADRs in neonates is paramount to improving 
pharmacovigilance in this population. Suspected ADRs need to be evaluated in several ways 
including causality, severity and avoidability. There are many ways to do each of these 
evaluations. 
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1.4.1 Causality 
Causality assessment is an important aspect of evaluating any ADR. The use of a causality 
assessment tool enables a structured and replicable assessment to be carried out which limits 
disagreements between assessors. Such tools may be used on an individual level by a 
suspecting clinician, but are also used by regulatory agencies such as the MHRA for the 
evaluation of ADR reports(65). Over 50 years ago Sir Austin Bradford Hill defined the aspects 
of association he considered to be important when evaluating the likelihood of causation, not 
specifically for ADRs, but for all biomedical topics(66). Whilst many causality assessment tools 
have been developed since these suggestions, few have been developed to be suitable for 
the paediatric population. 
The Naranjo algorithm is a widely-used causality assessment method. In the ADRIC research 
programme however, it was concluded that the Naranjo algorithm was not suitable to be used 
to assess paediatric ADRs. Consequently a new tool was developed for children and when 
compared to the Naranjo algorithm showed greater inter-rater reliability(65). The Liverpool 
ADR causality assessment tool (LCAT) produced in ADRIC has not been assessed in 
neonates. A neonatal modification of the Naranjo algorithm was developed recently in one 
centre but this has not been validated in another site(67). 
1.4.2 Severity 
A clinician’s decision to stop or reduce the dose of a drug causing an ADR may be affected 
by the severity of the ADR and a risk-benefit assessment. The team who conducted the ADRIC 
study used the Hartwig severity scale to assess the severity of the ADRs occurring in the 
paediatric inpatient population and those patients admitted due to an ADR. The team of 
investigators reported that whilst the Hartwig severity scale was easy to use, it may not be 
appropriate for assessing paediatric ADRs. In ADRIC’s first study, a pilot study looking at 
ADRs causing admission to a paediatric hospital, the investigators deemed every child that 
was admitted to the hospital due to an ADR as ‘needing treatment’. This meant that all ADRs 
were given a severity rating of at least 3, even if once the child had been admitted no active 
treatment or withdrawal of the suspected drug was actually needed(68).  
Opinions regarding an ADR’s severity will differ between clinicians, whether using assessment 
tools or not. The views of the patients experiencing them are also likely to be different in many 
cases. This difference could be even more profound in the paediatric population who may be 
easily distressed by the effects of an ADR, and in their parents who stand witness. ADRIC 
recognised this in a larger inpatient study and subsequently investigated parent views on 
ADRs(17,69).  
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The severity of ADRs may not be entirely apparent in neonates, making this hard to assess. 
Some long-term effects may not appear until several years after the event.  A severity score 
for assessing ADRs in neonates has recently been developed by the International Neonatal 
Consortium but has not yet been validated in any population.  
1.4.3 Avoidability 
Assessing the avoidability of an ADR contributes to clinician education, overall assessment of 
case management and the evaluation of different treatment options. Hartwig also developed 
a preventability questionnaire consisting of four questions(70). The ADRIC research 
programme used the Hallas scale of avoidability in the pilot study and found 33% of the ADRs 
causing admission to hospital ‘possibly avoidable’, though none could be deemed ‘definitely 
avoidable’. The team of investigators thought the classifications in the tool were too broad. In 
the larger study of ADRs causing paediatric admissions just over one fifth of the ADRs were 
deemed to be definitely or possibly avoidable, and this figure increased when analysing only 
the ADRs not associated with oncology patients(18). The decision was made in the inpatient 
ADRIC study not to assess avoidability of the ADRs due to the absence of an appropriate tool 
suitable to assess the cases(17). As a result of this research programme, a paediatric 
avoidability tool was developed. Whilst the tool was designed to be appropriate to use to 
assess paediatric ADRs, its use is not limited to the paediatric population. It has not yet been 
validated in neonates(71). 
1.5 Conclusion 
In conclusion, the identification and evaluation of ADRs in neonates, with the aim of improving 
the safety of medicines, is far behind the standard in older populations. The pharmacokinetics 
and pharmacodynamics exhibited by neonates differ to those in older children and adults. 
Therefore, neonates require their own medicines and will exhibit different ADRs, but the 
practice of monitoring the side-effects of medicines is haphazard and is not influencing 
change. The current method of reporting ADRs does not collect all the information needed to 
assess a neonatal ADR and thus the rate of underreporting seen using currently available 
methods is substantial. This is unsatisfactory for several reasons. Despite the legal initiatives 
that aim to encourage further work, the lack of research into medicines for neonates means 
many will receive unlicensed or off-label medicines for which there is little information about 
safety. Because of this, ADR reporting in this vulnerable population should take an even higher 
priority. ADRs are an important health problem which cost significant money, but the lack of 
pharmacovigilance, both in routine practice and research, means knowledge about neonatal 
ADRs is lacking. What is beginning to be understood is that the incidence of ADRs in neonates 
is significant, they are characteristically different to those in adults, and occur because of 
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different risk factors and drugs from different sources. To increase understanding, the 
evaluation of neonatal ADRs that are identified is very important, but less research has been 
done into how to do this in neonates. There are multiple tools to use for this but very few are 
designed for paediatric populations, and adult tools have rarely been tested for their use in 
children or neonates. The use of inappropriate assessment tools could be leading to the 
generation of inaccurate and unreliable data. It is important that pharmacovigilance research 
now expands to include optimising the evaluation of neonatal ADRs, as well as their 
identification.    
1.6 Aims and objectives 
In order to address the issues outlined above, the aim of this study was to improve the 
understanding and assessment of neonatal ADRs.  
In order to meet this aim, the study set the following objectives 
Primary objective: 
To generate prospective neonatal ADR data to allow the comparison of several causality tools 
in the neonatal setting 
Secondary objectives: 
a) To make preliminary estimates of the frequency and incidence of ADRs in neonates 
admitted to the NICU at Liverpool Women’s Hospital over a nine-week period 
b) To describe the ADRs occurring in the neonatal population 
c) To consider how reporting of ADRs in a neonatal setting may be improved including 
trialling a neonate-specific surveillance system  
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Chapter 2: Systematic review protocol 
In the early stages of the project, a protocol for a systematic review of ADRs in neonates was 
developed and can be found below. The search strategy was tested in four databases and the 
results found in the search at the end of 2016 are included below.  
2.1 Objectives 
 
Primary:  
a) To investigate the characteristics of adverse drug reactions that occur in neonates 
 
Characteristics will be defined by recording the following data from studies: 
• Clinical presentation of the ADR  
• Corrected gestational ages of neonates at time of experiencing ADRs 
• Gestational ages at birth of neonates experiencing ADRs 
• Weights of neonates at time of experiencing ADRs 
• Birth-weights of neonates experiencing ADRs 
• Risk factors considered for neonates developing ADRs 
• Outcomes of ADRs 
• Severity of ADRs 
 
b) To investigate which drugs most commonly cause adverse drug reactions in neonates 
 
Drugs will be defined by recording the following data from studies: 
• Name of drug 
• Class of drug (by Anatomical Therapeutic Chemical classification) 
• Unlicensed/off-label status 
• Route of administration 
• Concomitant medications 
 
Secondary: 
a) To investigate the frequency/incidence of adverse drug reactions in neonates as 
reported in previous studies 
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2.2 Review question development 
The following concepts were considered when designing the research question for this 
systematic review 
Adverse drug reactions in neonates 
Concept 1 Concept 2  Concept 3 Concept 4 
Neonates Adverse drug 
reactions 
Pharmacological 
interventions 
Observational studies 
 
2.3 Evidence gathering and study selection 
2.3.1 Evidence gathering 
There will be four techniques used for gathering evidence 
 
• Database searching 
Databases may be searched using a pre-determined strategy (table 3) 
searching all fields available 
• Contact with experts 
Experts in the field of ADRs in neonates will be contacted via email to discuss 
access to any published or unpublished work not returned by the database 
search for use in the review 
• References searching 
Following on from database searches the references of relevant papers will be 
searched in order to identify any potential papers not returned by the original 
database search 
 
All identified literature will be exported for online storage via Mendeley referencing software. 
This will aid with the exclusion process and management of references during the review.  
 
2.3.2 Eligibility criteria 
• Types of studies 
Included studies: observational studies studying ADRs in neonates including 
both retrospective and prospective studies in any setting 
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Studies will be eligible from any year of publication from any country of 
publication 
Observational studies studying ADRs in a larger paediatric population where it is 
possible to define the included neonatal population and data is provided on the 
neonatal population alone will also be included 
Excluded studies:  
Observational studies looking at ADRs in a paediatric paper where it is not 
possible to define the included neonatal population and/or data is not provided 
on the neonatal population alone 
Studies not written in English will only be excluded once reasonable effort has 
been made to obtain a translation 
• Types of participants 
Neonates in any setting- neonates born premature will be included in the review 
however neonates more than 28 days post their estimated date of delivery will 
be excluded. This definition will allow for the inclusion of neonates born preterm. 
• Types of interventions 
Adverse drug reactions to any medication, including aromatherapy, homeopathy 
and natural/herbal remedies. This will include exposure to drugs pre-conception, 
in pregnancy, during labour and through breast feeding.  
Any clinical event which meets the definition of an ADR used in this review as 
defined by Allegaert et al as ‘an unintended and harmful effect resulting from the 
use of medications intended for diagnostic or therapeutic reasons (irrespective 
of the dose)’(10).  
2.4 Paper exclusion and data extraction 
2.4.1 Paper exclusion method 
Review at title level: 
• Exclude if does not study human participants 
• Exclude if does not include any of the concept 1 synonyms in the title 
• Exclude if does not include any of the concept 2 synonyms in the title 
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Review at abstract level:  
• Exclude if not deemed relevant to review i.e. the keyword relating to concept 3 should 
refer to a pharmacological intervention and not any other kind of intervention e.g. 
surgical or procedural 
 
Review at full publication level:  
• Does the paper study a population as defined by ‘babies born at any gestation who 
are not more than 28 days post their estimated date of delivery’- exclude if this 
population is not studied or if it is not possible to extract data on this population alone 
if included in a larger paediatric population 
 
Reasons to exclude at the abstract and full publication stage will be will be documented. 
A sample of 10% of the excluded papers will be reviewed by the supervisor using the 
above methods to ensure valid exclusion has taken place by the research student. Any 
disagreement will be followed up involving a third reviewer if necessary. Any papers with 
uncertain inclusion or exclusion will be reviewed by the educational supervisor(s) and 
decided by discussion between the research team.   
2.4.2 Data extraction 
Following the identification of appropriate literature, each paper will be summarised and 
evaluated using a predefined paper evaluation form. Data will be extracted using a data 
extraction form created by the researcher to enable relevant data extraction. 
The following data will be extracted for each study meeting the inclusion criteria: 
Study characteristics: 
• Country 
• Year conducted  
• Duration  
• Number of sites  
• Design  
• Clinical setting  
• Number of neonates  
• Whether neonates included as part of larger paediatric population 
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Identification of ADR: 
• Definition of ADR used  
• Definition of drug exposure used (included details of whether maternal/paternal 
exposure and breast feeding were considered) 
• Incidence definition and calculation (if included) 
• Details of any causality assessments carried out 
• Details of any severity assessments carried out 
• Details of any avoidability assessments carried out 
• Who conducted the assessments 
• Methods used to identify and report ADRs 
 
Information relating to the ADR: 
• Clinical presentation 
• Associated drugs/drug classification  
• Associated risk factors identified 
 
Once this data has been extracted it will be stored on a password-controlled predesigned 
spreadsheet on a University or personal computer.  
2.4.3 Assessment of methodological quality of included studies: 
In a recent research programme conducted in Merseyside (the Adverse Drug Reactions 
in Children programme), a quality assessment form for critically appraising observational 
studies of adverse drug reactions was created specifically for the systematic review. This 
form will be used in this new systematic review. It takes into consideration study design, 
ADR identification method and causality, severity and avoidability assessments(4).   
2.5 Dissemination 
Results of this systematic review will be: 
• reported to Trust bodies 
• presented at regional meetings 
• submitted to MHRA 
• submitted for publication by peer-reviewed journals. 
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Table 3 Pre-determined search strategy for systematic review 
Pre-determined search strategy  
Concept 1 
1. neonat* 
2. Exp neonate 
3. Exp newborn 
4. (neonat* or newborn* or new born* or new-born* or baby or babies) 
5. Exp child 
6. Exp adolescent  
7. (young adj 2 (person* or people or adult* or individual* or women or woman or 
men or man)).ti,ab. 
8. Exp student* 
9. Puberty/  
10. Paediatrics/ 
11. Pediatrics/ 
12. (infan* or child* or schoolchild* or kid or kids or toddler* or adoles* or teen* or boy* 
or girl* or minor* or juvenile* or youth* or kindergar* or nurser* or puber* or 
prepuber* or pubescen* or prepubescen* or pre pubescen* or paediatric* or 
pediatric* or schoolage*).ti,ab.  
 
Concept 2 
1. side-effect*.ti,ab. 
2. Side effect*.ti,ab.  
3. (drug induced or drug related or drug safety).ti,ab 
4. tolerability.ti,ab. 
5. harm*.ti,ab. 
6. adrs.ti,ab. 
7. (adverse adj2 (effect or effects or reaction or reactions or event or events or 
outcome or outcomes)).ti,ab  
8. (toxic adj3 (effect* or reaction* or event* or outcome*)).ti,ab 
9. exp product surveillance, postmarketing or exp adverse drug reaction reporting 
systems or exp drug toxicity or exp abnormalities, drug induced or exp drug 
hypersensitivity 
Concept 3 
1. (drug* or pharmaceutical* or medicin* or intervention*).ti,ab. 
2. pharmaceutical preparations 
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3. (herbal* or plant* or herb* or aromatherap* or aroma therap* or homeopath*).ti,ab. 
4. Medicine, Chinese Traditional/ or Plant Preparations/ or Plants, Medicinal/ or Plant 
Extracts/ or Drugs, Chinese Herbal/ 
5. Aromatherapy 
Concept 4 
1. Health Care Surveys 
2. Retrospective studies 
3. Prospective studies 
4. Cohort studies 
5. Observational stud*.ti,ab. 
6. (prospectiv* adj3 review*).ti,ab. 
7. (prospectiv* adj3 stud*).ti,ab. 
8. (retrospectiv* adj3 review*).ti,ab. 
9. (retrospectiv* adj3 stud*).ti,ab. 
10. population-based stud*.ti,ab. 
11. cohort stud*.ti,ab. 
12. incidence stud*.ti,ab. 
13. Sn.fs 
14. Epps’s 
15. monitor*.ti,ab. 
16. Surveillance.ti,ab. 
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Table 4 Test run of search strategy using four databases 
 
  
Scopus original 
articles returned: 
11,076 
 
PubMed original 
articles returned: 
5227 
ScienceDirect 
original articles 
returned: 1,372 
Web of Science 
original articles 
returned: 27  
Scopus articles after 
article type limitations 
applied: 10,750 
PubMed articles 
returned after article 
type limitations 
applied: 5205 
ScienceDirect 
articles returned 
after article type 
limitations applied: 
1,372311 
Web of Science 
articles returned 
after article type 
limitations applied: 
n/a 
Scopus articles after 
duplicates removed: 
10609  
PubMed articles 
after duplicates 
removed: 5199 
ScienceDirect 
articles after 
duplicates 
removed:1353 
Web of Science 
articles after 
duplicates 
removed: 24 
Total number of combined articles: 17185    
Total number of combined articles after duplicates removed: 12289 
Remaining papers after exclusion at title level: 
Remaining papers after exclusion at abstract level: 
Remaining papers after exclusion at full paper level: 
Final number of papers (including re-inclusion papers):  
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Chapter 3: Methodology 
Due to the highly demanding and emotive nature of neonatal care, ADR reporting is often 
overlooked in day to day practice. There is an aspect of educated guesswork in neonatal 
prescribing due to the lack of inclusion of children, infants and neonates in drug trials, and so 
thorough pharmacovigilance in this population should be a part of good clinical practice. 
Though the benefits of improving reporting are clear, it is important to consider the costs too. 
There are financial costs of introducing new protocols, resources and jobs but also costs to 
the workload and morale of staff and families already facing a difficult experience.   
To be able to generate prospective neonatal ADR data, careful consideration of methodology 
to effectively identify, record and evaluate neonatal ADRs was needed. Proposed methods 
needed to be effectively integrated into neonatal care, whilst utilising the addition of an 
independent researcher. To begin to understand how reporting and evaluating ADRs in 
neonates can be improved, this study trialled the implementation of a neonate-specific ADR 
data collection proforma, used by a standalone researcher prospectively observing for 
neonatal ADR cases. These cases were then used to evaluate causality assessment tools to 
determine their use for assessing neonatal ADRs.   
3.1.1 Study setting 
This study was conducted at the University of Liverpool and the clinical site of Liverpool 
Women’s Hospital, Richard Cooke Neonatal Unit. The unit is a tertiary neonatal unit with 44 
cots; 12 for intensive care, 12 for high dependency care and 20 for low dependency care. The 
unit treats neonates born prematurely or with medical or surgical conditions requiring 
treatment from the North West of England, North Wales, Isle of Man and the rest of the UK(1).    
3.1.2 Study introduction  
From October 2016, the researcher attended the neonatal unit and the daily ward rounds and 
handovers to introduce the study to the NICU staff. Efforts were made to introduce the study 
to the majority of staff individually, who were encouraged to ask questions. Advice was sought 
from the unit’s neonatal research nurses who helped in the introduction and advised effective 
ways of disseminating information regarding the study.    
In addition to this, the study was formally introduced to staff with a presentation and Q&A 
session at the following meetings: 
Senior nurse meeting: 11th October 2016  
Clinical Governance Day: 22nd November 2016  
Consultants meeting: 29th November 2016 
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These formal presentations were in addition to informal day to day conversations with ward 
staff and posters and flyers about the study displayed in staff areas. Staff include Health Care 
Assistants (HCAs), neonatal nurses, advanced neonatal nurse practitioners (ANNPs), junior 
doctors, consultants, researchers and pharmacists.  
3.1.3 Study materials design 
To begin data collection, it was necessary to create a data collection proforma to collect all 
the information needed to reliably evaluate a neonatal ADR.  
The creation of the data collection proforma took several weeks and several versions were 
adapted before the final version was reached. Firstly, all fields that are included in a Yellow 
Card report form were outlined. Some required adaptation to enable the collection of neonate-
specific data, such as age and weight. Other areas were expanded upon to collect further 
relevant information, for example, extra fields added into medical history to ensure information 
was also collected regarding labour, pregnancy and maternal history. The ‘Council for 
International Organisations of Medical Sciences’ suspected adverse reaction report form, 
which is frequently used to report ADRs occurring in clinical trials, was also consulted and 
additional fields added to the data collection proforma.    
Following this, the proforma was discussed with neonatal consultants, nurses and research 
nurses, as well as the pharmacists who worked on the ADRIC project. Further adaptations 
were made to the proforma following their suggestions, many of which were regarding the 
usability of the tool, for example, how to record changes in laboratory investigations.  
Finally, when the three causality assessment tools that were to be evaluated had been decided 
upon, these were reviewed to make sure the data collection proforma would collect all the 
information necessary to use these tools. Some fields were added for this, for example, a field 
prompting commentary on the existence of any positive re-challenges or histories.   
The method of identifying neonatal ADRs, using the data collection proforma when attending 
NICU ward rounds and following up cases from patient notes, was piloted during October and 
November 2016. Further adjustments were made to the proforma following the piloting of the 
data collection. Version 9.0 was used as the final version in the study, a copy of which can be 
seen below. The proforma was converted into an excel spreadsheet to enable the inputting of 
data directly into the computer where possible.  
An ‘ADR alert form’, for use by any NICU member of staff to alert the researcher to suspected 
ADR cases, was also designed. This can be found in appendix 2.
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3.2 ADR case collection 
3.2.1 Participants 
Neonates admitted to the neonatal unit between 30th January and 31st March 2017 were 
considered for inclusion in the study. Neonates were eligible provided they were no more than 
28 days post-term for corrected gestational age at the time of recruitment to the study. This 
included neonates who were already inpatients on the unit when the data collection period 
began. Although previous studies have collected data on all neonates or children admitted to 
a unit, this study only recruited and collected data on neonates who were suspected to have 
suffered an ADR. This decision was made because the study aimed to compare causality 
assessment methods and this required detailed ascertainment of the course and outcome of 
neonatal ADR cases. Although data was not collected regarding those neonates not 
experiencing an ADR, the researcher kept brief anonymised handwritten notes regarding the 
ongoing care of each neonate for record should they later experience a suspected ADR.  
A formal sample size calculation was not performed as this study was an exploratory analysis 
rather than a hypothesis test, and the project was time-limited. To characterise tools used to 
evaluate suspected ADRs in neonates, the study needed to collect enough suspected ADR 
cases. Previous work has used between 50 and 100 cases of ADRs to do this(65)(67). 
3.2.2 ADR case data collection 
The data collection period was nine weeks long from 30th January to 31st March 2017. The 
daily NICU handover and ward round were attended by the researcher four times a week, 
usually Monday, Tuesday, Thursday and Friday. On these four days, the ward round for the 
intensive care cots was monitored three times and the ward round for the high-dependency 
and low-dependency beds once. The unit also has eight transitional care cots but these were 
not monitored.  
The purpose of attending the daily handover and ward round was to allow the researcher to 
monitor the care of the neonates on the NICU, focussing on drug prescription and possible 
symptoms of ADRs. During the ward round the researcher could listen to staff conversation, 
ask questions and review drug charts. 
Following the ward round a daily structured review was undertaken of neonates’ notes on 
BadgerNet, the electronic patient notes database used on the LWH NICU. An outline of the 
steps undertaken in a structured review can be found below. The notes of neonates suspected 
to be suffering from an ADR were reviewed first and other notes reviewed with any remaining 
time.  
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Structured review guidelines 
COMPLETING A DAILY STRUCTURED CLINICAL REVIEW OF A NEONATE 
Following attendance at either ITU/HDU ward round a structured clinical review of neonates’ 
notes should be undertaken. This document provides guidance on how this may best be done.  
Step 1: problem focussed:   
Complete a Suspected ADR form where appropriate
All suspected cases should be reported, even if mild, unlikely 
or uncertain
If an ADR is now suspected review full notes to consider this further
Consider:
- What alternative reasons are there for this clinical problem?
- Does the pattern of the ADR fit with the time of drug first being administered/stopped where applicable?
- Have any changes of dose of the drug affected the clinical problem?
- Is there any literature detailing similar cases?
Assess whether neonate is receiving any medications known to cause clinical problem 
Refer to ADRIN educational tool page 8 and 9-
ADRs and drugs which can cause them. 
e.g. ampicillin, cefotaxime, caffeine citrate
Define each of patient's clinical problems
This may be prompted either by ward round 
conversation or can be studied from ward round 
clinical review summaries or from the clinical 
summary tab- active diagnoses 
e.g. Jaundice
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Step 2: drug focussed 
  
Complete a Suspected ADR form where appropriate
All suspected cases should be reported, even if mild, 
unlikely or uncertain
If an ADR is now suspected review full notes to consider this further
Consider:
- What alternative reasons are there for this clinical problem?
- Does the pattern of the ADR fit with the time of drug first being administered/stopped where 
applicable?
- Have any changes of dose of the drug affected the clinical problem?
- Is there any literature detailing similar cases?
Using the ADRIN educational tool and searching the BNF for children consider whether 
the patient is suffering any of the side-effects known to the drugs the patient is receiving
This should be done for each drug in 
turn
e.g. Linezolid, known to cause blood 
disorders
Review the drugs that a patient is receiving by selecting the drugs, infusions and lines tab 
on BadgerNet
Both drugs and infusions should be 
studied
To review further details about the drug e.g. 
dose, select the drug. This is particularly 
important for infusions where often the full drug 
name will not display until selected
58 
 
To improve the detection of ADRs in neonates, time was spent piloting the study, and reading 
about common neonatal ADRs and previous research in this area. An educational tool was 
also developed outlining details of neonatal ADRs; common ADRs, serious ADRs, ADRs from 
frequently used medicines on the NICU, drugs causing ADRs unique to neonates, ADRs from 
antibiotics and anti-fungals, drugs known to cause extravasation injuries and off-label and 
unlicensed drugs prescribed on the unit. This educational tool was used for reference at all 
ward rounds. The British National Formulary for children online (BNFc) was consulted for any 
further information required.      
In addition to researcher ward presence, ‘ADR alert forms’ were available to all staff to 
complete where necessary. These allowed staff to alert the researcher to any suspected ADRs 
in a neonate they were caring for. Staff were encouraged at regular intervals throughout the 
data collection period to complete these forms for all suspected ADRs, regardless of perceived 
severity and causality, and they were reassured that any reported suspicions would be further 
analysed by the study team. These forms were placed inside the drug information folders used 
by staff when prescribing and administering drugs. These folders were checked on a regular 
basis by the researcher for any completed forms.    
If an ADR was suspected for any neonate a ‘Suspected ADR in a Neonate’ data collection 
proforma was completed by the researcher for each ADR case. Each case was entered 
directly into the password-protected spreadsheet version of the data collection form and stored 
securely on a university computer. Parental consent was not taken to recruit the neonate to 
the study as the information collected was considered routine data monitored as part of daily 
care. Parents were not informed that the study was being undertaken, but staff members were 
briefed to answer any parents’ questions by explaining that drug safety is routinely monitored 
on the unit as part of the care provided. Each neonate who was suspected to have suffered 
an ADR was given a study number and a paper copy only of the study numbers and 
corresponding neonate hospital numbers was kept in a locked drawer in the card or code 
access only research department of the Institute for Women’s and Children’s Health located 
at the Liverpool Women’s Hospital site.   
Once a case report was collected for a suspected ADR, the ADR in question was followed up 
for a minimum of two weeks. If the clinical sign or symptom had resolved or improved by the 
two-week point, the outcome was recorded as ‘improvement of clinical 
symptoms/observations/investigations’. If the clinical sign or symptom had not improved by 
this point, it continued to be monitored until either the reaction resolved/improved, the outcome 
of ‘no change in/deterioration of clinical symptoms/observations/investigations’ could be 
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justified, or the neonate was discharged. This methodology was decided upon as this was a 
single investigator study with limited time.   
In this study, the decision was made to collect and report data regarding any suspected ADRs 
regardless of their severity and previously published information. This aimed to maximise the 
opportunity to observe neonatal ADRs for a continuous time and to provide a wide range of 
cases for the comparison of causality assessment tools.  
Once the data collection period had finished, Yellow Card reports were submitted to the MHRA 
for all cases that were given a probable or definite causality rating by the principal investigator 
using the Liverpool ADR Causality Assessment Tool.  
3.2.3 Drug inclusion and exclusion 
Reactions to any drugs prescribed to any neonate on the neonatal unit were included in this 
study, regardless of licensing or label status. Drugs causing ADRs were classified into groups 
using the Anatomical Therapeutic Chemical (ATC) classification method designed by the 
WHO Collaborating Centre for Drug Statistics Methodology(72). Using this classification, 
drugs were classified by first and second order classifications only. The licensing and labelling 
statuses of the drugs were confirmed by checking the Summary of Product Characteristics via 
the EMA website, and discussing any queries with a senior member of the research team. 
Drugs prescribed to the neonate when in any other ward or hospital were not included. This 
includes drugs prescribed to the neonate when on the labour ward, e.g. resuscitation drugs.   
Blood products, except for immunoglobulins, were not included. Enteral feeds, including infant 
formulas, were not classified as drugs in this study. Drugs that were used by the father or 
mother preconception or by the mother during pregnancy, labour or breastfeeding were also 
included if they resulted in a neonatal ADR, but the information regarding the doses and 
prescription of these drugs was sometimes limited. Recreational drugs were included in this 
study but the classification and quantification was more difficult. Recreational drugs refers to 
the use of illegal and legal drugs without medical supervision, as defined and described in the 
British Medical Journal(73). It covers four main categories of drugs; analgesics, depressants, 
stimulants and hallucinogens(73).  
3.2.4 ADR definition 
The ADR definition used in this study was that by Allegaert et al as ‘an unintended and harmful 
effect resulting from the use of medications intended for diagnostic or therapeutic reasons 
(irrespective of the dose)’(10). This definition was considered the most appropriate for this 
study as it enables the inclusion of drugs that are unlicensed or off-label by discounting dose 
as a factor. Reactions that had begun before the first day of data collection were included 
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providing the reaction was still occurring when data collection commenced. Medication errors 
were not included in this study as the focus was to be on adverse drug reactions occurring 
under correct prescribing, and a large study surveying medication errors had recently taken 
place on the unit.     
3.3 Comparison of results to Yellow Card reports to the MHRA 
To further evaluate the ADRs reported in this study, the collected cases were compared to 
neonatal ADRs that were reported to the MHRA in a different time set. This was done by 
analysing a paper by Hawcutt et al that described all the neonatal ADR reports to the MHRA 
between 2001 and 2010(6). The results outlined in this paper were compared to the results of 
this prospective observational study. Comparisons were made between the frequency and 
rate of reporting, gender of neonates, reaction types reported and drugs suspected. The two 
sets of results were tabulated for comparison.  
3.4 Causality assessment process 
Following the data collection period, causality assessments were performed by multiple 
assessors on a sample of the total cases. The sample was chosen by including only one case 
of an ADR where there were multiple cases of similar ADRs, and not including ADRs caused 
by parental drug use. This process aimed to assess the use of three different currently existing 
causality assessment tools.  
3.4.1 Three compared methods  
Karch and Lasagna algorithm 
It was decided to assess the Karch and Lasagna algorithm following its use in a recent 
prospective observational study into adverse drug reactions in neonates, conducted in Spain 
by Belén Rivas et al (46). The exact version of the tool that was used in the study was obtained 
and translated into English. The algorithm was developed in the 1970s. Karch and Lasagna 
recognised that categorising and evaluating ADRs depended on the clinical judgement of 
clinicians, which varied between individuals. Their proposed definitions for ‘definite’, 
‘probable’, ’possible’, ‘conditional’ and ‘unlikely’ ADRs aimed to encourage more objective 
evaluation of ADRs and define ‘tolerance limits’ for the unavoidable variation in clinician 
opinion(74)(75).  
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Scoring of the algorithm of the Spanish Pharmacovigilance system  
A. Temporal sequence  
- Compatible + 2 
- Compatible but not coherent + 1  
- No information 0 
- Incompatible -1 
- ADR appears on withdrawing/withholding medicine -2 
 
B. Previous Knowledge  
- ADR well known, +2 
- ADR known (occasional references), +1 
- ADR unknown, 0 
- Information against the connection, -1  
 
C. Effect of the withdrawal from medicine  
- ADR improves, +2  
- ADR doesn't improve, -2  
- They don't withdraw the medicine and ADR doesn't improve, +1 
- They don't withdraw the medicine and ADR improves, -2 
- There isn't information, 0 
- ADR fatal or irreversible, 0  
- They don't withdraw medicine, ADR improves by tolerance/ resistance, +1 
- They don't withdraw medicine, ADR improves by treatment, +1  
 
D. Return of ADR after re-exposure to the drug 
- Positive: ADR appears, +3 
- Negative: ADR doesn't appear, -1 
- There isn't re-exposure or sufficient information, 0 
- ADR fatal or irreversible, 0  
- Similar previous reaction with another pharmaceutical speciality/specialisation, +1   
- Similar previous reaction with another drug, +1 
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E. Existing/ Existence of alternative causes 
- A more plausible alternative explanation, -3 
- An equal alternative explanation -2 
- Or less plausible, -1  
- There isn't information that establishes this, 0  
- There isn't sufficient information that dismisses this, +1 
 
F. Contributing factors which favour the causal relationship, +1 
 
G. Extra Examinations (serum levels of medicine, biopsies, radiological examinations, 
allergic testing, etc.), +1   
 
A+B+C+D+E+F+G = Causal Relationship  
- Unlikely, ≤0 
- Conditional, 1-3  
- Possible, 4-5  
- Likely, 6-7 
- Definite, ≥8  
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New Adverse Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units (Du 
Lehr) 
The ‘New Adverse Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units’ 
(referred to here as the Du Lehr algorithm) was designed by Wei Du et al at Wayne State 
University, Detroit, USA. The team aimed to create an ADR causality assessment tool that 
would be suitable and specific to the neonatal population. They recognised the increased risk 
of ADRs in critically ill neonates in intensive care receiving multiple different medications, and 
that existing algorithms often disagree with the opinions of experts. They hoped their tool 
would apply consideration to the impact of underlying disease and polypharmacy as well as 
weighting the contributions of different factors. The algorithm was created by comparing 
experts’ classifications of a sample of real neonatal ADR cases with their assessments using 
a new 24 item questionnaire. Statistical analysis of the classifications resulted in removal of 
some questions, so that the final product is a 13-item questionnaire with weighted scoring for 
yes, no or not applicable answers. The questionnaire was validated using a further 50 
prospectively collected neonatal ADR cases, but as far as is known at present, has not been 
further validated outside of this setting(67).  
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New Adverse Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units (Du Lehr) 
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Liverpool Adverse Drug Reaction Causality Assessment Tool 
The ‘Liverpool Adverse Drug Reaction Causality Assessment Tool’ (LCAT) was developed as 
part of the Adverse Drug Reactions in Children (ADRIC) research programme conducted in 
the North West of England. Whilst conducting the prospective observational studies earlier in 
the programme, difficulties were faced when trying to use the Naranjo algorithm to assess the 
paediatric ADR cases. Investigators found that many cases were being classified as unknown 
despite multiple expert opinions agreeing otherwise. The research team also noted that the 
justifications for the weighting of each question and the scoring boundaries are not available 
in any accessible publication. The existing questions in the Naranjo algorithm were reviewed 
by seven investigators at a consensus meeting and each question retained, removed, modified 
or combined with another. A new algorithm was created from these decisions and validated 
through several processes using prospectively collected cases and measuring kappa scores. 
The resulting product was a flowchart of ten questions which leads the user to a causality 
assessment of either ‘unlikely’, ‘possible’, ‘probable’ or ‘definite’(65). The Liverpool ADR 
Causality Assessment Tool was produced following difficulties assessing paediatric ADR 
causality, but was designed to be used to assess ADRs in any age group. When the LCAT 
was used to evaluate paediatric ADR cases it showed greater inter-rater reliability than the 
Naranjo method. However, the population observed for ADR cases only included a limited 
number of neonates, as only surgical inpatient neonates were included in ADRIC. It is not 
known whether the LCAT will be appropriate for assessing neonatal ADRs. As neonates 
exhibit different pharmacokinetics and dynamics to those of older children, it is likely that 
neonates will require population-specific causality assessment methods. However, as there is 
currently only one known neonate-specific causality assessment method, other options need 
to be explored. The LCAT was designed to be appropriate for use for assessing paediatric 
ADRs and so may prove more appropriate for the neonatal population than other tools that 
have proven difficult to use in children, such as the Naranjo. The decision was made to validate 
it’s use in the neonatal population in this study.     
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Liverpool Adverse Drug Reaction Causality Assessment Tool 
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3.4.2 Assessment process  
Summaries of each ADR case were created using information gathered in the ‘Suspected 
Adverse Drug Reaction in a Neonate’ proforma. The summaries included the main information 
regarding the demographics of the neonate, details of the suspected causative drug including 
dose and timings, a narrative of the reaction itself, the reaction outcome, any significant labour, 
pregnancy or maternal history and any significant medical history or possible differential 
diagnoses. Further information from the full case spreadsheet could be requested from the 
researcher at any time, who could collect additional information from the electronic notes 
system if necessary.  
Copies of the case summaries were given to six assessors, who are detailed in table 5. The 
assessors were each asked to use the three different causality assessment tools to evaluate 
the causality of each ADR case. Each assessor was asked to record their assessment of each 
case using each of the three tools, resulting in three assessments per assessor per case. The 
process of doing the causality assessments was explained to each assessor either in person 
or via email. Assessors were given up to one month to complete all assessments. The process 
of performing the causality assessments was trialled by the two student supervisors prior to 
the process being undertaken by other assessors.  
The assessors were also asked to complete a brief questionnaire regarding the use of each 
of the three tools after they had completed the assessments, a copy of which can be found in 
appendix 3. An informal conversation was also had with each assessor upon the completion 
of the assessments regarding any difficulties and opinions on the task.   
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Table 5 Details of the six individuals who carried out causality assessments 
Assessor Initials Designation Years of neonatal 
experience 
Assessor 1 BP Consultant 
neonatologist 
10 
Assessor 2 BY Consultant 
neonatologist 
30 
Assessor 3 BS Consultant 
neonatologist 
35 
Assessor 4 MT Consultant 
neonatologist 
25 
Assessor 5 DH Consultant clinical 
pharmacologist 
7 
Assessor 6 JM Specialty registrar 
(ST6) 
5 
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3.5 Severity assessment 
Whilst a neonate-specific method of assessing the severity of ADRs is under development, 
there are currently no known methods of assessing severity of ADRs in this population that 
have been validated. However, it was considered important to evaluate the severity of the 
ADRs that occurred in this study. Therefore a severity assessment of each case was 
undertaken by the principal investigator using a method outlined in a previous study conducted 
into ADRs in children in the 1990s(76).  
The severity ratings were outlined as follows: 
1. Severe: fatal or potentially life-threatening.  
2. Moderate: requiring treatment or prolonging stay in hospital.  
3. Mild: no treatment required and no effect on length of stay in hospital. 
3.6 Statistical analysis  
3.6.1 Statistical analysis of ADR cases 
Upon completion of the ADR data collection each ADR case was reviewed and data extracted 
to form collated results. ADR incidence was calculated and expressed as the number of 
neonates experiencing at least one ADR over the total number of neonates who were 
inpatients on the unit for at least one day in the nine-week observation period. Other data was 
represented as frequencies, percentages, ranges, modes and medians. The categorisation of 
neonates by age and weight used definitions outlined by the EMA in the ‘Guideline on the 
investigation of medicinal products in the term and preterm neonate’(12).  
A Fisher’s exact test was used to compare the frequency of ADRs by gender occurring on the 
unit. Sub-group analysis was undertaken using the chi-squared test within the population 
identified as suffering ADRs. These calculations were performed as part of an exploratory 
secondary analysis and were not intended to draw conclusions from.    
The decision was made to include all observed suspected ADRs in the ADR case analysis. 
Previous studies have included only those ADRs with the highest causality ratings but it was 
decided that the validation needed to include all degrees of causality.  
3.6.2 Statistical analysis of causality assessments  
Upon the completion of all causality assessments by the six assessors the results for each 
assessor were inputted into a spreadsheet and tabulated for clear presentation. A chi squared 
test was performed to determine the significance of the number of times each rating was 
assigned using each tool.  
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Inter-rater reliability: 
Inter-rater reliability was measured by calculating non-weighted and weighted kappa scores. 
Kappa scores aim to measure the level of agreement between two sets of data above that that 
would be expected to have occurred by chance alone. Weighted kappas take the amount of 
difference between pair-wise assessments into consideration e.g. two assessments of definite 
and probable show better agreement than two assessments of definite and unlikely(77).    
Percentage exact agreement and percentage extreme disagreement were also calculated to 
show the level of concordance between pairs of assessors. Extreme disagreement was 
defined as a difference of more than one causality interval between the pair-wise assessments 
e.g. one assessor gives a definite rating where the other gives a possible rating.  
A global kappa score was also calculated. This single figure shows the level of agreement 
between all six assessors for each tool.  
Inter-tool reliability: 
Inter-tool reliability was also measured by calculating kappa scores to measure agreement 
between the ratings for the same cases assessed by the same assessor using two different 
tools. The purpose of this was to analyse whether any two tools produced similar outcomes. 
This was also measured by calculating non-weighted and weighted kappa scores.   
A difficulty was faced when comparing the Karch and Lasagna algorithm to the other two 
algorithms; the Karch and Lasagna algorithm has five possible outcomes whereas the others 
have four. Due to the limited amount of research in this field and the need to make a 
comparison between all tools, a decision was made to adjust for this. Two of the outcome 
categories in the Karch and Lasagna algorithm were merged to form one outcome. It was 
decided to merge the categories ‘conditional’ and ‘possible’ as neither of the other two tools 
contained a ‘conditional’ outcome. This left the tool with four categories: ‘definite’, ‘likely’, 
‘possible’ and ‘unlikely’. The likely category was translated to have the same meaning as the 
‘probable’ category used in the other two tools.   
The level of kappa acceptability for both inter-rater an inter-tool reliability was chosen to be 
the same as that used in the ADRIC research programme: <0.2=poor, 0.21-0.40=fair, 0.41-
0.60=moderate, 0.61-0.80=good, 0.81-1.00=very good. This was in reference to literature by 
Altman(65,77).    
The following statistical software packages were used for the statistical analyses:  
SPSS: IBM® SPSS Statistics® 
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IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM 
Corp. 
GraphPad QuickCalc free web calculator: GraphPad QuickCalcs Website 
www.graphpad.com/quickcalcs/ Accessed May 2017 
3.6.3 Study approval  
Sponsorship for this study was obtained from the University of Liverpool on 10th November 
2016 after a full committee review, as this project was conducted as part of an MPhil thesis. 
This approval was for the proposed study outlined in the study protocol found in appendix 1. 
Appropriate ethical approval was sought through an IRAS application. Ethical approval was 
granted from the Proportionate Review Sub-Committee of the Wales REC 7 on 7th December 
2016, reference number 16/WA/0379. HRA approval was granted on 19th January 2017 and 
thus sponsorship permission to proceed was provided on 27th January 2017.   
3.7 Discussion  
Designing this research study took careful planning, and with very few previous studies 
published, there were limited sources of guidance. Many significant decisions were made 
regarding the methods of data collection and evaluation for the study. One decision was with 
regards to who would complete the data collection proforma when an ADR case was 
suspected. Originally it was planned to make the proformas available to any member of staff 
to use to report a suspected ADR. However, initial feedback from staff raised concerns that 
they would not have time to do this or would not know what details to include. From this 
feedback, the decision was made for the researcher to complete all data collection forms, with 
staff having the opportunity to use the ADR alert forms. This enabled a consistent data 
collection process so that the data and detail collected for each ADR case were as similar as 
possible. This was particularly important for the causality assessment process. 
Having the researcher complete the data collection proformas also avoided missing data. 
However, in a small sample of cases it was difficult to collect all necessary data. In other 
cases, when the electronic patient notes were searched, it was hard to distinguish between a 
lack of information because it was omitted accidentally, or omitted because it was considered 
unimportant. In these situations, questions could be asked to the clinical team, and suspicions 
monitored before recording an ADR case. Some information will never be recorded, and this 
is often not a study limitation but an unavoidable matter of life.  
Another significant decision was taken with regards to informing parents about the 
occurrences of ADRs suspected in the study. The Health and Social Care Act 2008 (Regulated 
Activities) Regulations 2014: Regulation 20 refers to the duty of candour(78). It outlines the 
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responsibilities of a healthcare provider to be open and honest with relevant service users, 
and how to communicate in the case of ‘notifiable safety incidents’ occurring. Notifiable safety 
incidents in this regulation are defined as those causing moderate or severe harm, or causing 
prolonged pain or psychological harm. Unit practice on the NICU observed in this study is only 
to disclose those ADRs considered severe to parents of neonates. As disclosing all observed 
ADRs in this research project would have disrupted unit practice, the decision was made not 
to inform parents of ADRs detected during this study. Severe ADRs detected by the clinical 
team would have been discussed with the parents in line with both unit practice and the duty 
of candour. This was approved by both ethical and sponsorship committees by means of 
reviewing the proposed study protocol when sponsorship and ethical approval were sought. 
As the ADRs observed in this study were suspected rather than confirmed, and many received 
low causality ratings when assessed, it could be considered unethical to disclose unclear 
information causing unnecessary worry.  
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Chapter 4: Prospective observation of adverse drug reactions in 
neonates  
To enable the collection of neonatal ADR cases, a prospective observational study was 
designed, piloted and conducted on the Richard Cooke Neonatal Unit at the Liverpool 
Women’s Hospital. Neonates were observed for nine weeks and continuous reviewing of the 
neonates’ clinical conditions and care over this time, in addition to contributions by staff, 
resulted in the collection of documented cases of suspected ADRs in neonates. The 
continuous prospective data collection method meant suspected cases were monitored and 
documented for several weeks to allow for a detailed documentation of the course of a 
suspected ADR. A wide range of reactions to many different drugs were suspected to have 
been suffered by both pre-term and term neonates with a range of medical and surgical 
conditions. The results below outline the spread of cases that were seen, and demonstrate 
some of the differences between ADRs recorded prospectively under research conditions and 
those submitted spontaneously to the MHRA.    
4.1 ADRs on the neonatal unit 
Over the data collection period, 151 neonates were admitted to the unit (neonates on the 
transitional care unit were not included in the study). The initial admissions were from the 
labour and midwife-led units (55), operating theatres (48) and post-natal ward within the 
hospital (36), and some from other hospitals (12). Finally, including the neonates who were 
already inpatients before the start date of the study (42), the total number of neonates studied 
was 193. In total, 63 reports detailing suspected ADRs were recorded for the study during the 
data collection period. Of the 63 ADR reports, 56 reports were thought to have arisen from 
medications prescribed for the neonate, and seven from maternal drugs. No reactions to 
prescribed paternal medications were observed in this study.  
Table 6 gives an overview of the number of ADR reports, the number of neonates involved 
and the number of reactions and suspected drugs the reports detailed.  
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Table 6 ADR reports and the number of neonates, reactions and drugs reported 
 Number 
of reports 
Number of 
neonates 
affected 
Number of 
ADRs detailed 
on the reports 
Number of 
drugs detailed 
on the reports 
ADR reports 
detailing 
prescriptions to 
neonate only 
56 28 68 78 
ADR reports 
detailing 
maternal 
prescriptions 
7 7 7 11 
Total 63 35 75 89 
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4.1.1 Neonate characteristics 
35 of the 193 neonates studied on the NICU over the nine weeks experienced an ADR. The 
incidence of neonates who suffered an ADR was therefore 18.1% (35/193). 
Of these 35 neonates, 21 were suspected to have experienced one ADR whilst 14 neonates 
were suspected to have experienced more than one ADR (Figure 1). The median and mode 
number of reports per neonate was one. Table 7 outlines the demographics of the neonates 
experiencing ADRs in this study and the number of reports filed for each subgroup. 
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Figure 1 Number of ADR reports per neonate (total number of reports=63) 
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Table 7 Demographics of neonates experiencing at least one ADR 
Neonate characteristics Number of 
neonates n=35(%) 
Number of suspected 
ADR reports n=63(%) 
Gender Male  24 (69) 48 (76) 
Female  11 (31) 15 (24) 
Gestational age 
at birth 
 
Extremely preterm 
(<28 weeks) 
12 (34) 
 
33 (52) 
Very preterm (28 
to <32 weeks)   
5 (14) 8 (13) 
Moderate to late 
preterm (32 to <37 
weeks)  
5 (14) 7(11) 
Term neonates 
(37- 42 weeks) 
13 (37) 15 (24) 
Birthweight by 
group 
Extremely low 
birthweight 
(<1000g) 
11 (31) 33 (52) 
Very low 
birthweight 
(<1500g) 
7 (20) 9 (14) 
Low birthweight 
(<2500g) 
5 (14) 7 (11) 
Normal birthweight 
(2500g – 4200g) 
12 (34) 
 
14 (22) 
Corrected 
gestational age 
at time of ADR 
<28 weeks 5 (14) 11 (18) 
28 to <32 weeks 10 (29) 15 (24) 
32 to <37 weeks
  
5 (14) 19 (54) 
37 + weeks 15 (43) 18 (29) 
Working weight 
at time of ADR 
<1000g 6 (17) 13(21) 
<1500g 9 (26) 20 (32) 
<2500g 8 (23) 15 (24) 
2500g – 4200g 12 (34) 15 (24) 
Multiple 
pregnancy 
Singleton 
pregnancy 
33 (94) 59 (94) 
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Neonate characteristics Number of 
neonates n=35(%) 
Number of suspected 
ADR reports n=63(%) 
Twin pregnancy 2 (6) 4 (6)  
Triplet pregnancy  0 (0) 0 (0) 
NB: In four cases, the gestational ages, and thus corrected gestational ages, of the neonates were 
estimated as the pregnancies were un-booked. Though included in this table, these cases were not 
included in any further calculations.  
In cases where the ADR lasted several weeks and weight changed, the minimum working weight during 
the ADR period was used for analysis. 
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The gestational ages of the neonates at birth ranged from 23 + 6 weeks to 40 + 4 weeks. The 
birth weights of the neonates ranged from 570g to 3990g and the mean birth weight was 
1874g. The neonates’ corrected gestational ages at time of experiencing an ADR ranged from 
26 + 1 weeks to 40 + 5 weeks. The neonates’ working weights at time of ADR ranged from 
580g to 3990g.  
At the time of ADR occurrence, 41 neonates were being cared for in ITU, 15 in HDU, one in 
the nursery, three in the post-natal wards and three on the delivery unit. In eight cases, the 
neonate required an escalation of care at the time of the ADR i.e. moving from HDU to ITU. 
The number of recorded concomitant drugs prescribed at time of ADR occurrence ranged from 
0 to 43, not including resuscitation drugs. The mean number of recorded concomitant drugs 
prescribed was 13 and the mode was 19. At the time of ADR occurrence, 79% of the neonates 
in the report were receiving five or more concomitant drugs, and 65% were receiving ten or 
more.  
A Fisher’s exact test compared neonates who did not suffer an ADR to those who did, and 
found there was no significant difference between gender groups (table 8).  
Within those neonates who were identified to have suffered an ADR, sub-group analyses were 
undertaken. Chi squared tests showed there to be significant differences in the number of 
ADRs experienced by neonates when categorised by gestational age at birth, birthweight, 
corrected gestational age at time of ADR and working weight at time of ADR. The calculated 
p-values are displayed in table 8.  
The increased number of ADRs seen in the older corrected gestational age category could be 
explained by sick neonates who were born extremely preterm requiring many medications 
when they enter this corrected gestational age category as a result of the comorbidities of 
prematurity.  
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Table 8 Results of statistical analysis of demographic subgroups 
Demographic factor Statistical test used Result (p value) 
Gender Fisher’s exact 0.1362 
  
Birthweight  Chi squared 0.0047  
Corrected gestational age 
at time of ADR 
Chi squared 0.0018   
Working weight Chi squared 0.0101  
Gestational age at birth Chi squared 0.0226  
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4.1.2 Drugs prescribed on the neonatal unit 
The medicines prescribed to all neonates on the unit during the study period, as captured by 
the BadgerNet electronic patient data system, are shown in table 9. 
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Table 9 Drugs prescribed to all neonates on the neonatal unit over nine-week period 
Drug Number of neonates prescribed drug 
over nine-week period 
Aciclovir  3 
Adrenaline  4 
Amiloride  1 
Amphotericin 1 
Amphotericin- liposomal 2 
Aquacel 1 
Benzylpenicillin 107 
Betamethasone eye drops  2 
Caffeine 47 
Clotrimazole cream 3 
Carobel 1 
Cefotaxime 5 
Chloral hydrate  2 
Chloramphenicol eye drops 1 
Chloramphenicol eye ointment 5 
Chlorhexidine powder 145 
Ciprofloxacin 9 
Co-amoxiclav 40 
Curosurf (surfactant) 2 
Cyclopentolate eye drops 0.5% 2 
Dalivit 78 
Dexamethasone 4 
Dextrose 10% 2 
Dobutamine 3 
Domperidone  1 
Dopamine 5 
E45 cream 6 
Fentanyl  2 
Fluconazole 15 
Folic acid 76 
Furosemide  13 
Gaviscon 2 
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Drug Number of neonates prescribed drug 
over nine-week period 
Gentamicin 126 
Glycerin suppository 1 
Heparinised saline 1 
Human normal immunoglobulin 1 
Hydrochlorothiazide 10 
Hydrocortisone 8 
Hypromellose eye drops 5 
Ibuprofen 5 
Immunoglobulin  2 
Insulin 2 
Linezolid 2 
Liothyronine sodium 1 
Magnesium glycerophosphate 1 
Meropenem 1 
Metronidazole 11 
Midazolam 5 
IV morphine 1 
Oral morphine 4 
Morphine sulphate 4 
Multivitamins 2 
Nitric oxide 5 
Nystatin suspension 32 
Ofloxacin eye drops 1 
Omeprazole 1 
Orobase 5 
Paracetamol 14 
Phenobarbital 2 
Phosphate 20 
Promethazine 2 
Propranolol 1 
Prostaglandin E2 2 
Ranitidine 7 
Sildenafil 1 
84 
 
Drug Number of neonates prescribed drug 
over nine-week period 
Sodium bicarbonate 2 
Sodium chloride 18 
Sodium feredetate 23 
Spironolactone 13 
Suxamethonium 1 
Teicoplanin 9 
Total Parenteral Nutrition 44 
Vancomycin 1 
Vecuronium 2 
Vitamin K 20 
Total 1009 
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4.1.3 ADR report characteristics 
75 different ADRs were suspected on 63 reports. The number of suspected ADRs exceeds 
the number of reports as some reports detailed two different reactions to the same drug(s). In 
these cases, reactions were grouped together e.g. both flat affect and respiratory depression 
caused by morphine.  
Reports of suspected ADRs to neonatal medications 
Table 10 details the reported reactions to drugs prescribed directly to the neonate (i.e. the 56 
of the 63 reports that do not detail reactions to maternal medications).
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Table 10 Clinical presentations of the observed ADRs and the drugs suspected to have caused 
them 
Clinical Presentation Total number 
of neonatal 
ADRs reported 
in study  
Drugs suspected to cause this 
reaction 
General disorders + 
administration site 
disorders: 
6   
Pyrexia 4  Aciclovir, prostaglandin E2 
Decreased weight gain 1  Dexamethasone 
Extravasation reaction 1  Dextrose 10% solution with sodium 
and potassium, aciclovir 
Blood and lymphatic 
system disorders: 
7  
Thrombocytopenia 3  Gentamicin, benzylpenicillin, linezolid 
Thrombocytopenia + 
leucopenia 
2  Benzylpenicillin 
Arterial thrombus 1  Immunoglobulins 
Neutropenia 1  Hydrochlorothiazide, spironolactone 
Cardiovascular disorders: 8   
Tachycardia 4  Dopamine, dobutamine, 
cyclopentolate eye drops, 
phenylephrine eye drops, 
hydrocortisone 
Hypertension 2  Dopamine, hydrocortisone 
Bradycardia 1  Propranolol 
Heart block 1  Digoxin 
Cardiopulmonary 
disorders: 
4  
Apnoeas + desaturations + 
bradycardia 
1  Prostaglandin E2 
Desaturations + bradycardia 1  Cyclopentolate eye drops, 
phenylephrine eye drops 
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Clinical Presentation Total number 
of neonatal 
ADRs reported 
in study  
Drugs suspected to cause this 
reaction 
Hypertension leading to 
pulmonary haemorrhage 
1 Dopamine  
Hypertension + large urine 
output 
1  Dopamine, dobutamine 
Respiratory disorders: 2   
Apnoea + desaturations + 
raised CRP 
1  Bexsero (meningococcal) 
immunisation 
Apnoea 1  Cyclopentolate eye drops, 
phenylephrine eye drops 
Gastrointestinal disorders: 7  
Constipation 2  Sodium feredetate 
Watery stoma losses 2  Co-amoxiclav, gentamicin 
Bloody GI aspirates 1  Hydrocortisone 
Diarrhoea 1  Aciclovir, ciprofloxacin, teicoplanin 
Vomiting 1  Cyclopentolate eye drops, 
phenylephrine eye drops 
Hepatobiliary disorders 0  
Renal and urinary 
disorders: 
6   
Renal failure/kidney injury 3 Gentamicin, benzylpenicillin 
Urinary retention 2 Midazolam, phenobarbital 
Reduced urine output 1  Vecuronium, midazolam 
Nervous system disorders: 6  
Flat affect 3  Morphine 
Cerebral haemorrhage 1  Dobutamine  
Respiratory depression 1  Morphine 
Respiratory depression + flat 
affect 
1  Morphine 
Metabolic disorders: 8   
Electrolyte disturbance 2  Furosemide, amiloride 
Hypernatraemia 2  Sodium supplements 
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Clinical Presentation Total number 
of neonatal 
ADRs reported 
in study  
Drugs suspected to cause this 
reaction 
Hyponatraemia 2  Hydrochlorothiazide, spironolactone 
Hyperglycaemia 1  Hydrocortisone 
Metabolic acidosis 1  Heparinised saline, sodium chloride 
Dermatological disorders: 0   
Investigation results: 2  
Deranged electrolytes, high 
creatinine, low calcium 
1  Gentamicin 
Raised creatinine 1  Furosemide 
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The 56 reports for suspected neonatal ADRs (63 total ADRs minus the seven suspected to be 
due to maternal medications) detailed a total of 78 prescriptions. Overall 31 different drugs 
were suspected to have caused neonatal ADRs. 36 ADRs were reported to be caused by one 
drug, 18 were reported to be caused by two drugs and two were reported to be caused by 
three drugs.  
Gentamicin was suspected to have caused the most ADRs (8), with morphine (6) and 
dopamine (5) being the next most common.   
The most common drug groups (by ATC classification) causing ADRs were those drugs in the 
cardiovascular system group (28), the anti-infectives for systemic use group (22) and the 
nervous system group (9). Details of the reactions suspected to have been caused by drugs 
in these groups can be found in table 11.  
Thirty ADR reports suspected one or more drugs that had been prescribed to the neonate off-
label. Table 12 lists these drugs and the number of ADRs reports that detailed them as 
suspected drugs.   
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Table 11 Drug groups (by ATC classification) and ADRs suspected to have been caused 
Drugs (by ATC classification) ATC code Number of times 
reported 
Number of 
neonates 
Alimentary tract and metabolism A 3 3 
Mineral substitutes A12 3 3 
Anti-infectives for systemic use J 22 13 
Anti-bacterials for systemic 
use 
J01 17 9 
Anti-virals for systemic use J05 3 2 
Immune sera and 
immunoglobulins 
J06 1 1 
Vaccines J07 1 1 
Blood and blood-forming organs B 4 4 
Antithrombotic agents B01 1 1 
Anti-anaemic preparations B03 2 2 
Blood substitutes and 
perfusion solutions 
B05 1 1 
Cardiovascular system C 28 15 
Cardiac therapy C01 14 7 
Diuretics  C03 10 5 
Vasoprotectives  C05 3 2 
Beta-blocking agents C07 1 1 
Musculoskeletal system M 2 2 
Muscle relaxants M03 2 2 
Nervous system N 9 9 
Nervous system- 
analgesics 
N02 5 5 
Nervous system- 
antiepileptics 
N03 1 1 
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Drugs (by ATC classification) ATC code Number of times 
reported 
Number of 
neonates 
Psycholeptics N05 3 3 
Sensory organs S 8 3 
Ophthalmologicals S01 8 3 
Systemic hormonal preparations H 2 2 
Corticosteroids for systemic 
use 
H02 2 (64) 2 
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Table 12 Drugs prescribed to the neonate off-label 
Name of drug prescribed off-label Number of ADR reports 
Amiloride 1 
Cyclopentolate eye drops 4 
Dexamethasone 1 
Dopamine 5 
Furosemide 3 
Immunoglobulins 1 
Hydrochlorothiazide 3 
Hydrocortisone 4 
Linezolid 1 
Morphine 5 
Phenobarbitone 1 
Sodium chloride 1 
Spironolactone 3 
Vecuronium 2 
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The ADRs to drugs prescribed to the neonate were evaluated through a severity assessment. 
A neonate-specific method of assessing severity of ADRs is still under development, so in this 
study a method which has previously been used to evaluate paediatric ADRs was used(76). 
The severity ratings given to each ADR report can be found in table 13. Of the 56 ADRs to 
neonatal prescriptions, 28 were classified as being mild ADRs, i.e. they did not require 
treatment or prolong the neonate’s stay in hospital and the remaining 28 were classified as 
moderate ADRs, i.e. they did require treatment or lengthen the neonate’s stay. No ADRs were 
classified as severe, i.e. being fatal or potentially life-threatening. It is possible that a neonate-
specific method of assessing severity may yield different results.   
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Table 13 All ADRs observed and the given severity ratings 
ADR Severity rating  
Hydrocortisone and hyperglycaemia Moderate 
Morphine and flat affect  Mild 
Hydrochlorothiazide/spironolactone and hyponatraemia Moderate 
Hydrochlorothiazide/spironolactone and hyponatraemia Mild 
Furosemide and electrolyte disturbance Moderate 
Furosemide/amiloride and electrolyte disturbance Moderate 
Hydrocortisone and bloody GI aspirates Moderate 
Oral morphine and flat affect Moderate 
Furosemide and raised creatinine Moderate 
Gentamicin and AKI Moderate 
Co-amoxiclav/gentamicin and watery stoma losses Mild 
Digoxin and heart block Moderate 
Dexamethasone and decreased weight gain  Mild 
Propranolol and bradycardia Moderate 
Sodium supplements and hypernatraemia Moderate 
Sodium feredetate and constipation Mild 
Dopamine and tachycardia Moderate 
Inotropes/hydrocortisone and high BP/pulmonary haemorrhage Moderate 
Gentamicin and acute renal failure Moderate 
Hydrochlorothiazide/spironolactone and neutropenia Mild 
Morphine and respiratory depression Moderate 
Sodium feredetate and constipation Mild 
Sodium supplements and hypernatraemia Mild 
Dextrose and extravasation reaction Mild 
Aciclovir and pyrexia Moderate 
Prostaglandin E2 and pyrexia Mild 
Gentamicin/benzylpenicillin and thrombocytopenia Mild 
Gentamicin and deranged electrolytes, high creatinine, low calcium Mild 
Gentamicin and thrombocytopenia Mild 
Phenylephrine/cyclopentolate eye drops and tachycardia Mild 
Meningococcal vaccine and apnoea, desaturations, raised CRP Moderate 
Phenylephrine/cyclopentolate eye drops and apnoea Moderate 
Phenylephrine/cyclopentolate eye drops and vomit Mild 
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ADR Severity rating  
Midazolam and urinary retention Mild 
Sodium chloride and metabolic acidosis Moderate 
Vecuronium and urinary retention Moderate 
Linezolid and thrombocytopenia Moderate 
Phenylephrine/cyclopentolate eye drops and bradycardia Moderate 
Benzylpenicillin and thrombocytopenia and leucopenia Mild 
Prostaglandin E2 and pyrexia Mild 
Prostaglandin E2 and apnoea, desaturations and bradycardia Mild 
Immunoglobulins and arterial thrombus Moderate 
Vecuronium/midazolam and reduced urine output Moderate 
Morphine and respiratory depression and flat affect Moderate 
Benzylpenicillin and thrombocytopenia and leucopenia Mild 
Morphine and flat affect Mild 
Inotropes and tachycardia Mild 
Dobutamine and cerebral haemorrhage Mild 
Inotropes and hypertension and large urine output Mild 
Gentamicin and renal impairment Moderate 
Dopamine and hypertension Moderate 
Antibiotics and diarrhoea Mild 
Co-amoxiclav/gentamicin and watery stoma losses Mild 
Hydrocortisone and hypertension Mild 
Prostaglandin E2 and pyrexia Mild 
Vecuronium and tachycardia Mild 
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The suspected drug was continued in 14 cases. The dose of the suspected drug was changed 
in 10 cases. The suspected drug was stopped in 34 cases. In 12 of these cases the drug was 
stopped due to the ADR and was only substituted with an alternative drug in two of the twelve 
cases.  
Of the 34 cases where the drug was stopped, 30 cases had a documented outcome of 
‘improvement of clinical symptoms/observations/investigations’. Of the 14 cases where the 
drug was continued, six had this same documented outcome, seven ‘no change of clinical 
symptoms/observations/investigations’ and one ‘deterioration of clinical 
symptoms/observations/investigations’.  
15 reports included details of treatment given due to the clinical sign that may have been 
caused by an ADR. Examples included hyponatraemia being treated with sodium 
supplements, platelets given in the case of thrombocytopenia and mechanical ventilation 
following respiratory depression. 
4.1.4 Suspected ADRs to maternal medication 
Of the 63 suspected ADRs, seven of these were suspected to be due to maternal medications. 
Two were due to opiates prescribed in labour, and the remaining five were due to medications 
taken during pregnancy.  
4.1.5 Reporter characteristics 
All ADR cases were reported by the researcher, but of these 16 were prompted by other ward 
staff (table 14). The ADR alert forms were used to report two cases, one by a nurse and one 
by a senior house officer (SHO).  
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Table 14 Number of alerts to ADRs by different members of clinical team 
Designation Number of alerts to ADRs 
Consultant 7 
Registrar 1 
SHO 6 
Nurse  2 
Pharmacist 0 
Other healthcare professional 0 
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4.2 Comparison to Yellow Card reports 
A recently published paper described all the Yellow Card reports detailing neonatal ADRs 
submitted to the MHRA between the years 2001 and 2010 in the UK(6). It was possible to 
compare the ADRs observed in this prospective observational study to those reported to the 
MHRA in the studied ten-year period.  
The most noticeable difference was the overall number of reports. The MHRA received 97 
neonatal ADR reports in the ten-year period, and 56 neonatal ADR reports were collected in 
the nine-week study period alone. 
Both sets of results report more ADRs occurring in males. It was not possible to compare the 
ages and weights of the neonates experiencing ADRs as the Yellow Card reports were missing 
some of this significant data. Whilst the paper establishes that the neonates were correctly 
identified as neonates by being less than 28 days old, it reports that only 23 of the Yellow Card 
reports gave an exact gestational age at birth.  
The most commonly reported drug in the 97 Yellow Cards was the swine flu vaccination (8) 
and a further three reports related to the DTPw HIB vaccination. This prospective 
observational study reported only one ADR to a vaccination. However, there was no known 
epidemic of swine flu during the study period and only a few neonates were inpatients when 
they reached the appropriate age for first immunisations to be given. This study reported the 
most reactions to gentamicin (8), morphine (6) and dopamine (5).   
The most commonly reported reactions on Yellow Card reports were dermatological reactions, 
yet ADRIN only observed one reaction of this kind, an extravasation reaction. Six Yellow Card 
reports detailed reactions causing bradycardia yet only one case of this was observed in this 
study. The study reported mainly cardiovascular and metabolic reactions (8 each) with single 
reaction types receiving the most reports being tachycardia and pyrexia (4 reports each).  
In its results and discussion, the paper details those drugs that received no Yellow Card 
reports despite having well documented safety warnings. These were codeine, ceftriaxone 
and Kaletra. This study did not observe any suspected reactions to these drugs which are not 
used on this neonatal unit. The paper also comments on the absence of any reports for 
surfactant and this study also did not observe any ADRs to surfactant. When the electronic 
patient notes system (BadgerNet) generated a report of all medicines prescribed to all 
neonates over the nine-week study period (table 9), only two neonates were reported to have 
received surfactant. This appears to be an underestimation, as although many more neonates 
will have received surfactant during this time, this drug is usually administered in the first few 
moments of life when the neonate is on the labour ward, and so therefore this drug will not be 
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recorded by BadgerNet as a drug prescribed on the neonatal unit. Drugs prescribed to the 
neonate before admission to the NNU were excluded in this study, so this may go some way 
to explain the absence of any ADR reports for surfactant in this study. However, as the BNFc 
does contain safety warnings for surfactant, it would be thought that some Yellow Card reports 
may have been filed in the 10 years studied in the comparison paper(6).  
Lastly the paper comments on a seemingly underreported number of ADRs to antibiotics, only 
ten, despite antibiotics being commonly used in neonatal care. This study observed 12 reports 
of neonatal ADRs to 17 antibiotic prescriptions, 22% of all suspected drugs.   
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Table 15 Comparison of neonatal Yellow Card reports submitted to the MHRA between 2001 
and 2010 and reports collected in the ADRIN study 
Factor Yellow Card reports  ADRIN study 
Frequency of reports 97 in 10 years 63 in 9 weeks 
Gender of neonates 
Males 
Females 
Unrecorded 
 
52 (53.6%) 
42 (43.3%) 
3 
 
48 (76.2%) 
15 (23.8%) 
0 
Most common reactions  Rashes- 14 
Erythema- 7 
Bradycardia- 6  
Tachycardia- 4 
Pyrexia- 4 
Flat affect- 3 
Most common drugs Swine flu vaccine- 8 
Caffeine- 5 
Gentamicin- 8 
Morphine- 6 
Dopamine- 5 
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4.3 Discussion 
Following on from the large-scale study into adverse drug reactions in children (ADRIC), this 
study has begun to contribute to the dataset involving ADRs in neonates. It took place in a 
tertiary neonatal unit treating both term and preterm neonates. The unit manages a wide range 
of medical and surgical conditions, including referred complex cases, many requiring multiple 
medications. For the neonatal population, this study is the first to compare three causality 
assessment methods that have been used to examine the extent to which a medicine can be 
ascribed to an adverse drug reaction.     
4.3.1 Incidence and frequency of reactions 
This study observed 63 reports of neonatal ADRs over a nine-week period, 56 of which were 
thought to be due to prescriptions for the neonate, and the remaining seven from medications 
used by the mother. Due to the limited resources and time, it was not possible to record data 
about neonates who were not reported to have experienced an ADR. Of the 193 neonates 
that were observed over the nine-week period, 35 were suspected to have experienced at 
least one ADR, an incidence of 18.1%. This is in keeping with a recent observational study 
into ADRs in neonates(46). However, there were factors which could have reduced the 
accuracy of this estimate, such as the method of ADR detection. As well as this, all observed 
ADRs are included in this calculation whereas previous studies have only included ADRs with 
the highest causality ratings in incidence calculations. Due to the difficulties in performing 
reliable causality assessments, some of which this study has demonstrated, a crude incidence 
rate was calculated.   
Previous studies have estimated ADRs to cause 0.2% of neonatal admissions(44). In this 
study, seven neonates were admitted from the delivery suite or post-natal ward with suspected 
ADRs, and six of these were suspected ADRs to maternal drugs. The incidence of ADRs 
causing admission has been estimated to be much higher in children, but several factors mean 
that neonates are much less likely to be admitted due to an ADR. Neonates, by WHO 
definition, only have 28 days to be classed as a neonate admitted with an ADR. Preterm 
neonates will have longer, but by being born preterm they will most definitely be admitted to 
neonatal care anyway. The majority of neonates in NICUs are those born preterm or suffering 
congenital defects or complications from labour and/or delivery. The dilution effect of these 
neonates masks those neonates who are admitted due to an ADR. A neonate discharged 
home well after birth is unlikely to need any medicines, and in this study any sick neonates 
admitted from home will have been admitted to the local children’s hospital, not the NICU 
studied. Additional research into ADRs causing neonates to be admitted from home, or those 
occurring in the community, may yield different results to the ADRIN study.  
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As sick neonates make up a relatively small proportion of the total number of inpatient children 
in the UK, a much larger scale study is needed to assess ADRs in neonates and to be able to 
give a valid estimate of incidence. The ADRIC programme was undertaken by a team of 
researchers at one of the largest children’s hospitals in the UK over a one-year period. One of 
the only prospective studies into neonatal ADRs to date also collected data over a one-year 
period, in which time 322 neonates were observed. Neonatal units are normally small such 
that an optimally designed study should be multi-centric. This opportunity was explored with 
ADRIN as another tertiary neonatal unit is located less than 20 miles away from LWH. The 
decision was made not to pursue this as it was thought that time and resources were better 
spent collecting reliable, accurate data from one site. The collection of ADR reports was 
undertaken by a single researcher, and whilst it would have been possible for additional people 
to do this in other sites, it would be difficult to regulate this to avoid bias. The addition of a 
researcher without any other clinical commitments would be necessary, as well as an identical 
introduction of the study to the second unit. ADRIC used a team of researchers trained in ADR 
data collection at one site who could communicate with each another if they faced any 
difficulties. There is most likely not a neonatal unit in the world large enough to conduct the 
same scale study at one site, but multiple researchers working at a unit each could be trained 
together and communicate processes and findings regularly.  
This study used the definition of an ADR defined by Allegaert(10). This definition allows for 
the inclusion of ADRs to drugs that have been prescribed unlicensed or off-label, a practice 
which commonly occurs in neonates. Had other definitions of ADRs been used for this study 
the frequencies of ADR reports seen may have been different.   
Many of the ADRs reported in this study would not have been included under Laurence’s 
definition. ‘A drug at doses intended for therapeutic effect (or prophylaxis or diagnosis)’ may 
not have allowed for the ADRs reported detailing off-label prescriptions in this study (30/63 
reports). A ‘harmful or significantly unpleasant effect’ would rule out those cases reported in 
this study that could be considered milder ADRs, even though many still affected the care of 
the neonate. Furthermore, it is impossible to tell which ADRs cause a ‘significantly unpleasant 
effect’ when the affected neonate cannot communicate symptoms to a clinician. What might 
seem to be a minor and/or easily treated reaction could be silently causing significant distress 
to the neonate e.g. urinary retention. Prediction of hazard from future use is also difficult to 
assess in a population where re-challenges are infrequent, and any future use may occur 
when the neonate is older and thus physiologically different(8). The same argument stands 
for Edwards and Aronson’s definition(9). 
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4.3.2 Types of reactions 
This prospective observational study observed a wide range of reaction types and there was 
at least one ADR report for nearly every organ system. It was noted that no hepatobiliary 
effects were reported. Some such ADRs may have been missed, as ADRs such as jaundice 
relating to TPN use are well documented. However, as is the case with many other 
investigations in neonates, changes in liver function tests are difficult to attribute to iatrogenic 
cause as they are commonly associated with other clinical conditions such as infection. The 
only reported ADR to affect the skin was an extravasation burn. On the NICU, drips used to 
administer IV medications to neonates are monitored very closely and any drug known to be 
an irritant to veins and skin is often administered through a long line. Another reason for this 
could be that many dermatological ADRs are immune-mediated and preterm neonates lack 
the immune exposure to build up the potential cross reactions.  
Although the most commonly reported ADRs types were in the cardiovascular and metabolic 
disorders categories, a larger scale study is needed to determine the full spread of neonatal 
ADR types. There are unique difficulties in observing some reactions in neonates. For 
example, it is difficult to detect some respiratory effects in neonates who are ventilated, as the 
neonates were in 36 of the 63 suspected ADR reports in this study. Gastrointestinal effects 
may become less apparent in neonates who are temporarily nil by mouth and skin changes 
can be difficult to distinguish from the very delicate and thin skin of a preterm neonate. As 
neonates cannot communicate, work is needed to define the physiological parameters in 
which neonatal norms lie, and further research is being conducted in this field.   
When the ADRs in this study were assessed for severity, 28 ADRs were assessed as being 
mild and 28 were assessed as being moderate. No ADRs were assessed as being severe. 
However, the severity assessment method used was not neonate-specific, and it is clear that 
the severity categories may be difficult to apply to this population. For example, this method 
of severity assessment refers to prolongation of patient stay. However, many sick preterm 
neonates will be inpatients for several months, so it will be difficult to assess whether an ADR 
truly prolonged an already lengthy stay. Additionally, some ADRs in neonates may not be 
treatable, but this does not necessarily mean they are not severe. Finally, in some neonates, 
it will be hard to assess whether an ADR is potentially life-threatening when being born very 
preterm in itself is extremely high risk. It is likely that using a neonate-specific method of 
assessing severity may yield significantly different results and find some of the collected cases 
as severe.     
Absence of communication by neonates makes it difficult to detect an ADR, but also to 
determine the pathophysiology. This study observed four reports of ADRs to eye drops used 
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for retinopathy of prematurity screening, cyclopentolate and phenylephrine eye drops. 
However, these eye drops are known to cause stinging in the eye, so it is impossible to know 
whether the effects observed were due to the drug itself, or the pain they caused. Whilst eye 
drops causing pain is ultimately still an ADR, it is difficult to suggest a solution when the full 
pathophysiology is unknown. The use of these drops in older children or adults must have first 
lead to the discovery that they cause pain, but the reaction profile in neonates could be 
different.   
The NICU studied in ADRIN was a tertiary unit treating extremely preterm and sick neonates. 
It would be interesting to compare the reactions suspected and reported in this study to those 
observed in secondary and primary units, those in the community and those in surgical units. 
These settings, whilst they all treat sick neonates, will use a different array of drugs in different 
proportions. The unit studied in ADRIN does not care for neonates receiving general 
anaesthetic as a surgical unit would. Neonates treated in the community are less likely to be 
suffering from additional comorbidities which would veil the diagnosis of an ADR. A separate 
study monitoring neonatal adverse drug reactions to drugs given in the community could be 
carried out.   
Further research could be done to follow up those neonates who do experience ADRs to 
observe the long-term effects. For example, oxygen is known to be linked to the development 
of retinopathy of prematurity in preterm neonates, but historically the effects were not observed 
until the neonate was older.  
4.3.3 Types of drugs 
The most common drug categories reported in this study were cardiovascular system drugs, 
anti-infectives for systemic use, nervous system drugs and sensory organ drugs. The data 
collection period in this study was too short to determine whether there was a predominance 
of ADRs in any drug categories, but larger scale studies may demonstrate if this is the case. 
It is difficult to determine whether certain drug types cause more ADRs because they are the 
most harmful or because they are more commonly prescribed, or indeed, a combination of 
both. 
It was interesting to note that there were no ADRs to surfactant observed in ADRIN. The 
ADRIN team were aware that no ADRs to surfactant were submitted via the Yellow Card 
Scheme between 2001 and 2010, and so were alert to cases of these ADRs(6). Despite this, 
none were observed. As surfactant is administered in the first few minutes of a neonate’s life, 
it is usually prescribed and documented before the neonate reaches the neonatal unit, and 
thus may not be suspected in ADRs that occur in the first few days of life. As shown in table 
9, there were only two neonates who received surfactant on the neonatal unit over the nine-
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week period. Experiments into the significance of surfactant in neonatal lung function and 
development first began in the late 1920s(79). For the past 25 years, surfactant has been an 
essential and commonly used drug in neonatal care and it is likely that these years of reviewed 
use has led to a safe drug(79). Although ADRs to surfactant have occurred in neonates in the 
past, it is likely that a larger study would be needed to detect these ADRs(49).        
A recent quasi-systematic review outlined the most commonly prescribed drugs in NICUs 
worldwide(24). It found nine of the top twenty most cited drugs were also listed on the A-
PINCH list, a list of medications that pose high risks if medication errors occur(80). The list 
includes anti-infectives, potassium and concentrated electrolytes, insulin and narcotics and 
sedatives, all of which are used on neonatal units. The other two groups, chemotherapy 
agents, and heparin and other anticoagulants, are not routinely used on neonatal units. 
Gentamicin and morphine, the most commonly reported drugs in this study, also appear on 
the A-PINCH list, and in total 22 of the 78 reported drugs in this study are A-PINCH listed 
drugs(24)(80). Worryingly, given that anti-infectives feature on the A-PINCH list, there were 
only ten UK Yellow Card reports detailing neonatal ADRs to antibiotics between 2001 and 
2010(6).  
The four ADRs to cyclopentolate and phenylephrine eye drops demonstrate that drugs used 
to support diagnostic procedures can cause ADRs, even those used for a common procedure 
in neonates. However, these ADRs could be considered minor and a short-lived price worth 
paying for better outcomes for the future eye sight of affected neonates. This demonstrates 
how reporting ADRs could have the ability to affect routine neonatal care, not just those drugs 
used for the sickest neonates.  
4.3.4 Risk factors  
There was insufficient data collected in this prospective study to carry out the statistical 
analysis necessary to comment on potential risk factors. Neonates represent a unique 
population in relation to risk factors. As the majority of neonates needing neonatal care input 
are born preterm, it may be hard to distinguish neonatal risk factors for developing an ADR 
from the risk factors for preterm birth. Previous literature has shown the number of medications 
and the percentage of unlicensed/off-label medications to be significantly associated with 
increased risk of an ADR(76). In ADRIN, 65% of the suspected ADR cases occurred in 
neonates who received 10 or more medications at the time the ADR was suspected to have 
occurred. It has been theorised elsewhere that ADRs to off-label or unlicensed drugs risk being 
unreported(81).    
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4.3.5 Reporting and underreporting 
This study observed a considerable number of ADR reports in a short data collection period. 
Though there are varied definitions, methodologies and guidance in neonatal 
pharmacovigilance, most research agrees that a considerable rate of underreporting is 
currently occurring.  
It is highly likely that underreporting also occurred in this study. The limited resources for the 
study meant it was impossible to monitor every neonate on the unit for possible ADRs 24 
hours a day, seven days a week. It is likely that the results of this study would have varied had 
the researcher been a clinician. This could be interpreted in different ways; that a more 
experienced clinician would detect more ADRs, they would better understand the pathologies 
mimicking them, or an experienced clinician would have been less sensitive to ADRs because 
many clinicians consider anticipated side effects not to be ADRs [Arnott, personal 
communication, unpublished results from ADRIC].   
It is difficult to measure the effectiveness of an ADR detection strategy without knowing the 
true number of ADRs that have occurred. In this study, one extravasation injury was detected 
and reported. BadgerNet, the electronic patient notes system, can generate a report of the 
number of extravasation injuries that have been documented in all patients’ notes in a given 
time period. Staff are also asked to complete an ‘adverse clinical event’ form for extravasation 
injuries. As one possible way of measuring the effectiveness of the ADR detection methods in 
this study, these three sources of information were compared. BadgerNet also only reported 
one extravasation injury in the nine-week study period, however this was a different 
extravasation injury to the one reported in the study. There were no adverse clinical event 
forms completed in the nine-week period. This suggests that the ADR detection and reporting 
intervention in ADRIN could be more effective than relying of staff reporting alone.   
However, even though the ADR detection and reporting intervention was effective in collecting 
cases of suspected ADRs in this study, it relied on an independent researcher. The reporting 
technique may need to be adjusted if it were to be implemented into clinical practice and 
undertaken by staff with other clinical duties. One consideration is the data collection proforma. 
As the researcher completed this in the study, the data collection process was consistent and 
omissions in detail were infrequent. However, the proforma may need to be adapted for it to 
be completed by staff in routine clinical practice. Some fields may need to be made more 
specific to collect the level of detail required for a causality assessment to be undertaken. 
Another possible adaptation could be to create an electronic copy of the ADR case reporting 
form which could be used alongside the electronic patient notes system. Certain fields could 
be automatically completed using data extracted from BadgerNet, which would save staff time. 
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A more sophisticated database that could do this was used successfully in the ADRIC 
programme. This concept could also work in reverse, prompting clinical staff to document 
details that may be relevant to an ADR when writing patient clinical notes. This would help 
alleviate some of the difficulties faced when it is not known whether certain details are not 
recorded because of human error, or because they were considered unimportant. For 
example, if a neonate were to be prescribed prostaglandin, prompts to comment on the 
neonate’s temperature could alert staff to an ADR and help with future data collection if an 
ADR were to occur. An electronic database could also help monitor neonates that do not 
experience an ADR. If data could automatically be collected on every neonate admitted to the 
unit over a given study period, some commentary may be able to be made regarding possible 
risk factors for developing an ADR.  
Of the 63 ADR reports collected, only 16 of these were prompted by members of staff other 
than the researcher. This was despite multiple efforts to ensure every member of staff was 
encouraged to report all ADRs throughout the data collection period and beyond. Doctors, and 
specifically consultants, reported the most suspected ADRs to the researcher whereas only 
two reports were prompted by nurses. However, more time was spent with the doctors on the 
unit through handovers and ward rounds and there are many more nursing staff who regularly 
change shifts. It was disappointing that no reports were prompted by pharmacists despite an 
introduction of the study to them, but further interventions to include pharmacists in the data 
collection may have prompted different results. Having a clinical pharmacist regularly present 
to consult with during the study would have enabled the researcher to query any ADRs, as 
well as helping alert the researcher to any further ADRs. ADRIC found that using clinical 
pharmacists was an effective way of collecting paediatric ADR cases. There is a strong 
argument for clinical pharmacists being the most appropriate staff members to monitor ADRs, 
either as independent researchers or as part of routine clinical practice, given the nature of 
their work and knowledge with regards to the safety of medicines. Had the data collection 
period been extended, it would have been interesting to observe whether additional, more 
varied educational and motivational interventions would have boosted the number of ADRs 
reported.  
Pharmacovigilance is defined by WHO as ‘the science and activities relating to the detection, 
assessment, understanding and prevention of adverse effects or any other drug-related 
problem’(43). This study addressed the detection and assessment of ADRs. Whilst the study 
demonstrated some methods that could be used for ADR detection, it also outlined some of 
the flaws with these methods and identified that more work is needed to make detection and 
assessment of ADRs a routine part of neonatal care. The addition of a standalone researcher 
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to collect reports of suspected ADRs resulted in the detection of a considerable number of 
ADRs, but it is not feasible to employ someone for this purpose alone.  
Whilst this study is one of the only existing studies detailing prospective observation of 
neonatal ADRs, more work exists detailing how ADR detection and reporting in children could 
be improved. In the late 1990s, establishing a Paediatric Regional Monitoring Centre was 
piloted to observe whether this intervention would stimulate ADR reporting. A significant 
increase in paediatric ADR reporting resulted, increasing the number of paediatric Yellow Card 
reports as a percentage of total Yellow Card reports for the region above the national average. 
However, still only one report of an ADR in a neonate was received using this approach (81). 
Other proposed methods for improving pharmacovigilance in neonates, some of which have 
been successful in adults, include computerised systems, studies into individual ADR signals, 
epidemiological approaches, pharmacogenomic approaches and increased involvement of 
families(11).   
Understanding and prevention of ADRs was not addressed in ADRIN, but the cases collected 
could be further assessed in future research to contribute to these aspects of 
pharmacovigilance.   
4.3.6 Comparison of results to Yellow Card reports to the MHRA 
The MHRA guidance on reporting paediatric ADRs changed recently to encourage the 
reporting of only those ADRs considered to be serious or result in harm. However this 
guidance was only published in September 2014 meaning the ADRs reported between 2001 
and 2010 should have been in line with the previous guidance to report all ADRs in 
children(13). The different rates of reporting of ADRs to neonatal medicines were 0.187 
reports/week and 6.22 reports/week for the Yellow Card Scheme and the ADRIN study 
respectively. The active surveillance performed in the study resulted in 33 times as many 
reports as routine submission to the MHRA.  
The Yellow Card reports detailed 11 reports of ADRs to vaccinations, yet the most commonly 
reported drugs in this study were gentamicin, morphine and dopamine. Vaccines receive a 
large amount of both positive and negative media attention and are often the subject of large 
public health campaigns. Media attention to publications such as the reprimanded MMR and 
autism hypothesis paper have not helped in encouraging parents to vaccinate their 
children(82). Many people feel concern over being given doses of pathological organisms, 
even though many vaccines are not live, such that high anxiety regarding their use makes 
patients more aware of side-effects and more likely to report them. Receiving a vaccination is 
stressful for both the child and the onlooking parent. These factors sensitise parents, patients 
and healthcare practitioners to the side-effects of vaccinations. However, even though 
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vaccinations received the highest number of Yellow Card reports, the number is low in 
comparison to the number of vaccines that would have been administered to neonates over 
the 10-year period.   
All suspected ADRs regardless of perceived severity and causality were reported in this 
prospective observational study. As anyone can report a suspected ADR to the Yellow Card 
Scheme, the 97 Yellow Card reports included reports of ADRs suffered by neonates in the 
community and reports by parents. The study only observed neonatal ADRs occurring in an 
inpatient setting and reporting by parents was not included. The ADRIC research programme 
conducted a qualitative study into the opinions of parents regarding reporting ADRs through 
the Yellow Card Scheme. A wide range of opinions were apparent, including the assumption 
that the task of ADR reporting needs to be carried out by professionals rather than parents. 
Some of the parents that were interviewed had children who had suffered an ADR that had 
not been reported through the Yellow Card Scheme. Following the interview, these parents 
were asked if they would like to now file a Yellow Card report, but all declined(69). Motivating 
and educating parents on reporting ADRs in their children could see a rise in the number of 
Yellow Card reports submitted, as well as increasing parental involvement in care.  
This study observed that most of the ADR reports that were prompted by other members of 
staff were done so by doctors, the majority by consultants. Over half of the Yellow Card reports 
were also reported by doctors. However, it is possible that the individual tasked with reporting 
the ADR was not always the same person who first suspected the ADR, both using the Yellow 
Card Scheme and in this study. More research could be conducted to identify which individuals 
are most likely to detect ADRs in their roles within the wider care team, and how 
pharmacovigilance could be effectively integrated into the different roles fulfilled by an MDT.  
It would also be interesting to see whether any neonatal ADR reports were submitted via the 
Yellow Card Scheme during the same nine-week period that the study observed. Given the 
rate of reporting during 2001 and 2010, it is likely that there would not have been enough 
reports to make a meaningful comparison.  
A neonate-specific data collection proforma was designed for this study to allow the collection 
of all the data that was thought necessary for an informed causality assessment of the ADR. 
Yellow Cards reports often do not record some basic demographical information, such as 
weight. There is also no prompt to be specific about corrected gestational age, and both 
factors are known to influence neonatal pharmacology. Some of the Yellow Cards submitted 
did not report gender. This shows it is not only the quantity of neonatal ADR reports to the 
Yellow Card Scheme which is concerning, but the quality of information recorded too.   
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4.3.7 Summary 
This prospective observational study has shown that ADRs occur in neonates and can impact 
their care. The spread of ADRs seen show that it is not only sick, preterm neonates that 
experience ADRs, and that some neonates will suffer multiple ADRs in a short time period. 
ADRs were observed to commonly prescribed drugs, some of which are used routinely for 
both diagnostic and therapeutic purposes. Although the focus of this study was on ADRs 
occurring to drugs prescribed directly to the neonate, some ADRs were observed as a result 
of drugs prescribed to the mother of the neonate during labour or pregnancy. A study focusing 
on these types of reactions alone could yield important results, and it is likely these ADRs 
would require unique evaluation methods. Additionally, a discrepancy between ADRs reported 
under research conditions and those being reported spontaneously is apparent. Educational 
and motivational interventions that are accepted by neonatal staff will be needed to improve 
reporting to encourage better pharmacovigilance for neonates.      
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Chapter 5: Causality assessment of adverse drug reactions in 
neonates 
Once an ADR is suspected in any patient, it is important to evaluate the ADR as part of good 
pharmacovigilance. Some algorithms exist to help clinicians to assess ADRs and have been 
in use for 40 years. However, research shows that these tools rarely produce a reliable 
outcome when compared with each another, perhaps leaving the clinician thinking their own 
judgement may be just as accurate and less time-consuming(83). 
The team who conducted the paediatric study (Adverse Drug Reactions in Children, ADRIC) 
found that existing tools were difficult to use to evaluate paediatric ADRs, particularly those 
occurring in paediatric in-patients. Neonates are likely to suffer similar burdens of ADRs, as 
has been described in the past and in the present(9)(46). This study evaluated the use of three 
causality assessment tools to determine their use for assessing ADRs in neonates. 
Six assessors undertook three assessments each of 34 cases, resulting in 102 assessments 
per assessor and 612 total assessments. Each case was therefore assessed 18 times.   
Table 16 shows the causality ratings assigned to each of the 34 cases by the six assessors. 
A chi squared test showed that the excess of definite ratings using the Du Lehr method was 
highly statistically significant, p-value < 0.001. This is suggestive of over-evaluation of 
causality of the ADR cases using the Du Lehr algorithm, leading to more neonatal ADRs being 
given definite ratings than would be agreed upon by expert consensus, or when using other 
methods of causality evaluation.  
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Table 16 Six assessors' causality ratings of 34 neonatal ADR cases using three different methods 
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15 5 1    5   1 2 3 1  
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16 3 2 1   2 1  3 1 3 2  
17 1 3 1  1  1 1 4  2 3 1 
18 4  1 1  4  1 1 1 3 2  
19 3 1 1 1  3  1 2 1 3 2  
20 1  2 3   1 1 4   6  
21  3 1 2  1  2 3 1 2 1 2 
22  1 1 3 1   1 5   4 2 
23  1 3 2     6  1 5  
24    1 5    6   1 5 
25 2 3 1   3  3  1 3 2  
26 2 2 1 1  2 1 2 1 1 4 1  
27 1 2  3    3 3  2 4  
28 2 3  1  3 1 2  1 3 2  
29  1 2 3    2 4  3 3  
30 3 3    5 1   4 2   
31  1 4 1     6   6  
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 Karch and Lasagna algorithm Du Lehr LCAT 
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32 4 1 1   4  1 1 3 3   
33  1 1 2 2   1 5  1 3 2 
34  3 1 2  1 1  4 1 1 4  
Grand total 
(n)  
39 46 47 53 19 39 13 36 116 19 69 98 18 
Grand total 
(%) 
19.1 22.5 23.0 26.0 9.31 19.1 6.86 17.6 56.4 9.31 33.8 48.0 8.82 
Number of 5 
or 6s in each 
column 
1 0 0 0 1 2 0 0 12 0 0 8 1 
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5.1 Inter-rater reliability  
Table 17 shows the number of times each rating was given by each assessor using each of 
the three tools.  
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Table 17 Frequency of ratings per assessor per tool 
Assessor Tool Unlikely Conditional Possible Probable/Likely Definite 
BP K+L 
algorithm 
9 3 6 12 4 
 Du Lehr 10 - 1 1 22 
 LCAT 10 - 0 20 4 
BY K+L 
algorithm 
9 10 6 8 1 
 Du Lehr 11 - 3 4 16 
 LCAT 5 - 9 17 3 
BS K+L 
algorithm 
5 11 9 8 1 
 Du Lehr 4 - 2 10 18 
 LCAT 1 - 12 19 2 
MT K+L 
algorithm 
10 8 9 5 2 
 Du Lehr 7 - 4 6 17 
 LCAT  - 20 13 1 
DH K+L 
algorithm 
3 4 14 10 3 
 Du Lehr 3 - 1 9 21 
 LCAT 2 - 8 20 4 
JM K+L 
algorithm 
3 11 3 9 8 
 Du Lehr 4 - 2 6 22 
 LCAT 2 - 11 17 4 
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Pair-wise kappa scores were measured between all six assessors using each of the three 
tools (tables 18, 19 and 20). Weighted kappa scores ranged from 0.148 to 0.454 for the Karch 
and Lasagna algorithm, 0.114 to 0.483 for the Du Lehr and 0.121 to 0.428 for the LCAT. The 
majority of weighted kappas for each pair-wise comparison for each tool corresponded to ‘fair’ 
inter-rater reliability.      
Percentage exact agreement between the ratings given to each case by each of two 
assessors, ranged from 14.7% to 41.2% for the Karch and Lasagna algorithm, 38.2% to 58.8% 
for the Du Lehr tool and 26.5% to 61.8% for the LCAT. Extreme disagreement ranged from 
8.82% to 35.3% for the Karch and Lasagna algorithm, 11.8% to 38.2% for the Du Lehr tool 
and 0% to 17.6% for the LCAT.  
All of the assessors were most likely to assign the causality rating of ‘definite’ using the Du 
Lehr method. All but one of the assessors were most likely to assign the causality rating of 
probable using the LCAT. The Karch and Lasagna algorithm led to more varied assessments. 
Global kappa scores were measured to outline the inter-rater agreement between all six 
assessors. These figures reflected the range of pair-wise kappas that were seen and can be 
found in table 21. 
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Table 18 Karch and Lasagna algorithm inter-rater reliability: red shading- ‘poor’ inter-rater reliability, orange shading- ‘fair’ inter-rater reliability, 
green shading- ‘moderate’ inter-rater reliability  
      Assessor 1           
      BP BY BS MT DH JM 
Assessor 
2 
BP 
%EA/ED   35.3%/32.4% 29.4%/ 20.6% 29.4%/35.3%  35.3%/32.4% 29.4%/23.5% 
Kappa score (95% CI)   
0.177 (-0.012 to 
0.366)  
0.117 (-0.060 to 
0.293) 
0.113 (-0.067 to 
0.293)  
 0.170 (-0.021 to 
0.361) 
0.130 (-0.043 to 
0.303)  
Weighted Kappa score   0.328 0.311 0.207  0.264 0.348 
  BY 
%EA/ED     32.4%/8.82% 41.2%/14.7%  32.4%/34.3% 35.3%/26.5% 
Kappa score (95% CI)     
0.113 (-0.100 to 
0.327) 
0.236 (0.021 to 
0.451)  
 0.152 (-0.035 to 
0.339) 
0.188 (0.002 to 
0.373)  
Weighted Kappa score     0.381 0.454  0.243 0.400 
  BS 
%EA/ED       29.4%/20.6% 38.2%/17.6%  23.5%/20.6% 
Kappa score (95% CI)       
0.088 (-0.112 to 
0.288)  
 0.196 (-0.018 to 
0.410) 
0.032 (-0.148 to 
0.211)  
Weighted Kappa score       0.278  0.364 0.293 
  MT 
%EA/ED          17.7%/26.5% 35.3%/35.3% 
Kappa score (95% CI)         
 -0.044 (-0.205 to 
0.117) 
0.213 (0.030 to 
0.395)  
Weighted Kappa score          0.148 0.284 
  DH 
%EA/ED            14.7%/29.4% 
Kappa score (95% CI)           
 -0.041 (-0.191 to 
0.109) 
Weighted Kappa score            0.154 
  JM 
%EA/ED        
Kappa score (95% CI)        
Weighted Kappa score             
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Table 19 Du Lehr inter-rater reliability: red shading- ‘poor’ inter-rater reliability, orange shading- ‘fair’ inter-rater reliability, green shading- 
‘moderate’ inter-rater reliability 
      Assessor 1           
      BP BY BS MT DH JM 
Assessor 
2 
BP 
%EA/ED   55.9%/26.5% 58.8%/23.5% 50.0%/29.4% 58.8%/23.5% 58.8%/26.5% 
Kappa score (95% CI)   
0.258 (0.027 to 
0.489)  
0.328 (0.132 to 
0.523) 
0.177 (-0.065 to 
0.418)  
0.272 (0.044 to 
0.500) 
0.237 (0.043 to 
0.432) 
Weighted Kappa score   0.372 0.397 0.240 0.316 0.330 
  BY 
%EA/ED     55.9%/26.5% 52.9%/17.7% 38.2%/38.2% 50.0%/26.5% 
Kappa score (95% CI)     
0.344 (0.134 to 
0.555) 
0.294 (0.076 to 
0.513) 
0.045 (-0.141 to 
0.232) 
0.208 (0.006 to 
0.410) 
Weighted Kappa score     0.394 0.483 0.114 0.352 
  BS 
%EA/ED       44.1%/20.6% 52.9%/11.8% 47.1%/20.6% 
Kappa score (95% CI)       
0.143 (-0.080 to 
0.367)  
0.193 (-0.076 to 
0.462) 
0.100 (-0.141 to 
0.341)  
Weighted Kappa score       0.316 0.368 0.277 
  MT 
%EA/ED          47.1%/23.5% 52.9%/26.5% 
Kappa score (95% CI)         
 0.150 (-0.040 to 
0.340) 
0.234 (-0.006 to 
0.473) 
Weighted Kappa score          0.240 0.316 
  DH 
%EA/ED            58.8%/20.6% 
Kappa score (95% CI)           
 0.240 (-0.016 to 
0.495) 
Weighted Kappa score            0.218 
  JM 
%EA/ED             
Kappa score (95% CI)             
Weighted Kappa score             
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Table 20 LCAT Inter-rater reliability: red shading- ‘poor’ inter-rater reliability, orange shading- ‘fair’ inter-rater reliability, green shading- ‘moderate’ 
inter-rater reliability 
      Assessor 1           
      BP BY BS MT DH JM 
Assessor 
2 
BP 
%EA/ED   50.0%/17.7% 41.2%/17.7% 26.5%/11.8% 44.1%/17.6% 55.9%/11.8% 
Kappa score (95% CI)   
0.233 (0.033 to 
0.434) 
0.103 (-0.049 to 
0.255) 
0.047 (-0.057 to 
0.151) 
0.103 (-0.106 to 
0.312) 
0.346 (0.152 to 
0.540) 
Weighted Kappa score   0.297 0.169 0.121 0.187 0.428 
  BY 
%EA/ED     55.9%/5.88% 55.9%/5.88% 61.8%/14.7% 52.9%/8.82% 
Kappa score (95% CI)     
0.279 (0.040 to 
0.517) 
0.112 (0.103 to 
0.541) 
0.388 (0.137 to 
0.639) 
0.271 (0.026 to 
0.516) 
Weighted Kappa score     0.356 0.355 0.368 0.345 
  BS 
%EA/ED       50.0%/0.00% 52.9%/0.00% 44.1%/5.88% 
Kappa score (95% CI)       
0.133 (-0.155 to 
0.422) 
0.188 (-0.114 to 
0.491) 
0.065 (-0.222 to 
0.352) 
Weighted Kappa score       0.213 0.327 0.142 
  MT 
%EA/ED        47.1%/8.82% 50.0%/2.94% 
Kappa score (95% CI)        
0.164 (-0.068 to 
0.396) 
0.187 (-0.066 to 
0.441) 
Weighted Kappa score        0.160 0.264 
  DH 
%EA/ED            50.0%/5.88% 
Kappa score (95% CI)           
0.184 (-0.094 to 
0.461) 
Weighted Kappa score            0.274 
  JM 
%EA/ED             
Kappa score (95% CI)             
Weighted Kappa score             
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Table 21 Global kappa scores for six assessors using three causality assessment methods 
Tool Global Kappa Confidence interval 
Karch and Lasagna  0.157 0.0741 – 0.239 
Du Lehr 0.254 0.139 – 0.369 
LCAT 0.209 0.121 – 0.297 
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5.2 Inter-tool reliability 
Weighted and non-weighted kappa scores were also calculated to measure the agreement 
when each assessor used different tools to assess the same 34 cases. This aimed to measure 
inter-tool reliability. There was significant variability between assessors, but some were 
consistent in their assessment regardless of the tool used. The highest kappa score was seen 
when comparing each assessor’s ratings using the Karch and Lasagna algorithm and the 
LCAT.   
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Table 22 Inter-tool reliability: red shading- ‘poor’ inter-tool reliability, orange shading- ‘fair’ inter-
tool reliability, green shading- ‘moderate’ inter-tool reliability, dark green shading- ‘good’ inter-
tool reliability 
Assessor  Karch and 
Lasagna and 
Du Lehr 
Karch and 
Lasagna and 
LCAT 
Du Lehr and 
LCAT 
BP Kappa score 
(95% CI) 
0.218 (0.087 to 
0.350) 
0.580 (0.386 to 
0.774) 
0.319 (0.183 to 
0.454) 
Weighted 
Kappa score 0.460 0.712 0.616 
BY Kappa score 
(95% CI) 
0.257 (0.109 to 
0.405) 
0.261 (0.037 to 
0.485) 
0.255 (0.094 to 
0.415) 
Weighted 
Kappa score 0.383 0.434 0.538 
BS Kappa score 
(95% CI) 
-0.022 (-0.157 to 
0.112) 
0.102 (-0.118 to 
0.321) 
0.058 (-0.108 to 
0.223) 
Weighted 
Kappa score 0.145 0.236 0.298 
MT Kappa score 
(95% CI) 
0.109 (-0.037 to 
0.255) 
0.183 (-0.043 to 
0.409) 
0.030 (-0.071 to 
0.130) 
Weighted 
Kappa score 0.246 0.360 0.239 
DH Kappa score 
(95% CI) 
0.067 (-0.072 to 
0.206) 
0.409 (0.184 to 
0.635) 
0.071 (-0.100 to 
0.242) 
Weighted 
Kappa score 0.227 0.533 0.285 
JM Kappa score 
(95% CI) 
0.194 (0.021 to 
0.367) 
0.455 (0.234 to 
0.676) 
0.165 (0.004 to 
0.325) 
Weighted 
Kappa score 0.348 0.591 0.338 
 
 
  
124 
 
5.3 Assessor view of tool usability 
After completing the causality assessments, each assessor was asked to complete a brief 
questionnaire evaluating each causality assessment tool. The assessors were asked to rate 
four statements regarding the usability of each tool on a Likert scale. The collated results can 
be seen in figures 2 to 5.  
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Figure 2 ‘The tool was easy to use’ - assessor opinions regarding three methods 
 
Figure 3 'The tool was appropriate to use for a neonatal ADR case' - assessor opinions regarding 
three methods 
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Figure 4 'The tool fairly assessed all causality aspects of the case' - assessor opinions regarding 
three methods 
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Figure 5 'I would use this tool in clinical practice if it were available' - assessor opinion 
regarding three methods 
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There was also opportunity in this questionnaire for free text regarding any aspect of the tool. 
Further to this some of the assessors reported their opinions verbally. Some commentary on 
the opinions has been shared below.  
Karch and Lasagna algorithm 
The Karch and Lasagna algorithm does not recognise the effect of changing the dose of 
medications as it only focuses on the effect of withdrawing or reintroducing the drug. This 
could lead the user to choose the option ‘they don’t withdraw the medicine and the ADR 
improves’, taking away two points from the final rating. As there is no alternative option, a 
reduction in drug dose which sees an ADR improve would have to fit under this category, 
reducing the likelihood of causality from a seemingly positive association. ADRs associated 
with a permanent or long-lasting effect also have difficulty fitting into a category here. For 
example, an extravasation burn does not immediately improve when the drug is stopped and 
is likely to remain if the drug is started through a different line.  
Sections F and G in this algorithm regarding ‘contributing factors which favour the causal 
relationship’ and ‘extra examinations’ were used in varying amounts by the different 
assessors, even though every assessor assessed the same cases. ‘Contributing factors which 
favour the causal relationship’ is open to individual interpretation, and some clinicians gave 
examples of what factors had led them to select the option; family history, timing of the ADR, 
improvements on stopping. Examples of ‘extra examinations’ used included abdominal x-rays 
and serum drug levels. 
‘New Adverse Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units’ 
algorithm (Du Lehr) 
The ‘New Adverse Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units’, like 
the Karch and Lasagna algorithm, requires the user to add multiple scores together to reach 
an outcome. The answer to each of the thirteen questions is weighted differently. To reach a 
rating of definite the assessor can score the reaction anywhere in the range of 14 to 51 
whereas to reach a possible rating the score can only range from 3 to 6.  The tool also allows 
limited answers to be given- yes, no or not applicable/unknown. Some of the questions lend 
themselves to a ‘maybe’ option, such as ‘was the adverse event likely a change (exacerbation, 
recurrence, complication, or new manifestation) in a pre-existing condition?’, yet this option is 
not available. 
The Liverpool Adverse Drug Reaction Causality Assessment Tool (LCAT) 
The LCAT appears the quickest tool to use as the clearly laid out flow chart leads the user 
directly to the outcome without the need for calculations.  
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Clinicians noted that it was very hard to reach a definite rating when assessing the neonatal 
ADR cases. The only way of reaching this outcome using the LCAT is if the neonate 
experiences a positive re-challenge of the suspected drug or has a history of suffering the 
same ADR. Whilst some neonates in the study did have histories of suffering the same or 
similar ADRs, this was usually in the less severe ADR cases. Re-challenges were rarely 
observed. Unlike the other tools, the LCAT does not provide an unknown option for all the 
questions. The assessors found this difficult for the questions ‘was there a positive re-
challenge?’ and ‘Is there a past history of the same event with this drug in this patient?’. Some 
of the ADR cases used in this study were experienced by neonates that were transferred to 
or from other hospitals throughout their care, and so the information regarding possible 
historical ADRs or re-challenges was not always available.  
The question ‘was the event associated with long-lasting disability or impairment?’ may also 
not be appropriate for use in neonates given that these factors may not be able to be assessed 
for some years. 
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5.4 Discussion 
The primary reason for collecting neonatal ADR data was to assess the use of three causality 
assessment tools to determine their appropriateness for neonatal clinical practice. A method 
which assesses the likelihood that a drug has caused a neonate harm, that is tested, 
population-specific and efficient, could greatly impact the health of neonates in the UK and 
other countries. If such a method were available in the everyday clinical care of neonates, 
clinicians could make informed decisions to adjust their prescriptions and reduce iatrogenic 
harm to this vulnerable population.  
5.4.1 Causality assessment tools   
In recent years, it has become apparent that many pre-existing ADR assessment tools are 
inappropriate for assessing paediatric ADRs. Recent attempts to overcome this have resulted 
in the creation of new tools, namely the Liverpool ADR Causality Assessment Tool (LCAT) 
created in ADRIC, and the ‘New Adverse Drug Reactions Algorithm for Infants in Neonatal 
Intensive Care Units’ created in the US(65)(67). The LCAT, although the product of a study 
into ADRs in children, was not designed specifically for this population. The ‘New Adverse 
Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units’ (referred to here as Du 
Lehr) has never been validated in a setting outside of that in which it was originally created. 
The Karch and Lasagna algorithm is an older tool which was not designed specifically for the 
paediatric population, but has been used in a recent observational study of neonatal 
ADRs(46).  
This study evaluated neonatal ADRs using the aforementioned tools, to determine whether 
any one, or a combination of different elements of each, is appropriate for use in a neonatal 
setting.  
5.4.2 Inter-rater reliability 
The results of evaluating the three causality assessment methods to determine their 
appropriateness for assessing neonatal ADRs show no clear optimum method. All three tools 
demonstrated only ‘fair’ inter-rater reliability when the tools were used by six different 
assessors to evaluate real neonatal ADR cases. There was little difference between the Kappa 
scores calculated to measure the pair-wise agreements for all assessors using each of the 
three tools. The Du Lehr method showed the lowest number of kappa scores corresponding 
to poor inter-rater reliability (1). Each tool only achieved one kappa score that corresponded 
to moderate inter-rater reliability. The global kappa scores showed the Du Lehr method 
demonstrated the best inter-rater reliability, but the score was only marginally higher than 
those for the other two tools. 
130 
 
The ranges of pair-wise weighted kappas were similar amongst all three tools. Only 6.67% of 
the kappas for each tool suggested ‘moderate’ inter-rater reliability. For the Karch and 
Lasagna algorithm 80% of the remaining kappas showed ‘fair’ inter-rater reliability with two 
kappas showing ‘poor’ inter-rater reliability. A third of the LCAT kappas suggested ‘poor’ inter-
rater reliability. The use of a causality assessment tool has the potential to direct clinical 
decision making and influence medicines prescribed to neonates, so it would be hoped that at 
least a ‘good’ level of inter-rater reliability would be exhibited by a tool before its use is 
encouraged in clinical practice. When the ADRIC research team designed the LCAT, the tool 
was adapted several times before it resulted in a global kappa score of 0.6, suggesting ‘good’ 
inter-rater reliability, and was published(65).  With the majority of pair-wise kappas indicating 
only ‘fair’ inter-rater reliability for all three tools, these tools may need to be adapted before 
they are appropriate to use in neonatal clinical care. The global kappa scores calculated in 
this study reflected the range of pair-wise kappas that were seen. The highest global kappa 
was for the Du Lehr algorithm, but each of the three global kappas only correlated to fair inter-
reliability.   
5.4.3 Inter-tool reliability 
The highest inter-tool reliability was observed between the Karch and Lasagna algorithm and 
the LCAT; 20% of the pair-wise kappas exhibited ‘good’ inter-rater reliability, 40% ‘moderate’ 
and the remaining ‘fair’ (table 22). However, this does not necessarily mean that these tools 
are the most appropriate for use, only that they most often lead the user to the same outcome 
regardless of whether this outcome is an over or under-estimate of causality. This suggests 
that it is important to be consistent in causality assessment methodology within 
pharmacovigilance studies. Additionally, consistent use across pharmacovigilance studies 
would mean easier comparison between results. In the normal process of evaluating a new 
method it is compared to the current gold standard method. In the ADRIN study there was not 
a gold-standard causality assessment tool to compare the three tools to, so making a 
judgement about the efficacy of each tool was difficult. The Naranjo algorithm is a well-known 
method for assessing ADRs, but the very creation of the LCAT came about due to difficulties 
using the Naranjo algorithm to assess cases of paediatric ADRs collected in ADRIC(65).  
To increase the precision of the estimates of the ‘true’ kappa scores, an ideal study would 
assess more than 34 cases. In the case of ADRIN, time limited the ability to do this, but the 
difficulty of finding enough assessors to commit to undertaking several hundred assessments 
must be a significant limitation in many studies.  
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5.4.4 Variability amongst causality assessment methods 
For the sample of 34 ADRs, the use of different causality assessment tools yielded a range of 
outcomes for each case. Previously published studies into ADRs have only reported on the 
ADRs deemed probable or definite using varying causality assessment methods, so as to 
report accurate data that are most likely to be witnessed in other studies and neonatal 
populations. A systematic review into pharmacovigilance studies conducted in children found 
significant variation in reported data, particularly with regards to the causality and severity 
assessments conducted and the methods used for these(4). Many studies do not declare the 
method of causality assessment used or the reason for selecting a certain method. This study 
found that a different number of ADRs would be reported for publication using each of the 
three tools evaluated. This also differed between assessors.    
If the Karch and Lasagna algorithm were used, the number of ADRs included in the reported 
data set would have ranged from 7 to 17 out of a maximum of 34 ADR reports, for the six 
assessors. For the Du Lehr this increased to 20 to 30 and the LCAT range was 14 to 24.  
Across the three tools and six assessors the percentage of ADRs that could have been 
included ranged from 20.6% to 88.2%.  Of the 34 cases that were assessed for causality, there 
was only one case that did not receive at least one probable or definite rating by any assessor 
using any of the three tools.   
This demonstrates that the method of causality assessment used in a study greatly affects the 
incidence rates and results reported, and thus the interpretations made by authors and 
readers. This difficulty also applies in deciding which ADRs to report to the MHRA. As there is 
no gold standard ADR causality assessment method specifically for the paediatric or neonatal 
population, it may be beneficial to encourage a universal way of presenting ADR data in this 
population.  
Whilst the creation of a ‘perfect’ tool is awaited, it may be best to agree on the most appropriate 
tool to be used in all studies in the interim. This way, the results of studies would be easier to 
compare. An agreement on which tool to use in all pharmacovigilance studies conducted in 
neonates, and which results to report (i.e. all but unlikely ADRs), would make it easier to 
compare results and draw interpretations about differences seen. Whilst it may be hard to 
decide upon and enforce a universally accepted methodology, an alternative option would be 
to agree on a method of displaying ADR results so that they are open to interpretation and 
analysis by the reader; for example, declaring the causality assessment method, assessor 
designations and ratings given to each case by each assessor. This may be impractical in 
studies that assess hundreds or thousands of cases.    
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The different ratings were given in differing amounts using each of the three tools. For 
example, using the Karch and Lasagna algorithm and the Du Lehr tool the unlikely rating was 
given 39 times in each, but using the LCAT this rating was only given 19 times. One reason 
for this could be that one of the two ways to reach an unlikely rating using the LCAT is to 
answer no to the question ‘do you suspect an adverse drug reaction?’. It would be hoped that 
this pathway would have been used infrequently in this study given that all the cases were 
collected following an original suspicion of an ADR, though differing opinions are to be 
expected. A definite rating was given using the Karch and Lasagna algorithm and the LCAT 
almost the same amount of times, 19 and 18 respectively. However, using the Du Lehr, 116 
‘definite’ causality ratings were given, over 50% of all assessments. When the ADRIC team 
designed the LCAT they originally found the tool reached the ‘definite’ rating for 85% of the 
paediatric cases assessed. The tool was reviewed and adjusted because of this(65). However, 
it is not reported what ratings were given when the Du Lehr algorithm was tested on 50 ADR 
cases when it was first validated internally, and whether or not any adjustments were made 
because of this(67). The Karch and Lasagna algorithm showed the largest variance in ratings 
given. Only two of the 34 cases when assessed using this tool received the same rating from 
five assessors and all six assessors never perfectly agreed using this tool. However, when 
using the Du Lehr tool and the LCAT, five or more assessors gave the same rating for the 
same case fourteen and nine times respectively.  
The Du Lehr algorithm produced the most definite ratings. A chi squared test produced a p 
value <0.001 suggesting that the excess of definite ratings seen when using this tool in 
comparison to the other two tools is highly significant. This suggests that the Du Lehr algorithm 
may be over-evaluating the neonatal ADRs to give more cases definite ratings than are rated 
definite by other tools, or by expert opinion. The LCAT was adapted when it was seen to 
produce an excess of definite ratings, but the Du Lehr method was not adjusted in this way(67). 
This may be a necessary adaptation to allow a fair evaluation of neonatal ADRs. When using 
the Du Lehr algorithm, the range of scores that all denote a definite rating is much wider than 
the range for those less likely ratings, so an adjustment in these parameters may lead to a 
more accurate assessment. 
The LCAT gave mainly probable ratings and the lowest number of definite ratings of any of 
the three tools. When the numbers of probable and definite ratings from the LCAT are 
combined, the number is identical to the number of definite ratings given by the Du Lehr (116). 
This suggests that the probable rating in the LCAT and the definite rating in the Du Lehr are 
assessing a similar concept. A definite rating can only be reached using the LCAT if there is 
a positive re-challenge or the presence of a history of the same ADR. The history of suffering 
an ADR is not explored in the Du Lehr algorithm, and answering negatively to the question 
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regarding re-challenge only deducts one point from the total score, meaning a definite rating 
can still be reached through many permutations. When the LCAT was adapted due to 
suspected over-assignment of ‘definite’ ratings, it was these two concepts that were added to 
the pathway to reach a definite rating using this tool. It would be interesting to revisit the first 
version of the LCAT tool to see if this tool would be more appropriate for assessing neonatal 
ADRs compared to the current one, given that re-challenges and/or histories may be rarer in 
these younger children.  
5.4.5 Variability amongst assessors 
The six assessors in this study have different designations and backgrounds but all had 
experience in working in clinical neonatology. This methodology was thought appropriate as 
assessors used in the ADRIC research programme also had different roles e.g. pharmacists, 
doctors and nurses. There were some cases where one assessor was in extreme 
disagreement with the majority of the other assessors using one of the tools, namely cases 
15, 18, 21 and 32. However the assessor who disagreed was different in every case. 
Unfortunately, although this was initially planned, time limited the ability of this study to recruit 
a wider variety of assessors, as all six assessors were doctors. It would have been interesting 
to see whether the inclusion of pharmacists and nurses would have changed the inter-rater 
reliability seen when using the three tools. However, in the wider use of causality assessment 
tools, designation of the user should not influence the outcome. An ideal tool should be able 
to be used by any health care professional, in any setting for assessing any ADR in any 
neonate.  
There was variability in the number of times each rating was given by each assessor using 
each of the tools (table 17). Four assessors each gave four definite ratings when using the 
LCAT. However only one of the definite ratings from each assessor was given to the same 
case. As the questions regarding re-challenge and history are reasonably objective, previous 
questions in the flow chart must have caused the discrepancy in ratings here. The questions 
preceding the final question leading to a definite rating include ‘what is the probability that the 
event was due to an underlying disease?’ and ‘was the event associated with long-lasting 
disability or impairment?’. Both these questions contain an element of subjectivity and can be 
difficult to assess in neonates who may be critically ill, and hence will likely have led to the 
difference in ratings given by the assessors for these cases.   
Assessors BP and BY demonstrated moderate and good inter-tool reliability, showing that 
they were consistent in their interpretation and assessment of the cases. However, their inter-
rater reliability scores were below average. This suggests that the assessors were assessing 
different concepts but each was consistent in their reasoning. Further clarification of some 
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aspects of the tools may help to avoid this, for example, objective definitions of some of the 
concepts, e.g. ‘contributing factors’ in the Karch and Lasagna algorithm.    
5.4.6 Characteristics of cases 
Some cases showed a large spread of results within and across all three tools, making it 
difficult to make a judgement of true causality. These cases were often the cases that were 
least well known with scarce previously published literature. It was also noted that for these 
cases there was not much documentation in the case summary of any alternative causes. 
Little evidence to rule out an alternative cause may have led the assessors to presume an 
alternative diagnosis was more likely.    
There were two cases where the assessors showed almost perfect agreement using two tools, 
one when using Du Lehr and the LCAT and the other when using Du Lehr and the Karch and 
Lasagna algorithm, but showed a spread of ratings across three categories when using the 
third tool. When using the Du Lehr to assess these two cases however, the assessors showed 
perfect agreement on a definite rating. It was noted that these two cases both contained more 
than one reaction to the same drug, and it was perhaps this that reduced inter-rater reliability 
for this case. These cases could be considered more complex and this could imply that the 
Du Lehr applies the most general approach to assessing causality. Some clinicians explained 
that they found it challenging to assess those ADR reports where more than one reaction had 
occurred. However, on reviewing all the ADRs that were assessed it was found that there was 
variability in rating for some, but not all, of the cases involving more than one reaction. Some 
of the Yellow Card reports reviewed in this study also reported more than one reaction per 
report.  
There were only three cases that showed some a majority agreement for an unlikely causality 
rating across at least two tools. For cases 15, 18 and 32 at least four of the six assessors 
agreed on an unlikely rating using the Karch and Lasagna and Du Lehr algorithms, but showed 
a spread of results when assessed using the LCAT. This may be due to the first question in 
the LCAT, ‘do you suspect an ADR?’. It was noted that these three cases detailed less well 
documented ADRs for which alternative explanations were more likely. There was most likely 
a suspected concurrent infection for one case, and the other two cases both occurred in 
extremely sick preterm neonates with multiple comorbidities. Case 30 demonstrated the most 
convincing majority rating of unlikely, with all six assessors using all three tools only choosing 
unlikely or conditional/possible ratings.  
When reviewing the assessments of individual cases, it is possible to hypothesis why different 
tools resulted in different outcomes.  
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Case study one 
The case of antibiotics leading to thrombocytopenia- case 21. This case, when assessed by 
one assessor, received a possible rating when using the LCAT and a definite rating using the 
Du Lehr algorithm. The final question when using the LCAT which leads the user to a possible 
rating is ‘Is there any objective evidence supportive of the causal ADR mechanism?’. As there 
is no such evidence for this case, the assessor cannot select another path and thus the 
possible rating is reached. Whilst questions 12 and 13 of the Du Lehr tool are similar to this 
question, answering them negatively does not exclude any causality outcome, and cases can 
still be given definite ratings, as seen in this case. In general, this case appeared difficult to 
assess amongst all assessors, receiving each of the five available outcomes at least once.  
Case study two 
Another interesting case was the report of a cerebral haemorrhage occurring after the 
administration of inotropes- case 32. Using the Karch and Lasagna and Du Lehr algorithms 
the case was assessed as being unlikely four out of six times. However, when using the LCAT 
it received the possible rating three times (three others unlikely).  Using the LCAT, the case is 
automatically given an unlikely rating when the assessor chooses not to suspect an ADR. It is 
presumed that this was how this rating was reached, given that the only other way of reaching 
an unlikely rating, (by answering negatively to ‘did the event appear after the drug was 
administered or dose increased?’) should not apply to this case. There must have been some 
information in the case summary that lead two assessors to suspect an ADR. As two 
assessors chose to suspect an ADR, the case was assessed as possible. It would have been 
interesting to observe whether all the other assessors would have reached the possible 
outcome had they chosen to suspect an ADR.  Both the Du Lehr and the LCAT require 
objective evidence to answer certain questions; the Du Lehr requires confirmation of an 
alternate aetiologic candidate and the LCAT requires evidence supportive of the causal ADR 
mechanism. These questions seem the opposite of each other. Both lead to a more likely 
causality rating when answered appropriately in favour of an ADR. With respect to the question 
in the LCAT, evidence in support of an ADR is much less likely in neonates than in other age 
groups because of the smaller knowledge base about the effects (intended and unintended) 
of medicines on neonates. On the other hand, with respect to the Du Lehr algorithm it is likely 
that a clinician will be able to consider multiple differentials for a clinical problem. Despite this 
case seeming to be thought unlikely by most assessors, it still received one definite rating 
using the Du Lehr algorithm.  
Case study three 
Extravasation reaction- case 18. Using the Karch and Lasagna algorithm and Du Lehr 
algorithm, one assessor rated the case as likely and definite, whilst all other assessors found 
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the case unlikely. Using the LCAT produced more variability in rating, finding the case unlikely, 
possible and probable. As with case study two, presuming the question ‘did the event appear 
after the drug was administered or dose increased?’ was answered accurately, the assessor 
who gave this case an unlikely rating must not have suspected an ADR. As no definition of an 
ADR was given to the assessors before undertaking the assessments, this suggests that 
different clinicians have differing opinions of what constitutes an ADR and may have believed 
an extravasation reaction to not be an ADR.  
Case study four 
The case of digoxin suspected to have caused heart block was consistently rated as probable 
or definite by all six assessors using all three tools- case 9. There were some defining features 
of this case that are likely to have made this possible. This case was the only one which 
included a documented serum drug level. This, combined with a finding from an imaging 
investigation, provided objective evidence to the assessor and reduces the need for clinician 
opinion on concepts such as alternative diagnoses and evidence supportive of the causal ADR 
mechanism. Other cases that were given mainly definite ratings across all three tools were 
well known ADRs or had a positive history of an ADR following previous exposure to the drug 
in the neonate concerned.  
5.4.7 Usability 
It is very important to acknowledge the opinions of practising clinicians on tool usability when 
considering implementing such a resource into the busy daily routine of clinical care. 
The data collected on the assessors’ opinions regarding the usability of each of the tools 
shows a slight preference for the Du Lehr algorithm as a tool to use in clinical practice, with 
the LCAT also seemingly more preferred than the Karch and Lasagna algorithm. Even though 
addition is required when using the Du Lehr algorithm, and the LCAT scored better on ease 
of use, the Du Lehr scored best with regards to its ability to appropriately and fairly assess a 
neonatal ADR case. To properly assess clinician opinion on each of the three tools their use 
should be trialled by a greater number of assessors. Opinions may differ depending on setting; 
the LCAT is perhaps easier to use quickly on a ward round, whilst the Du Lehr or Karch and 
Lasagna methods may be more appropriate for group discussion in an MDT.  
Overall, the range of opinions exhibited by the assessors throughout the questionnaire makes 
it difficult to determine if one tool was preferred overall. It may be a challenge to design a tool 
which is accepted by a wide range of users. However, five of the six assessors said that they 
would use at least one tool in clinical practice, showing practising clinicians are receptive to 
introducing a method of further evaluating neonatal ADRs.   
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All the tools require an element of ‘previous knowledge’ which is likely to vary between 
clinicians and their experiences. Answering questions regarding previous documentation of 
ADRs may require the use of the BNF which costs the clinician time. In addition to this, rarer 
or less well-known ADRs are more likely to be ignored if they generate unlikely causality 
ratings. This goes against the purpose of reporting less well-known suspected ADRs to the 
MHRA to understand more about drugs which may have very little safety information.   
5.4.8 Question adaptation 
The combination of statistical analysis and the opinions of the assessing clinicians suggests 
all three tools could be improved to be more suitable to use in the neonatal population.  
The Karch and Lasagna algorithm currently does not recognise the impact of reducing the 
dose of a drug. ‘Withdrawal’ is interpreted as stopping a medication altogether, but a slight 
adjustment in this tool to ‘withdrawal/dose reduction’ may produce a fairer outcome.  
The LCAT uses the question ‘was the event associated with long-lasting disability or 
impairment?’. The follow-up of neonates that are born prematurely or experience medical or 
surgical conditions may continue for several years, thus making it difficult to fully answer this 
question when assessing a recent ADR in a neonate. If a timescale were applied to the 
question, or if it were adjusted to read ‘do you suspect the event may result in long-lasting 
disability or impairment?’, it could be better applied to the neonatal population. This would 
however, incur another subjective question, potentially further reducing inter-rater reliability. 
The long-term impact of ADRs in neonates, and the possibility that some ADRs may prove 
beneficial in later life, is an area of pharmacovigilance research that needs further exploration.   
The presence of a history of an individual suffering an ADR, or a positive re-challenge, greatly 
increases the causality. However, it can often be difficult to assess these factors in neonates 
who may be a matter of days old and in whom re-challenges are often not ethically justifiable. 
All three tools assess one or both factors and place great importance on them. In the LCAT, 
a positive history or re-challenge is the only way to reach a definite rating.  A more suitable 
route of reaching a likely causality outcome may need to be considered for this population. 
From this point of view, the Karch and Lasagna algorithm and ‘New Adverse Drug Reactions 
Algorithm for Infants in Neonatal Intensive Care Units’ tool could be considered more 
appropriate to use in the neonatal population as they still allow a ‘definite’ causality result to 
be reached in the absence of a positive history or re-challenge. However, the terms used in 
these concepts are not clearly defined in these tools. There is no explanation of how long after 
the initial dose of drug a subsequent dose must be given to be classified as a re-challenge. At 
some point, there must be a change between suffering an ADR because of a re-challenge and 
suffering a subsequent episode of an ADR for which there is a history. Harmonising these 
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definitions may present challenges in a population where a few weeks in age difference 
represents significant changes in pharmacokinetics and pharmacodynamics.  
The first question in LCAT, ‘do you suspect an ADR?’, leads straight to unlikely if answered 
negatively. It could be argued that this defeats the aim of using causality assessment tools 
and does not prompt a clinician to consider an ADR. It could be thought a wasted question 
when a clinician not suspecting an ADR is unlikely to use the tool in the first place.  
The variation in how the Karch and Lasagna algorithm was used by the different assessors 
suggests further clarification may be needed to improve its reliability. This is particularly 
apparent in sections F and G (contributing factors which favour the causal relationship and 
extra examinations) where for the same set of cases, the number of times F and G were used 
varied greatly between assessors. Some examples of which things justify points in these 
sections are given, but it is widely open to user opinion. Causality tools are most helpful if they 
lead users to a result which can be reached consistently amongst a group of users whose 
opinions may have differed had the assessment been made by personal judgement alone.   
The Karch and Lasagna algorithm allows the user to select one of several options for each 
section of the assessment whereas the Du Lehr algorithm only allows the user to select ‘yes’ 
‘no’ or ‘unknown’. The LCAT only provides the ‘unassessable’ or ‘unsure’ option twice. Whilst 
a limited amount of options reduces the variability between assessors, some cases may go 
unassessed if they do not fit into the available options. This could lead to the dismissal of a 
case if it is not able to be assessed for causality. For example, the questions regarding positive 
re-challenges and histories both only allow a yes or no answer. However, the nature of 
neonatal care is such that neonates are sometimes transferred between care, and the answer 
here may not be known. As there is no unknown option, the user is left to decide for themselves 
what action to take, and some may choose to discontinue the evaluation altogether. In respect 
to this difficulty, the other two tools are advantageous as the answers to other questions 
supersede difficulty answering some questions. However, three of the six assessors ‘strongly 
agreed’ that the LCAT was easy to use, whilst the other 50% either ‘agreed’ or ‘neither agreed 
nor disagreed’. Designing a tool which is both effective and accepted by clinicians in everyday 
practice will take careful planning.    
The results presented in this study suggest that no one tool stands out as being the optimal 
method to be implemented into clinical practice in its current format. From the analysis 
performed it has been observed that there are benefits and flaws of different aspects of each 
tool including design, ease of use and questions. However, despite the difficulties that have 
been highlighted, each of the tools were able to assess neonatal ADRs, and show scope to 
be adapted, to improve their specificity for neonatal ADRs, and inter-rater reliability. Combining 
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optimal elements of each method into a new tool could also be successful. The slight 
improvement in inter-rater reliability seen when using the Du Lehr algorithm suggests neonate-
specific methods are advantageous. Following on from this, questions that are difficult to apply 
to this population, such as those regarding re-challenge and history, could be removed or 
adapted so as not to be defining. Questions with more than yes and no outcomes, such as 
those in the Karch and Lasagna algorithm, will assess the broadest range of ADRs. 
Subjectivity of use could be reduced by using clear definitions and examples. Whilst needing 
to use calculations and/or the BNFc may reduce usability, a compromise regarding this may 
have to be reached to allow accurate ADR assessment.    
5.4.9 Wider applications 
Effective causality assessment methods would have wide benefits for paediatric 
pharmacovigilance. In one of the only other known prospective studies observing neonatal 
ADRs, Belén Rivas reported that the causality assessment of the ADRs observed was the 
study’s main limitation. They also comment on difficulties labelling cases as definite without 
re-challenges, and underestimation of the incidence of ADRs because causality assessments 
deem them less likely(46). ADRIC made the decision to exclude paediatric patients in intensive 
care because the causality assessment was too difficult in this cohort(17). By the very nature 
of neonatal care, a large proportion of neonates will be cared for in intensive care, only further 
demonstrating that population-tailored assessment tools would benefit this population greatly. 
As pharmacology is also affected by concurrent illness, it may be necessary to have yet 
another method of assessing ADRs in these sickest of children, but there are resource 
implications.  
Clinicians will always have differing opinions in all elements of clinical practice, so an optimal 
causality tool would need to account for these variations. However, one perspective is that the 
design of causality assessment tools will not be able to be improved much beyond their current 
abilities, and instead the investigation of ADRs as a possible differential diagnosis should be 
improved. The cases that saw the best inter-rater agreement were those with objective 
evidence, such as drug serum levels or imaging investigations. Increased investigation of 
possible ADRs would help to generate awareness amongst clinical staff and subsequently 
lead to better causality assessment and reporting. However, increasing the investigation of 
suspected ADRs will rely on improving clinician understanding and appreciation of ADRs in 
neonates.  
5.4.10 Summary 
In summary, this study has highlighted that the three evaluated causality assessment methods 
differ in their approach to assessing ADRs, leading to varied assessments of neonatal ADR 
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cases. Only one of the three tools was designed to be used to assess neonatal ADRs. 
Difficulties were faced when trying to apply some of the questions in the other two tools to this 
unique population. This, coupled with the improvement in inter-rater reliability seen when using 
a neonate-specific method, suggests that a population-specific method could be 
advantageous. A wide range of assessments seen for individual cases suggests that both the 
ADR in question, and how to use the tools, were interpreted differently by each assessor. It 
will be challenging to design a tool that can adjust for this inevitable difference in opinion, 
whilst still being acceptable and efficient for use in clinical practice. Some aspects of the 
evaluated tools have the potential for adjustment to improve their use for the neonatal 
population, and the wider implications of designing an appropriate causality assessment 
method for this population have been discussed. This study has highlighted the need for an 
effective method of assessing the causality of neonatal ADRs. A full evaluation of such ADRs 
will also require severity and avoidability assessments, and future research focussing on these 
areas will help to bring pharmacovigilance in neonates in line with that of older populations.   
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Chapter 6: Strengths, limitations, future research and conclusions 
The ADRIN study has explored a new area of pharmacovigilance in neonates. As the number 
of studies describing ADRs in neonates is increasing, optimal methods for evaluating neonatal 
ADRs need to be identified to be able to evaluate the findings of such studies. This study has 
characterised three causality assessment methods and provided an insight into how suitable 
the three methods are in their current format. Beyond causality assessment, there are other 
ways in which a neonatal ADRs should be evaluated, and different population-tailored 
methods of doing this should be explored in future research.  
6.1 Strengths of the study 
6.1.1 Study design 
Many previous studies into ADRs in children have been conducted retrospectively whereas 
this study was conducted prospectively. Observing ADRs prospectively allowed the 
researcher to capture the progression of an ADR as it developed. Any uncertain information 
could be queried with the medical staff caring for the neonate at the time an ADR was 
suspected. Retrospective pharmacovigilance studies often face limitations with omissions in 
data that would have been of value. This was found when reviewing Yellow Cards, many were 
missing basic demographic information(6). Prospective observation collects data that reflects 
recent practice, which is useful to those reviewing the literature. It would have been difficult to 
test the causality assessment methods on retrospectively collected ADR cases. In the first 
instance, it is likely that it would be difficult to find a large enough source of previously collected 
neonatal ADR cases. Secondly, any such sources, for example Yellow Card reports, may not 
contain a spread of ADRs that will range from unlikely to definite in causality.  
The methods used in this study were piloted before data collection began. This included the 
method of detecting and collecting ADR cases and the causality assessment processes. From 
these pilot activities, changes were made to the data collection materials, which prompted the 
collection of additional data that influenced the causality assessments made. Moreover, 
exposure to the neonatal clinical setting educated the researcher in neonatal medicine and 
ADRs. 
Conducting the prospective observation at the Liverpool Women’s Hospital NICU was 
advantageous as this is a large tertiary unit seeing a range of cases. Despite the data 
collection period being much shorter, the number of neonates observed in this study was 
almost two thirds of the number of neonates that were observed in the one year data collection 
period in Belén Rivas’ recent study(46).     
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The researcher who collected data on suspected ADRs was a medical student completing a 
master degree between the fourth and fifth years of training. Having no clinical involvement in 
the care of the neonates, the researcher could focus solely on looking for possible ADRs 
without any pressures to fulfil other roles.  
In the ADRIC study the causality assessments were carried out at consensus meetings. In 
this study in neonates, the assessors were given paper copies of the assessments to complete 
in their own time and they could contact the researcher should they want more information 
from the complete case data. At consensus meetings assessors may be influenced by the 
opinions of the other attendees, so the methods used in this study avoided this bias. It was 
felt that independent conduction of the causality assessments best reflected how the tools 
may be used in clinical practice.  
6.1.2 Aims of the study 
The aims of the study targeted one methodological aspect of evaluating neonatal ADRs, 
through causality. This focused approach worked well in the limited time and meant a 
significant number of assessors could commit the time to performing over 100 assessments 
each. Had severity and avoidability methods also been evaluated, it may have been necessary 
to divide the group of assessors. As a result, using only two assessors to evaluate each 
assessment area, it would not have been possible to demonstrate the range of inter-rater 
reliability seen and the potential influence of the different profiles of the assessors. Evaluating 
only causality meant three tools could be compared.  
Another strength of this study was the recruitment of assessors with a range of experience. 
This provided a good reflection of how the tool would function if used in clinical practice, as it 
would be used by health care practitioners with differing roles and amounts of experience. 
Secondly, the assessor opinions that helped to provide an assessment of the worth of each 
tool varied greatly, and it is likely that some of this variance was due to differing profiles of the 
assessors.  
6.1.3 Scope for further research    
The results of the ADRIN study are novel, but the research has also highlighted pathways for 
subsequent studies. There was a significant amount of other data collected that could be 
further analysed. Secondary to this, the cases collected may be a useful source for other 
studies designing new methods of ADR assessment, and a collaboration of this nature has 
already been explored with regards to severity assessments. The exploration of the causality 
assessment methods has identified areas of research that could subsequently be undertaken 
to create effective causality assessment methods for neonatal pharmacovigilance.  
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6.2 Limitations 
6.2.1 Study materials and resources 
Analysis of patient notes provided most of the data collected in this study. The electronic notes 
system used on the neonatal unit was BadgerNet. Paper drug charts were reviewed where 
necessary to complement this source. The validity of the data may have been improved if 
collected on a unit where electronic prescriptions are used. BadgerNet also does not allow 
access to mothers’ records which would have facilitated the collection of data regarding 
maternal drug use, pregnancy history, labour history etc.   
The data collection was undertaken by a single researcher whilst members of staff on the 
neonatal unit had the opportunity to contribute by informing the researcher of suspected ADRs 
through the ADR alert forms or notification in person.  Having only one researcher to collect 
data meant it was not possible to continuously monitor all activity on the unit. Additional 
researchers to collect data would have facilitated daily attendance at both ITU and HDU ward 
rounds, a chance to attend ward rounds seven days a week as opposed to four, and a greater 
number of patients’ notes being reviewed for ADRs each day. The ADRIC research 
programme had a team of researchers to collect data, and more sophisticated databases 
which allowed some data to be collected automatically. Additional researchers for this study 
would have enabled multiple sites to be observed. There were two local hospitals that could 
have been included in this study: a children’s hospital which cares for neonates post-surgery 
and on a paediatric intensive care unit, and a local district general hospital with a tertiary 
neonatal unit. Having at least one researcher based at each of these hospitals would have 
allowed for a larger data set, as well as enabling comparisons to be made between the data 
sets from each hospital.  
6.2.2 Underreporting  
There is a vicious cycle whereby a lack of understanding about neonatal pharmacology leads 
to less concern regarding ADRs and less research into pharmacovigilance. This, coupled with 
the absence of materials available to help detect and assess neonatal ADRs, sees ADRs 
dismissed as inevitable and unpreventable problems of neonatal care. With further education 
and resources these issues could be overcome, but there will always remain a challenge when 
trying to detect the ‘signal amongst the noise’ when it comes to ADRs in sick neonates.    
Disappointingly in ADRIN, the ADR alert forms were only used twice in nine weeks. The 
number of ADR reports prompted by other clinicians (16), was more encouraging but still only 
accounted for 25% of the total number of ADRs reported. The observational study, including 
the implementation of the ADR alert forms, was introduced every day for one week at both the 
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doctors’ and nurses’ handover at the beginning of the study, so it was hoped that most staff 
would have been aware of the ADR alert forms. This was in addition to introductions, posters, 
flyers and researcher presence throughout the study period. This low rate of reporting by other 
staff is likely to be multifactorial. Lack of confidence in ADR reporting, poor understanding of 
the definition of an ADR and limited time due to other clinical priorities are just a few of these 
factors.   
There are always going to be challenges in introducing an activity which draws attention to 
harm to a patient, which has resulted from attempts to cure and care, and which may not be 
rectifiable by those reporting the harms. ADRs are often unpredictable and unavoidable, but 
this does not mean those involved do not feel guilt. Though ADRs are different from medical 
errors, some individuals may feel responsible for the outcome.  
The level of staff involvement in the ADRIN study suggests further efforts are needed to make 
ADR reporting a routine part of everyday clinical practice. A qualitative study evaluating the 
opinions and experiences of clinical staff regarding ADRs and pharmacovigilance practices 
could help to identify why reporting is so low. By interviewing staff who spend the most time 
caring for neonates, the level of understanding about pharmacovigilance, as well as individual 
suggestions for improving the knowledge base and motivation could be captured. This would 
help to decide the most effective engagement strategy to improve reporting practices.    
6.3 Future research 
ADRIN has contributed to the data set involving neonatal ADRs, but there is significant scope 
for further research in this area. Beyond the detection of ADRs in neonates, this study has 
demonstrated the difficulties in performing causality assessments of neonatal ADRs using 
currently existing methodologies. 
6.3.1 Extending ADRIN  
If more time and funding were available, the scope of this study could be significantly 
broadened. Ideally, the data collection period would be extended to a minimum of one year. 
This would increase the number and range of ADRs observed, and allow for the follow up of 
cases for a longer time, providing a more valid assessment of aspects of the cases such as 
re-challenges, histories and the evolution of signs and symptoms. Even further time would 
allow for the conduction of the proposed systematic review, enabling a full examination of 
pharmacovigilance studies in neonates worldwide. A minimum of two full-time independent 
staff to collect ADR cases would increase the number of suspected ADR cases and make the 
detection process more thorough. Employing extra research staff would also allow for the 
collection of data regarding all babies, including those who are not suspected to have suffered 
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an ADR. The ADRIC study employed pharmacists to carry out the ADR detection process, 
and as this was a success, pharmacists could also be used to collect neonatal ADR data. If 
possible, feedback from the pharmacists who collected data for the ADRIC study could help 
to train staff, to learn from their experiences and create an effective detection method. If it 
were possible for electronic prescribing to be initiated on the unit, the validity and accuracy of 
data collected regarding drug prescribing would be likely to improve. Data collection could be 
further legitimised by gaining access to maternal notes. An electronic database that could 
automatically draw information from all of these sources would save time, increasing that 
available for ADR detection. This was successful in ADRIC.  
Additional funding could be used to trial various staff motivational and educational 
interventions to examine their impact on increasing ADR reporting. This could include 
educational learning days for all ward staff and incentives to report suspected ADRs. 
Investment into exploring the opinions of parents regarding ADRs and encouraging their input 
into pharmacovigilance could also obtain interesting results in this novel area of research, and 
may boost ADR reporting. 
With regards to the causality assessment process, an ideal panel of assessors would be 
recruited externally. More time and funds would allow for a variety of different assessors to be 
sought, including pharmacists, who could be trained together in the process of causality 
assessment. The same, or different, assessors could also complete severity and avoidability 
assessments to broaden the evaluation of ADR cases.  
Despite there being many ways in which this study could have been improved with more 
funding and time, the core design of the study was successful and has provided an example 
of an effective method of studying ADRs in neonates, and its results. The prospective study 
design proved an advantageous way of collecting neonatal ADR data, and so even with extra 
resources, prospective data collection should still be followed where practical. The data 
collection proforma that was designed for this study is transferable to other settings and has 
the scope to be adapted for electronic use. The main benefit of extra resources to this study 
would be in the increased detection of ADRs and the wider promotion of pharmacovigilance 
in a vulnerable population.    
6.3.2 Identifying ADRs in neonates  
In order to encourage ADR reporting in neonates, effective methods for identifying neonatal 
ADRs will need to be implemented. In ADRIN, the observational approach was effective when 
conducted by a standalone researcher, but more efficient methods may be necessary to 
integrate pharmacovigilance into busy clinical environments. Both the BNFc and Yellow Card 
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Scheme are now available as electronic systems, and the use of computerised surveillance 
methods of ADR detection have been trialled in adult and paediatric populations(84),(85). 
The merit of a computerised system has its basis in the detection of changes in laboratory 
investigations before changes in clinical signs can be detected. The difficulty with this in the 
neonatal population is that the physiological parameters considered normal for this age group 
are poorly defined. For example, where a rise in liver enzymes could be a signal of drug 
hepatotoxicity in adults, relatively high levels of liver enzymes are seen in sick preterm 
neonates with a number of different conditions(86). Ongoing work in this field will help to define 
the parameters of normal physiology in neonates such that the use of a computerised method 
of ADR detection in this population may be possible, which could help to reduce 
underreporting in this busy clinical setting. However, the aim of a computerised system should 
be to alert staff to possible ADRs that may need reporting, simultaneously increasing 
education, not to remove the responsibility of reporting ADRs altogether.        
Promoting parental reporting of ADRs also has the potential to reduce underreporting, as there 
is a philosophy that no one is more expert in a child than their parents. Qualitative studies 
have suggested that parents are often disappointed with the communication they receive 
regarding side-effects of medicines administered to their child. However, opinions were 
positively different in parents of children in an oncology setting, suggesting that those clinicians 
using the most potentially harmful medications may be better at communicating the associated 
risks(87). This could also be the case in a neonatal setting, but opinions of parents have not 
been explored as greatly in neonatal units. Difficulty arises where pharmacology knowledge 
is lacking as there is a fine balance between being honest with concerned parents and 
withholding uncertain information that may generate unnecessary worry. A clinician may need 
to make a judgement of this based on each unique family, the condition of their child and other 
aspects of the family dynamics e.g. other siblings and emotional, social and financial strains. 
In neonatology, it may even be possible to discuss this concept in antenatal counselling. 
However, this study has shown that opinions regarding the causality of ADRs differs greatly 
between clinicians, and therefore not receiving information regarding ADRs may be preferable 
to hearing mixed opinions.       
6.3.3 Understanding ADRs in neonates 
Over the past few decades an increased amount of research into monitoring and reporting 
ADRs and promoting paediatric medicines research has led to improved medicines for 
children. However, there is still some way to go in understanding why individuals suffer ADRs, 
and this activity was not undertaken in this first ADRIN study. Future research could focus on 
the long term follow up of neonates suffering ADRs to analyse whether any beneficial 
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outcomes occur following ADRs. Conversely, drugs which appear to be beneficial in the short-
term may give rise to long-term effects. Making parents aware of ADRs and the possible long-
term effects of medications means they could monitor and report suspected long-term drug 
effects in their child that may not be detected by the clinicians who cared for them as a 
neonate.  
Pharmacogenomics is an area of medicine which is of growing interest in many specialties. 
Pharmacogenomics refers to the influence of an individual’s genotype on the action of a drug 
and the risk of ADRs. Future work into pharmacogenomics in paediatrics could help to 
increase the safety of drugs in children. However, as with most aspects of paediatric medicine, 
there are differences in this population which mean different pharmacogenomics studies and 
methods will need to be designed compared to those already tried in adults. For example, the 
expression of certain genes changes with age and development.    
6.3.4 Evaluating ADRs in neonates 
ADRIN has demonstrated that further work needs to be conducted to create effective methods 
of evaluating ADRs in neonates. This could include the adaptation of currently existing tools, 
such as those evaluated in this study. Identification of aspects of current tools that need to be 
adapted to optimise their use will be needed, and some suggestions have been made in this 
work. In addition to this, encouraging the creation of new neonate-specific tools should be 
encouraged, or at the very least paediatric-specific tools. However, any newly proposed 
methods will need to be tested on neonatal ADR cases, and these take time to identify and 
record. The lack of a gold standard method of assessing ADR causality in children makes it 
difficult to measure the efficacy of newly proposed methods as there is no current standard 
practice. If an effective method of assessing causality of ADRs in the neonatal population were 
to be designed, its implementation into clinical practice could help to significantly reduce the 
current level of underreporting being seen.  
A full evaluation of an ADR should also include severity assessment. A team of investigators 
based in Belgium have recently been working on a tool to assess the severity of adverse drug 
reactions in neonates. The tool was created with the aim of creating a method to better assess 
ADRs occurring in clinical trials. However, there is no reason why it would not be helpful in 
assessing ADRs occurring in routine neonatal care.  
Contact was made with the research team who created the tool to attempt some collaborative 
work in validating the proposed tool. The latest version of the tool was made available to see 
whether it could be used to assess the severity of the cases collected in the prospective 
observational study. Upon review by the research team it became apparent that the 
information in the case summaries used for the causality assessments was not adequate to 
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complete severity assessments using the proposed new tool. However, the process of 
collecting the extra information needed from the electronic notes was piloted by the principal 
investigator and a method for extracting the extra information was created in the form of an 
excel proforma. It is hoped that future work can be conducted using the cases collected in the 
ADRIN study to continue this collaboration. Having both a causality and a severity assessment 
of an ADR produces a more thorough evaluation and helps to highlight those cases that may 
be less well known but just as important to acknowledge and act upon. For example, a 
causality assessment alone may see possible ADRs being put aside, but possible severe 
ADRs may deserve more attention than those that are likely but mild.  
It is unfortunate that there was not time to assess avoidability in this study. This evaluation 
would have been very interesting in the neonatal population where fewer tested drugs are 
available to treat very sick neonates. It may be that many neonatal ADRs are unavoidable due 
to the lack of tested alternative medicines. However, the underreporting of neonatal ADRs 
means that the there is a lack of information for the MHRA to identify where alternatives may 
be necessary.   
6.4 Conclusion 
In conclusion, this work has demonstrated that the three tools evaluated do not reliably assess 
neonatal adverse drug reactions, which occur at a significant frequency, and are different to 
those exhibited by older children and adults. Marked inter-rater variability was seen across all 
three tools when pair-wise and global comparisons were made between the ratings assigned 
to the same cases by six different assessors. The potential benefits of neonate-specific 
causality assessment methodology have been demonstrated by the difficulties encountered 
using general methods to assess the neonatal ADRs collected in this study. However, even a 
method designed specifically for assessing neonatal ADRs was shown to have only ‘fair’ inter-
rater reliability and appeared to over-estimate the causality of ADRs when compared to other 
methods.   
Measuring inter-tool reliability identified that varying the method of causality assessment used 
can give rise to unreliable results. Whilst some assessors showed internal consistency, the 
majority did not, suggesting that the consistent use of one method, within and across future 
neonatal ADR studies, will produce the most reliable results.  This is supported by the differing 
amounts of use of each rating by each tool; the Du Lehr and the LCAT saw similar numbers 
of definite and probable ratings respectively, suggesting that they were assessing the same 
concept.  
The three tools all exhibit different formats which influenced how the tool was used by each of 
the assessors, and their opinions on the usability of the tool and likelihood of successful 
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implementation into clinical practice. In general, it will be a challenge to design a tool 
appreciated by all users, but there are some aspects which were disliked or liked by the 
assessors in this study. Designing a new tool should consider clinician opinion as well as 
practical issues such as time necessary to use the tool and any additional requirements which 
may discourage use, such as calculations or requirement of a BNF. Any newly created 
methods need to be evaluated and validated both internally and externally. These processes 
could take significant time and expertise, but carrying them out could help to significantly boost 
ADR reporting and consequently improve the safety of medicines for this vulnerable 
population.  
The ADRIN study has gone beyond describing neonatal ADRs by evaluating the methodology 
that might be helpful when further assessing, understanding, and preventing them. The 
research has demonstrated a lack of appropriate ADR causality assessment methods that can 
reliably be used in the neonatal population. This is not the only area of research that is lacking 
in neonatal pharmacovigilance. A systematic review into ADRs in neonates should be carried 
out to determine the spread of neonatal ADRs seen worldwide and to identify other areas of 
research that may need expanding to maximise the safety of medicines in this population. 
Severity and avoidability assessment methods also need to be characterised.  
It may take many years and significant work to bring pharmacovigilance practices in neonates 
in line with those of adult populations. Many aspects of neonatal care are advancing rapidly 
and a balanced assessment of benefits and harms of new and existing medicines is essential. 
Accordingly, research into the methodology of neonatal pharmacovigilance is of great 
importance.      
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Appendix 1 - Study protocol 
ADRIN 1: Methodology 
Adverse Drug Reactions in Neonates 1: What are the best ways to 
evaluate suspected adverse drug reactions in neonates?  
Version 6. 04.10.16 
 
Study Team 
Chief Investigator:  
Dr Mark Turner (Senior Lecturer in Neonatology / Honorary Consultant Neonatologist) 
Co‐investigators:  
Eve Roberts (MPhil Student) 
Dr Daniel Hawcutt (Senior Lecturer in Paediatric Clinical Pharmacology) 
 
Clinical Queries 
Clinical queries should be directed to Dr Mark Turner who will direct the query to the 
appropriate person. 
Sponsor 
The University of Liverpool is the research Sponsor for this Study. For further information 
regarding the sponsorship conditions, please contact: 
Alex Astor 
Head of Research Support – Health and Life Sciences 
University of Liverpool 
Research Support Office 
2nd Floor Block D Waterhouse Building 
3 Brownlow Street 
Liverpool L69 3GL 
sponsor@liv.ac.uk   
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Funder 
The project will be conducted by Eve Roberts, MPhil student, University of Liverpool.  
No consumables are required for the running of this study and therefore no additional funding 
will be required. 
 
STUDY SUMMARY 
This protocol describes the ADRIN Methodology Study and provides information about 
procedures for entering participants. Every care was taken in its drafting, but corrections or 
amendments may be necessary. These will be circulated to investigators in the Study. 
Problems relating to this Study should be referred, in the first instance, to the Chief 
Investigator. 
This study will adhere to the principles outlined in the NHS Research Governance Framework 
for Health and Social Care (2nd edition). It will be conducted in compliance with the protocol, 
the Data Protection Act and other regulatory requirements as appropriate. 
 
GLOSSARY OF ABBREVIATIONS 
ADRIN Adverse Drug Reactions in Neonates 
NICU Neonatal Intensive Care Unit 
LWH Liverpool Women’s Hospital 
ADR  Adverse Drug Reaction 
MHRA Medicines and Healthcare products Regulatory Agency 
SPSS Statistical Package for Social Sciences 
 
TITLE  
Adverse Drug Reactions in Neonates 1: What are the best ways to evaluate suspected 
adverse drug reactions in neonates?  
DESIGN  
Prospective observational cohort study  
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AIMS 
a) To characterise causality, severity and avoidability tools used to evaluate possible ADRs to 
determine the use of these tools in the neonatal setting  
b) To estimate the frequency of ADRs in neonates admitted to the NICU at Liverpool Women’s 
Hospital over a 6-month period 
c) To describe the ADRs, and identify risk factors for developing ADRs, in the neonatal 
population 
d) To consider how reporting of ADRs in a neonatal setting may be improved by trialling a 
neonate-specific surveillance system and staff education and motivation interventions 
 
OUTCOME MEASURES  
•Recommendations about which causality, severity and avoidability assessments are 
appropriate for the evaluation of neonatal ADRs.  
•Estimates of the frequency of suspected ADRs in neonates and further clinical details about 
suspected ADRs and the population affected. This aims to extend understanding of the nature 
of ADRs and potential risk factors for developing an ADR in the neonatal population 
•Recommendations about surveillance for ADRs among neonates 
 
POPULATION ELIGIBILITY 
All neonates admitted to the neonatal unit at Liverpool Women’s Hospital 
DURATION 
9 months 
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1. INTRODUCTION 
1.1 BACKGROUND 
The Liverpool Women’s Hospital Neonatal Unit treats over 1000 neonates a year from all over 
the United Kingdom, from an approximate total of 90,000 neonates admitted to neonatal care 
each year in the UK (1) (2). Many of these neonates will be prescribed medicines, and yet 
most previous pharmacovigilance studies have omitted part or all of the inpatient neonatal 
population from their work. An adverse drug reaction is defined by the World Health 
Organisation as ‘a response to a drug which is noxious and unintended, and which occurs at 
doses normally used in man’(3). Recent studies into adverse drug reactions in children have 
indicated a considerable health risk for this population, with incidence rates ranging from 0.4% 
to 10.3% for paediatric hospital admissions related to ADRs and 0.6% to 16.8% for the 
proportion of children experiencing an ADR during their admission(4). Between 2000 and 2009 
the highest number of ADR reports for children was in children under one year of age but to 
date there is limited research studying ADRs in neonates alone (5).   
1.2 RATIONALE FOR CURRENT STUDY 
ADRs are an important source of morbidity and resource use 
A study set in two Merseyside hospitals found that 6.5% of admissions among adults related 
to an ADR, of which 80% were directly due to the ADR. These admissions accounted for 4% 
of the hospitals’ bed capacity. When extrapolated to the whole NHS, the cost of ADRs was 
estimated to be £466m (2004; €706m, $847m) (6). 
A similar study in a Merseyside children’s hospital found that 2.9% of admissions were due to 
ADRs (7). Among children who spent more than 48 hours in hospital 18% experienced at least 
one ADR (8). 
The team who conducted the paediatric study (Adverse Drug Reactions in Children, ADRIC) 
found that existing tools were difficult to use with children, particularly in-patients. 
Neonates are often admitted for weeks or months after birth and are exposed to multiple 
medications. They are likely to suffer similar burdens of ADRs. This burden was described in 
the past and in the present (9) (10). However, patterns of care differ across time and place. 
The tools used to evaluate ADRs in neonates have not been characterised in detail and may 
not be appropriate. 
There is a specific need to look for, and evaluate, suspected ADRs in neonates. 
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Neonates are subject to different adverse drug reaction profiles in comparison to older children 
and adults. The reasons behind this are multiple. The development of a child from conception 
to adulthood is dynamic, and changes in organ function and body composition affect 
pharmacodynamics and pharmacokinetics. There are further sources of ADRs to be 
considered in neonates including those drugs administered to the parents of the neonate pre-
conception, in pregnancy, in labour and during breast feeding. As neonatal inpatients are often 
sick or premature neonates, they commonly receive multiple drugs and a linear correlation 
between the incidence of ADRs and exposure to four or more medications has been 
demonstrated (11). A study conducted in a neonatal intensive care unit reported that 29.6% 
of neonates received more than four medications and 7.6% received 10 or more (12). Further 
studies show that up to 90% of inpatient neonates in neonatal intensive care receive off-label 
or unlicensed medications which multiple studies suggest is a risk factor for developing an 
ADR (13) (14). There are also some medications which are uniquely harmful to neonates (15). 
Hence there is a need to study ADRs exclusively in this youngest group of patients.   
When we studied ADRs in children we found that methods could not be transferred directly 
from adults. The methods currently available to evaluate suspected ADRs in neonates have 
been poorly characterised. Suspected ADRs need to be evaluated in several ways including 
causality, severity and avoidability. There are many ways to do each of these evaluations. 
Causality: Naranjo was not suitable in children. In ADRIC a new tool was developed for 
children but this has not been assessed in neonates. A neonatal modification of Naranjo was 
developed recently in one centre but this has not been validated in another site. 
Severity: Hartwig not suitable in neonates: severity may not be apparent and important 
changes may not affect care. A severity score is under development in Belgium and needs to 
be validated. 
Avoidability: A paediatric avoidability score was developed in ADRIC but has not been 
validated in neonates. 
Current surveillance methods are not adequate 
Also concerning is the suspected rate of underreporting for ADRs in all populations which is 
estimated to be approximately 95% (16) (17). Premature neonates are considered to be at an 
increased risk of suffering from an unrecognised or unreported ADR due to diagnostic 
overshadowing commonly seen in prematurity.   
In addition to the complex medical practice seen in neonatal care, there are few resources in 
place to encourage ADR reporting in this population. The MHRA advises the reporting of any 
suspected ADR in children, however a recent study reported that only 97 Yellow Cards were 
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completed for neonates in the 10-year period between 2001 and 2010(18). The current Yellow 
Card Scheme does not measure all outcomes needed to assess an ADR in a neonate. 
Reporting on factors which may have influenced the occurrence of an ADR in a neonate, such 
as gestational age at birth, are not routinely collected using the current Yellow Card Scheme 
and thus this area cannot be further studied unless provided voluntarily by the reporter. Some 
neonatal ADRs are being reported through the Yellow Card Scheme but to date no clinical 
warnings issued by the MHRA appear to have been influenced by those reports submitted in 
the UK (18).  
Due to the highly demanding and emotive nature of neonatal care, ADR reporting is often 
overlooked in day to day practice. There is an aspect of educated guesswork in neonatal 
prescribing due to the lack of inclusion of children, infants and neonates in drug trials and so 
thorough pharmacovigilance in this population is vital.  
2. STUDY OBJECTIVES 
Primary objective: 
a) To compare several causality, severity and avoidability tools used to evaluate possible 
ADRs to determine their use in the neonatal setting  
 
Secondary objectives: 
a) To make preliminary estimates of the frequency/incidence of ADRs in neonates 
admitted to the NICU at Liverpool Women’s Hospital over a six-month period 
b) To describe the ADRs, and identify risk factors for developing ADRs, in the neonatal 
population 
c) To consider how reporting of ADRs in a neonatal setting may be improved including 
trialling a neonate-specific surveillance system and staff education and motivation 
interventions 
3. STUDY DESIGN 
Type of study:  
A prospective observational cohort study carried out over nine months with detailed evaluation 
of cases of suspected ADRs 
Type of subjects: 
Neonates admitted to the LWH Neonatal care unit  
Study setting: 
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Neonatal unit at the Liverpool Women’s Hospital - all nurseries included  
 
3.1 STUDY OUTCOME MEASURES 
•Causality, severity and avoidability assessments of the collected ADR cases to enable further 
analysis to determine the use of such tools in a neonatal setting 
•The frequency of suspected ADRs in neonates admitted to the NICU at the LWH and further 
clinical details about suspected ADRs and the population affected. This aims to demonstrate 
the nature of ADRs and potential risk factors for developing an ADR in the neonatal population 
 
4. PARTICIPANT ENTRY 
4.1 PARTICIPANT INCLUSION CRITERIA  
Neonates admitted to the LWH Neonatal care unit  
4.2 PARTICIPANT EXCLUSION CRITERIA 
Neonates who are more than 28 days post their estimated date of delivery 
4.3 WITHDRAWAL CRITERIA 
N/A 
4.4 DRUG INCLUSION CRITERIA 
Continuous infusions, regular medications, stat/one-off and as-required drugs prescribed to 
the neonate, including parenteral nutrition 
Continuous infusions, regular medications, stat/one-off and as-required drugs prescribed to 
the mother pre-conception, during pregnancy or labour or during breastfeeding/expressing 
breastmilk  
4.5 DRUG EXCLUSION CRITERIA 
•All blood products with the exception of immunoglobulins 
•All enteral feeds   
4.6 ADR INCLUSION CRITERIA 
An ADR as defined by Allegaert et al as ‘an unintended and harmful effect resulting from the 
use of medications intended for diagnostic or therapeutic reasons (irrespective of the 
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dose)’(19) experienced by any neonate and suspected to be caused by a drug which meets 
the inclusion criteria in this study. This definition was chosen to acknowledge the inclusion of 
off-label and unlicensed prescribing in this population.  
4.7 ADR EXCLUSION CRITERIA 
•Any ADR suspected to be caused by a drug excluded from the study  
•Medication errors that are not associated with harm 
 
5. STUDY METHODS 
5.1 Overview of methods 
All neonates will be reviewed using several methods: 
1) Visit to the cot side by the researcher 4 – 5 times a week 
2) Review of the clinical record including prescription charts and Pharmacy 
records  
3) Questions to clinical staff by the researcher 4 – 5 times a week 
4) Reporting cards for staff to use 
If any of these methods yield a suspected ADR a detailed form about that episode will be 
completed using relevant information extracted from the clinical record. 
No new data will be collected or recorded for the purposes of this study. 
The data extract will be used to: 
a) construct anonymised summaries of each episode – the summaries will be used to conduct 
reviews of the episode for causality, severity and avoidability 
b) prepare aggregated, anonymised data to calculate frequencies of the events. 
An aggregated, anonymised dataset for all neonates in the unit (with and without suspected 
ADRs) will be prepared in order to provide comparator data for frequencies. 
5.2 DATA EXTRACTED FROM CLINICAL RECORD FOR ANALYSIS OF SUSPECTED 
ADRs 
The following data will be recorded for any neonate suspected to be suffering from an ADR 
• Study identifier (ADRIN ID number) 
• Gender 
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• Gestational age at birth 
• Birth weight 
• Post-natal age 
• Weight at time of event 
• Multiple pregnancy status 
• Date on day of event 
• Medication history (including details of drug, dose, route, date started, date stopped, 
indication) within three days prior to the event 
• Details of drug(s) suspected to be causing ADR – whether the drug was prescribed 
off-label or unlicensed 
• Description of event (including signs and symptoms, change in observations, change 
in investigation results, drug changes/treatment required, details of re-challenge, 
patient history of this reaction, outcome of the reaction, date and timing of reaction, 
type A or B) 
• Any significant event preceding reaction e.g. general anaesthetic 
• Details of respiratory support (mechanical ventilation or non-invasive) in the three days 
prior to the event 
• Ongoing medical or surgical conditions including congenital anomalies 
• Past medical or surgical conditions 
• Details of patient feeding within three days of the event 
• Details of drugs taken by breastfeeding mother (including details of drug, dose, route, 
date started, date stopped, indication and whether the drug was prescribed off-label or 
unlicensed) 
• APGAR scores at birth 
• CRIB II score in first 24 hours of life 
• Nature of birth including mode of delivery and complications in labour 
• Details of drugs given to mother in labour (including details of drug, dose, route, date 
started, date stopped, indication) 
• Details of drugs given to mother in pregnancy (including details of drug, dose, route, 
date started, date stopped, indication) 
• Details of significant pregnancy history 
• Details of significant maternal medical history 
• Age, gravidity and parity of mother 
• Details of report (including date, person raising ADR suspicion, person reporting ADR, 
data source, reminder to complete Yellow Card)  
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5.3 DATA SOURCES  
The neonatal unit electronic notes database ‘BadgerNet’ will be the main source of data for 
this study. This has access to demographic details, admission and discharge details, medical 
notes, nursing notes, medication histories, laboratory results, imaging results, observation 
charts and other note and chart sections. Some data will also be collected from verbal 
conversations with staff caring for the patient.  
In addition to the above methods, data collection forms will be available on the ward for use 
by any member of staff who wishes to complete a form for a neonate. There will also be a 
‘trigger tool’ available on the ward- a concise form allowing a member of staff to alert the 
researcher to a suspected ADR that they think needs following up.    
 
5.4 TIMING OF DATA COLLECTION: 
During periods of data collection, the neonatal unit daily ward round will be attended by the 
researcher Monday - Friday. It is hoped that clinicians will inform the researcher of any 
possible ADR suspicions and this will be prompted by a single question on the daily review 
sheet. Any suspected ADR discussed on the ward round will be documented on the same 
day. Following the ward round a structured clinical review of the care notes on BadgerNet from 
the previous 24 hours will be undertaken for each patient to look for any further ADRs not 
discussed during the ward round. On a Monday, the previous 72 hours will be reviewed. 
At the end of the study period, reports from BadgetNet for the data collection periods will be 
generated to provide denominator data for the study. The reports generated will include: 
• The total number of neonates admitted to the unit  
• The gestational ages at birth of all neonates admitted to the unit 
• The birthweights of all neonates admitted to the unit 
• The total number of drugs prescribed to each neonate during their admission 
• The total number of neonates receiving each drug  
• The total number of neonates diagnosed with predefined illnesses of interest  
5.5 DATA HANDLING 
Data will be recorded on a paper data collection form initially and then entered into a password 
locked study spreadsheet created for this study. The study spreadsheet will be stored on a 
password locked University computer based at LWH that is backed up regularly according to 
University Computer Services protocol.  
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Data will be recorded on the paper and spreadsheet using an ADRIN ID number (study 
number unique to the neonate) and the date of the event. A separate list of ADRIN ID numbers 
will be linked to neonate identifiers. That is, the data will be pseudoanonymised. 
The study team will have responsibility for: data collection, recording and quality acting in 
accordance with the Data Protection Act.  
Data will be retained for 21 years in light of the possibility that ADRs in neonates may have 
consequences in later life.  
5.6 COMMUNICATING ADRS TO CLINICIANS 
All ADRs that are deemed possible, probable or definite after the causality assessments have 
been carried out will be communicated to the lead consultant for the patient.   
The CI, who is an experienced consultant neonatologist with expertise in reviewing ADRs, will 
be available at all times to review the clinical importance of data and findings 
5.7 ADR REPORTING TO THE MHRA 
After the causality assessments have been carried out, all ADRs that are deemed possible, 
probable or definite ADRs will be reported to the MHRA using the well-established Yellow 
Card Scheme. An electronic copy of the Yellow Card report will be sent to the lead consultant 
for the patient. 
5.8 CAUSALITY ASSESSMENTS  
This study will look into evaluating three causality tools for their use to assess ADRs in 
neonates. The three causality tools used will be: 
1) The Liverpool Causality Assessment Tool (20) 
2) New Adverse Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units 
(21) 
3) A tool used in a recent prospective cohort study of ADRs in neonates conducted in 
Spain (10)  
Each ADR report will be assessed using all three causality tools by at least two independent 
assessors. All assessments with be done independently using anonymised event reports.  
Re-challenge:  
In this study, a re-challenge will be considered as the re-administration of a medicine before 
the neonate is finally discharged from the unit. A medication that is re-administered outside 
the neonatal unit at LWH will not be considered a re-challenge as this information would not 
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have been available at the time the first reaction occurred. This will aid the completion of the 
Liverpool Causality Assessment Tool. 
 
If the outcome of the causality assessment is unanimous in all assessments the report will be 
filed and a Yellow Card report sent to the MHRA as outlined above.  
If no consensus is reached the case will be reviewed by a senior investigator. They will not 
know the outcome of the previous assessments and a separate, causality assessment will be 
carried out. The outcome of this assessment will be considered as the final outcome and 
Yellow Card report will be sent to the MHRA if the ADR is deemed definite, probable or 
possible.  
 
5.9 SEVERITY ASSESSMENTS  
This study will look into evaluating two ADR severity assessment tools for their use to assess 
ADRs in neonates. The two severity tools used will be: 
1) A new severity tool currently under development in Europe 
2) A tool used in a recent prospective cohort study of ADRs in neonates conducted in 
Spain (10) 
Each ADR report will be assessed using both severity tools by at least two independent 
assessors. All assessments with be done independently.  
If the outcome of the severity assessment is the same in all assessments the case will be 
assigned a severity rating as per that tool.  
If no consensus is reached the case will be reviewed by a senior investigator. They will not 
know the outcome of the previous assessments and a separate, severity assessment will be 
carried out. The outcome of this assessment will be considered as the final outcome and the 
case will be assigned a severity rating as per that tool.  
5.10 AVOIDABILITY ASSESSMENTS 
This study will look into evaluating two ADR avoidability assessment tools for their use to 
assess ADRs in neonates. The two severity tools used will be: 
1) The Liverpool avoidability assessment tool (22) 
2) The Hallas scale (23) 
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Each ADR report will be assessed using both avoidability tools by at least two independent 
assessors. All assessments with be done independently.  
If the outcome of the avoidability assessment is the same in all assessments the case will be 
assigned an avoidability rating as per that tool.  
If no consensus is reached the case will be reviewed by a senior investigator. They will not 
know the outcome of the previous assessments and a separate, avoidability assessment will 
be carried out. The outcome of this assessment will be considered as the final outcome and 
the case will be assigned an avoidability rating as per that tool.  
5.11 STATISTICAL ANALYSIS 
Following the completion of causality, severity and avoidability assessments, statistical 
analysis will be carried out in order to determine the use of these tools in the neonatal setting.  
Appropriate statistical tests will be conducted using SPSS software and advice will be sought 
from a university statistician where required. 95% confidence intervals will be used where 
appropriate.   
Percentage agreement for the separate causality, severity and avoidability tools will be 
estimated using a kappa statistic. Percentage disagreement will be calculated where 
assessment scores using the same tool for the same case by two or more investigators are 
discordant.  A global kappa score to estimate agreement between three or more assessors 
will also be conducted. Pairwise kappa scores will then be compared with global kappa scores.  
Statistical analysis as carried out in two recent papers will be used as a model to guide the 
analysis in this study (20, 21).   
5.12 DISCONTINUATION RULES 
Discontinuation rules are not anticipated to be required for this study 
 
 
6. ADVERSE EVENTS 
Although the study is about adverse events and ADRs, no adverse events are anticipated to 
arise because of the study. Any concerning behaviour noted throughout the duration of this 
study will be reported to Dr Mark Turner for further investigation.  
Parents and visitors may become aware of the data collection. All unit staff will be briefed 
about the study so that they can explain to parents and visitors that the unit pay continuous 
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attention to the quality of care provided to the neonates and that this study is investigating how 
best to examine the impact of medicines on the neonates. 
No neonates will receive any change of treatment because of this study. 
7. STATISTICS AND DATA ANALYSIS 
All data collected from this study will be entered into a password locked spreadsheet 
specifically designed for this study and carefully tabulated to allow further analysis 
Data will be analysed using SPSS software. A p value of ≤ 0.05 will be considered significant 
for all data analysis.  
Appropriate statistical tests will be used to analyse the data generated in this study and a 
university statistician consulted if further assistance required.  
A comparison will be made between the number of Yellow Card reports generated in this study 
and the number of Yellow Card reports for neonates in a recent 10-year period as 
demonstrated in a recent review of all reports between 2001 and 2010(18). 
7.1 SAMPLE SIZE 
The primary goal of this study is to characterise tools used to evaluate suspected ADRs in 
neonates. The study needs to collect enough suspected ADRs to do this. Previous work has 
used between 50 and 100 cases of ADRs to do this. 
A formal sample size calculation has not been calculated because: 
1. Sample size calculations are not easy for comparative studies 
2. The project is time-limited because it is an MPhil project. 
On the basis of experience with ADRIC and previous surveillance for ADRs among neonates, 
the supervisors are confident that 6 – 9 months data collection is sufficient to gather enough 
suspected ADRs to characterise tools used to evaluate suspected ADRs and to address the 
secondary objectives. 
 
8. REGULATORY ISSUES 
8.1 ETHICS APPROVAL 
The Chief Investigator has obtained approval from the North West – Liverpool East Research 
Ethics Committee. The study must be submitted for Site Specific Assessment (SSA) at each 
participating NHS Trust. The Chief Investigator will require a copy of the Trust R&D approval 
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letter before accepting participants into the study. The study will be conducted in accordance 
with the recommendations for physicians involved in research on human subjects adopted by 
the 18th World Medical Assembly, Helsinki 1964 and later revisions.  
8.2 CONSENT 
Consent will not be obtained from participants in this study as only collection of routine clinical 
data is required and all data will be pseudoanonymised for analysis. 
8.3 CONFIDENTIALITY  
The Chief Investigator will preserve the confidentiality of participants taking part in the study 
and will abide by the Data Protection Act. Data will be recorded on a paper data collection 
form initially and then entered into a password locked study spreadsheet created for this study. 
The study spreadsheet will be stored on a password locked University computer based at 
LWH that is backed up regularly according to University Computer Services protocol.  
Data will be recorded on the paper and spreadsheet using an ADRIN ID number (study 
number unique to the neonate) and the date of the event. A separate list of ADRIN ID numbers 
will be linked to neonate identifiers. That is, the data will be pseudoanonymised. 
 
8.4 INDEMNITY 
The University of Liverpool holds Indemnity and insurance cover with Marsh UK LTD, which 
apply to this study. 
8.5 SPONSOR  
The University of Liverpool will act as the Sponsor for this study. Delegated responsibilities 
will be assigned to the NHS trusts taking part in this study. 
8.6 FUNDING  
The project will be conducted by Eve Roberts, MPhil student, University of Liverpool.  
No consumables are required for the running of this study and therefore no additional funding 
will be required. 
8.7 AUDITS 
The study may be subject to inspection and audit by the University of Liverpool under their 
remit as sponsor and other regulatory bodies to ensure adherence to GCP and the NHS 
Research Governance Framework for Health and Social Care (2nd edition). 
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9. STUDY MANAGEMENT 
The day‐to‐day management of the study will be coordinated through Eve Roberts. 
10. END OF STUDY 
Latest date of participant recruitment to the study: 1st July 2017 
The spreadsheet used for the storage and analysis of data recorded in this study will be closed 
one month after the recruitment of the last participant  
Submission date: August 2017 
11. ARCHIVING 
Data will be retained for 21 years after the completion of this study in light of the possibility 
that ADRs in neonates may have consequences in later life.  
Work completed on this study will be stored on M: Drive under the supervision of Dr Mark 
Turner. The password-protected computer used is located in a locked office at the Centre for 
Women’s and Children’s Health Research at the LWH.  Access to this department is by 
activated staff identification badge only.  
All data will be archived as per the guidance of the research and development department at 
the Liverpool Women’s Hospital and further advice sought if required.   
12. PUBLICATION POLICY 
Results of this study will be: 
• reported to Trust bodies 
• presented at regional meetings 
• submitted to MHRA 
• submitted for publication by peer-reviewed journals. 
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Date Event 
Wednesday 5th October 2016 Sponsorship application submitted to the 
University of Liverpool 
Wednesday 19th October 2016 Review by JRO Non-Interventional 
Sponsorship Sub-Committee 
Wednesday 25th October 2016 Latest date for outcome report from 
committee 
October 2016 Finalise systematic review protocol and 
begin literature search 
Ethical approval application 
November 2016 Continue systematic review and begin data 
collection 
November 2016– April 2017 Data collection 
May- August 2017 Final data collection, end of study, thesis 
write up and submission, corrections and 
Viva exam 
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Appendix 2 - ADR alert form  
 
ADRIN Study ADR Alert form  
Please complete this form if you believe a baby on the unit may have experienced an 
adverse drug reaction 
Thank you in advance, 
The Adverse Drug Reactions in Neonates team 
 
Baby hospital number: W 
Date and time reaction suspected: ___:___am/pm 
___/___/___      
 
Brief detail of event (please include drug(s)) 
Your name and 
role 
 
 
On completion please fold in half and leave in folder to be collected by research team 
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Appendix 3 - Causality tool evaluation form  
 
Karch and Lasagna algorithm: 
(Please rate the following aspects of the tool- strongly disagree, disagree, neither agree nor disagree, 
agree, strongly agree) 
 SD D N A SA 
The tool was easy to use      
The tool was appropriate to use for a neonatal ADR case      
The tool fairly assessed all causality aspects of the case      
I would use this tool if it were available in clinical practice      
Further comments about this tool: 
 
 
 
 
 
 
 
New Adverse Drug Reactions Algorithm for Infants in Neonatal Intensive Care Units: 
(Please rate the following aspects of the tool- strongly disagree, disagree, neither agree nor disagree, 
agree, strongly agree) 
 SD D N A SA 
The tool was easy to use      
The tool was appropriate to use for a neonatal ADR case      
The tool fairly assessed all causality aspects of the case      
I would use this tool if it were available in clinical practice      
Further comments about this tool: 
 
 
 
 
 
 
Liverpool ADR Causality Assessment Tool: 
(Please rate the following aspects of the tool- strongly disagree, disagree, neither agree nor disagree, 
agree, strongly agree) 
 SD D N A SA 
The tool was easy to use      
The tool was appropriate to use for a neonatal ADR case      
The tool fairly assessed all causality aspects of the case      
I would use this tool if it were available in clinical practice      
Further comments about this tool: 
 
 
 
 
 
 
 
 
